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Chapter One 
 
Introduction 
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Overview of the Problem 
In the United States, an estimated 1,700,000 people are diagnosed with cancer of some 
type annually, and 600,000 die from the disease[1]. Nearly 40% of men and women will 
be diagnosed with cancer during their lifetime. Economically, the burden of cancer is 
significant, with a national expenditure of nearly $125 billion. Since life expectancy is 
rising and the incidence of cancer increases with age, the financial costs of cancer are 
expected to reach $150 billion by the year 2020[2], [3].  
 
What is cancer?  
Cancer is the name that characterizes a collection of more than 200 diseases that may 
occur anywhere in the body, in which cells proliferate without control[3], [4]. A tumor is 
an abnormal increase in the size of tissue. The designation of a malignant tumor is 
characterized by tissue growth due to cancer cells that are permanently proliferating and 
have the ability to invade other sites[5]. In most cases, if the growth is localized and 
controlled within the defined region, the tumor is considered benign and non-invasive[6]. 
The physical location of tumors at the primary and distant sites marks the stage of cancer 
and spreading of the tumor. The grade is a description  
of the cellular architecture based on histological evaluation where tissues with a 
prevalence of unhealthy and poorly differentiated cells are graded higher[7]–[9].  
 
There are five different categories of cancer depending on its origin in the body. i) 
Carcinoma is cancer that originates in the epithelial tissue that lines the internal organs 
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and layers of the skin. It is the most common type of cancer. Within this category are 
basal cell carcinoma (deep epithelial layer), transitional cell carcinoma (transitional 
layer), and adenocarcinoma which originates in adenomatous glandular cells. 
Adenocarcinoma is the most common cancer of digestive organ[4]. One specific example 
as it related to this thesis work, 95 percent of colorectal cancers are adenocarcinomas. ii) 
Sarcomas are very rare and comprises of cancers that begin in the connective tissues and 
musculoskeletal system. They include cancer of the nerves, tendons, cartilage, fat, 
vessels, muscles, bones. iii) Leukemia comprise of cancers that originate from blood and 
blood-forming tissue. iv) Lymphomas are cancers of lymphatic origin that affect the 
immune system. v) Central nervous system cancers are another form of malignancy that 
arise when cells of the brain and spinal cord uncontrollably proliferate[1], [4].  
 
Under normal conditions, cells undergo mitotic division as needed (replacement of old 
cells and damage cells, etc.) under strict growth regulation. There are different molecular 
and cellular modifications that can act to enable cellular bypassing of mitotic control. 
These alterations provoke disruptions in distinct regulatory mechanisms of growth[10]–
[13]. The onset and progression of tumors rely on complex multistep processes whereby 
compound defects cooperatively advance cancer. Multiple chemicals, biological and even 
social carcinogens can act as a trigger of these processes[3].  
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The Hallmarks of Cancer 
According to Hanahan and Weinberg, authors of "the Hallmarks of Cancer," defects 
leading to six cellular pathophysiological traits are common to all cancers. They include 
cell growth signal autonomy, insensitivity to anti-growth signals, escape apoptosis, 
limitless proliferation, sustained angiogenesis, and metastasis[14]. Growth signal 
autonomy: the activities of healthy cells, including growing, is dependent on the signals 
released from distal and proximal cellular neighbors[14]–[16]. Growth signals are 
required for cells to become proliferative. The signals are highly dependent on cell 
surface receptors embedded in the plasma membrane that binds the signaling factor. In 
tissue, quiescent cells do not proliferate without the cellular message to do so. Cancer can 
arise from mutations that cause cells to acquire the ability to generate their own growth 
signal thereby proliferating independent of environmental stimulations[14]. In many 
cases, the cancer cells overexpress the receptors to a growth signal and are hyper-
stimulated. The most complex and therapeutically difficult to target growth signal-
independence are those where there are defects downstream of the cell surface receptor. 
Mutations in mitogen-activated protein kinase (MAPK) pathway are examples of such 
autonomy and are involved in about 25% of cancers[17]–[19]. This pathway will be 
discussed extensively and is a primary subject of a study described in a later chapter. 
Briefly, signaling of this pathway transmits (in order) from activation receptor tyrosine 
kinases (RTKs)-son of sevenless (SOS)-rat sarcoma (Ras) rapidly accelerated 
fibrosarcoma (Raf)-MAPKs ->proliferation[17], [20]. In many cancers, genetic and 
structural alteration in Ras, Raf, and other MAPKs leads to constitutive signaling towards 
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cell proliferation without the need of RTK activation.  
 
Insensitivity to anti-growth signals: This characteristic is closely related to the growth 
signal autonomy. There are mechanisms in place to halt signaling and prevent hyper-
proliferation of cells[14], [16]. The extracellular matrix is embedded with factors that act 
to regulate cellular growth and migration chemically and physically. All normal cells 
monitor and respond to the regulatory signals of their environment[20]. However, 
malignant cells tend to have altered expression of several proteins that allows them to 
avoid various signals to become quiescent. In the colon, the protein adenomatous 
polyposis coli (APC) helps control the division of cells by mediating the cells' interaction 
with neighboring cells, association to the matrix, and proper segregation of 
chromosomes. As a "gatekeeper gene," mutations in the APC contribute to approximately 
80% of all colon cancers[10], [21]–[24]. 
 
Escape apoptosis: Cell death through apoptosis occurs through a series programmed 
events that act to destroy unwanted cells. Apoptosis is necessary for embryological 
development, preventing the spread of infections by signaling the killing affected cells, 
and cellular turnover. Apoptosis can be triggered externally by a neighboring cell or the 
extracellular environment or internally through pro-apoptotic stimuli-releasing proteins 
from the intermembrane of the mitochondria[25]–[27]. One of the most important tumor-
suppressor molecules is the p53 protein. P53 can sense genetic alterations and trigger 
programmed cell death through both extrinsic and intrinsic pathways. Approximately half 
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of all cancers demonstrate the lost or inactivation of p53[28]–[32]. An alteration in 
proteins that influences the apoptotic machinery can allow many cancer cells to continue 
proliferating. Furthermore, cancers that do not respond to apoptotic signals often show 
resistant to chemotherapies aimed at triggering cell death[14], [16].  
 
Limitless proliferation: The ability to bypass growth regulation and escape cellular death 
is crucial for the onset of cancer. However, every cell is limited in their number of 
replications. None of the above-mentioned events can increase the number of replications 
a cell can undergo intrinsically.  Without environmental control, a typical cell can only 
replicate to a finite amount based on telomere shortening; at this point the cells enter the 
non-growing stage of senescence[33], [34]. The loss of suppressor molecules p53 and 
pRb can allow cells to escape senescence and continue replicating. Significant 
chromosomal instability and genetic alterations takes place in aged-cells dividing beyond 
senescence[13], [35], [36]. However, these defective later-generation cells are supposed 
to enter what is known as cellular crisis where massive cell deaths occur. Tumors are a 
consequence of a rare population of cells acquiring defects that immortalizes the cells 
beyond the crisis. Limitless replication phenotype is perhaps the most crucial 
characteristic for tumor growth. Only 1 of 10,000,000 cells escape crisis with this 
ability[14]. 
 
Sustained angiogenesis: Every cell in the body requires a constant supply of nutrients. In 
tissues, essential nutrients including glucose, water, and oxygen are obtained via capillary 
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blood vessels that are within 100 µm of each cell. The process of angiogenesis is the 
formation of new blood vessels as result of increasing demand for nutrition and 
oxygen[37]. Normally, this process is due to cellular increase in aerobic activity, healing, 
and various other ischemic processes. Angiogenesis is essential in a growing tumor. The 
size to which a tumor can grow is limited in the supply of vessels to that 
environment[14], [38], [39]. One of the main characteristic of aggressively proliferating 
malignant tumors is hypoxia, which describe microenvironments of low oxygen. Primary 
research investigating how hypoxic conditions can change the behavior of cancer cells is 
presented in a later chapter. In order for tumors to avoid catastrophe, cancer cells must be 
able to manipulate the process of angiogenesis. Normal blood vessel formation is tightly 
regulated. Vascular endothelial derived growth factor (VEGF) and other angiogenetic 
factors can be produced by many cell types to recruit and stimulate the division of vessel-
forming endothelial cells[14], [38], [40].  Matured blood vessels functionally distinct to 
the corresponding tissue are established through a complex system of stimulatory and 
inhibitory signals. Tumor cells are able to hijack this system because of their acquired 
ability to constantly produce vast amounts of stimulatory factors such as VEGF. Tumors 
without this ability can often act to cause other cells to release angiogenesis factors. 
Sustained angiogenesis as malignant cells proliferate is vital in maintaining the tumor 
microenvironment[41], [42]. 
 
Metastasis: The mortality rate of cancer directly correlates to tumor metastasis. Over 90% 
of cancer-related deaths are due to the migration and subsequent invasion of distal sites 
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by the tumor[43]–[45]. The ability to proliferate and evade cell death is often not enough 
to maintain a tumor even with increased blood vessel formation. No matter how much 
resources supplied to the tumor, the physical space will eventually limit population size. 
At later stages in cancer development, cancer cells can leave the primary tumor and 
invade the neighboring tissue or seek a distal site by accessing the blood and lymphatic 
vessels[14], [45], [46]. Some tumors can pass from one circulatory system to another. 
Another type of dissemination is transcoelomic metastasis which is a process found in 
majority of late-stage ovarian cancer.  Transcoelomic metastasis is the migration of 
malignant cells from the ovaries to the lining of abdominal organs[47]–[49].  
 
Cancer cells can display both single cell and collective migration, where groups of cells 
attached to one another are mobile as a unit[50], [51]. The cells must possess some 
exceptional characteristics to successfully established tumor growth at a secondary site. 
Malignant cells must employ several strategies and bypass multiple barriers of invasion. 
It is by no surprise that cross-talk exists between many oncogenic pathways and those 
involved in cellular motility[52]–[57]. Cancer, once developed, can succeed in some 
phases of tumor progression and not others. Progression is highly dependent on both 
intrinsic and extrinsic abilities of the malignant cell to interact with and influence the 
tissue microenvironment[51], [58].  Metastasis is subdivided into four major phases: 
invasion, intravasation, survival, and extravasation[59]–[62]. Cells are attached to their 
surround extracellular environment (ECM) via adhesion molecules including 
immunoglobulins and the calcium-dependent cadherin family proteins[63]. The role that 
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changes in the expression cadherin molecules play in cancer invasion has been studied 
extensively. Normal levels of E-cadherin act to bind cells to the ECM. Multiple studies 
have associate reductions in E-cadherin with epithelial to mesenchymal transition (EMT) 
whereby cells lose their epithelial phenotype and become more stem-like and 
multipotent[63], [64]. Loss of E-cadherin is often accompanied by an increase in the 
expression of N-cadherin. N-cadherin promotes cell motility and is a marker of 
mesenchymal cells. Several molecular pathways including Ras-MAPK and WNT 
pathways act to regulate the expression levels of E/N-cadherin[65]–[68]. Mutations in 
these two pathways often lead to very aggressive and invasive tumors.  
 
If motility is acquired, another barrier that cancer cells must overcome to successfully 
metastasize is the basement membrane that exists as a dense meshwork and creates a 
physical blockade between epithelial cells and the stroma[69], [70]. The stroma is the 
connective and structural tissue that surrounds organ tissue. The stroma provides a 
framework within which the vascular, nervous, and lymphatic system can interact with 
tissues. Metastatic cancer cells are capable of secreting ECM-degrading proteases 
including matrix metalloproteinases (MMPs) to access the stroma. Breaking down the 
basement membrane also results in the leakage of multiple growth factors that are trapped 
within the ECM[71]. Once access to the stroma is obtained, cancers must exit the primary 
tumor environment by entering the circulatory system. The blood vessels near tumor 
tissue are often malformed with thin and leaky walls since angiogenesis in such tissue are 
unregulated[41].  This makes entry into the circulation much easier for cancers. Once 
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tumor cells intravasate into circulation, they must survive the harsh environment 
presented by several circulatory factors. While circulating, tumor cells are in danger of 
being eradicated by immune cells and other circulatory forces. To survive, they often 
attach themselves to platelet cells and or coagulating molecules (thrombin, fibrinogen, 
etc.)[72]–[74]  
 
There are multiple ways in which circulating tumor cells can extravasate. Endothelial 
cells turnover in the blood vessel wall and create temporary gaps. Tumor cells can 
passively attach themselves to these gaps[75], [76]. Also, tumor cells associated with 
platelets can more easily find vulnerable regions for attachment to vessel wall because 
damage vessels attract platelets[77]. To secure attachment at their arrest region, tumor 
cells can form cell-cell adhesion to endothelial cells. Once there, the tumor can grow until 
this lesion physically penetrates the vessel. Another way tumor cells can exit circulation 
is by stimulating endothelial cell detachment and disorganization of the wall[78], [79]. 
Upon reaching the secondary site, the malignant cell must survive the environmental 
conditions, acquire nutrients, and proliferate. Cancers can undergo this entire process of 
metastasizing and still fail to develop at a secondary site. Tumor-promoting interaction 
with the ECM at every stage of the cancer progression process is crucial[20]. It has been 
recognized for many years that tumors exhibit organ-preference patterns metastasis. The 
frequent targeting of particular organs for metastasis is a consequence of the growth-
promoting interactions amongst cancer and non-cancer cells that occurs their 
microenvironment[80], [81].  
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Figure 1.1. The hallmarks of cancer. Most cancers function by acquiring six 
similar set of capabilities during tumorigenesis. (Adapted from Hanahan and 
Weinberg. Cell, January 2000). 
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The tumor microenvironment  
 
Despite all of their cell and molecular advantages, cancer cells cancer cannot manifest as 
a tumor with the assistance of other cells. The functional capability of every cell is 
facilitated by the genes and subsequent corresponding proteins they express. Cancer cells, 
despite aberrant expression of multiple genes, do not possess the ability to perform every 
function. Thus, they must be able to "teach" or coach other cells of various functions to 
perform much of the task necessary to progress. A tumor is not merely a lump of cancer 
cells, but a complex micro-society with a diverse population of corrupt cellular 
members[51]. This dense milieu is referred to as the tumor microenvironment (TME). 
TME is the histological niche of progressing cancers. This tissue environment is complex 
and heterogeneous and composed of the malignant cells and various other non-malignant 
tissue cells. Malignant cells of the TME are capable of interacting with the other cells of 
this region to create and maintain an environment that supports their own survival and 
growth[20], [82], [83]. The TME is structurally and functionally under the complete 
control of its inhabitant cancer cells. The TME consist of several major cancer-supporting 
stromal components: vascular cells, cancer-associated immune cells, and cancer-
associated fibroblasts. These components collectively play a role in each of the hallmarks 
of cancer.  
 
Vascular component: Vessel formation in the tumor microenvironment occurs with an 
almost "by all means necessary" approach. At the size of approximately 1-2 mm
3
, tumors 
typically become too demanding for the existing local blood vessels[84]. The 
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environmental condition is highly ischemic with a lack of diffusion of oxygen and waste 
clearance. Tumor cells are capable of surviving this environment by initiating new vessel 
formation through a variety of methods[38], [39]. Earlier, I was mentioned that formation 
of new vessels could occur in response to VEGF release. The release of VEGF and other 
pro-angiogenic molecules for vessel sprouting from pre-existing vasculature is heavily 
dependent on hypoxia[39], [84]. Hence, starvation of the tissue region where the cancer 
home can in itself promote the vascular component already existing in that environment 
to supply the tumor with new vessels. A less familiar method of vascularization of the 
tumor TME is the process of intussusceptive angiogenesis (IA)[85]. This process is 
extremely fast and does not require the proliferation of new endothelial cells. During IA, 
existing endothelial cells can be triggered to remodel themselves to have a thinner 
morphology within hours. With little energy expenditure, preexisting vessel segments can 
form weak transvascular tissue columns to diverge circulation[86]–[88]. IA can occur 
alone or alongside true vessel sprouting for reasons not well understood. However, it has 
been hypothesized to be a possible mechanism of resistance to anti-angiogenesis 
agents[89].  
 
During the early days of tumor-angiogenesis research, vasculature was thought to be a 
result of pre-existing TME vessels sprouting new branches. In 1997, Asahara et al. 
reported the existence and isolation of CD34-positive mononuclear blood cells with 
endothelial cell-like phenotype differentiation[90]. These endothelial cell progenitors 
(EPC) were capable of forming in vitro tube-like structures[91]. Multiple studies since 
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have demonstrated that EPCs are recruited to low hypoxia tissue environment including 
tumor growth and participate in increased angiogenesis[92]. Their recruitment to tumor 
sites can be maintained with cancer-released pro-angiogenic factors. Much of the EPC 
work has been focus cardiovascular ischemic related tissue pathologies. However, 
studies, including work done by Capillo et al. have shown that pharmacological 
immobilization of EPCs can inhibit tumor vasculature[93].  
 
One of the most unique and strange properties of some tumors is the ability to 
dedifferentiate into cells that can form their own tube-like structures. The process 
described as vasculogenic mimicry demonstrates a secondary circulation system 
formation capability that allows tumors exist independent of angiogenesis[94]–[97]. 
Another unique phenomenon related to tumor vasculature is vessel co-option[98], [99]. In 
some rare cases, tumors can grow without the need to stimulate vascularization of the 
TME. It appears that avascular TME are most prominent in brain and lung malignancies 
where the tissues are well-vascularized[100], [101]. 
 
Immune component: The characteristic and function of immune response to tumor 
growth are very complicated, and is dependent upon the tissue, organ, location, and 
tumor grade[16], [102]. All tumors are infiltrated by a variety of immune-related cells. 
The primary function of the immune system is to defend against pathogens and eliminate 
factors that perturb homeostasis. To do that, the system is designed to mobilize multiple 
specialized cells that make up its innate and adaptive response[103], [104]. Intercellular 
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crosstalk between innate and adaptive systems is critical to immune response and 
prevention of chronic disturbance in homeostasis[105]–[107]. Malignant cells can cut the 
communication pipeline between the innate and adaptive immune system in the 
TME[74], [107]–[110]. Overall, the immune system is designed to combat radical cells 
such as cancer. However, cancer cells have the ability to not only invade, but also to 
manipulate immune cells to support the maintenance of the TME. Because of their 
surveillance functions, immune cells are capable of producing a variety of factors to 
modulate both cell division and death, and regulators of matrix remodeling. These 
characteristics can become very useful to a growing tumor when under the control of 
malignant cells[48], [111], [112].  
 
Cancer-associated fibroblasts: Cancer-associated fibroblasts (CAFs) are the most 
dominant component of the TME[40], [113], [114]. Fibroblasts are part of the robust 
heterotypic cellular response to the tumor. Fibroblasts are perhaps the most versatile cells 
in the TME with the ability to perform several structural functions, exhibit pluripotency, 
and survive in environmentally severe tissues[115], [116]. Fibroblasts activate in 
response to tissue injury and other stress stimuli. The fast-growing cancer cells in the 
TME are often representative of chronic tissue injury. Both the cancer cells and the 
immune cells infiltrating can release factors that recruit fibroblasts to the tumor site[114], 
[117]–[119]. The recruitment is largely mediated by transforming growth factor-β 
(TGFβ), platelet-derived growth factor (PDGF), and fibroblast growth factor 2 (FGF2) as 
a means to confine and eliminate cancer[120]. However, the cancer cells can release 
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PDGF and other factors to control fibroblast behavior[119], [121]. The sustained 
response and activation of fibroblasts in tumors often lead to a pathologically hardened 
fibrous tissue that can protect malignant cells from cancer therapy[122].  
 
The ability of malignant cells to drive cancer progress in the tumor microenvironment 
heavily depends on intercellular interactions[20], [58]. The cancer-supporting cells 
mentioned above are under the control of cancer cells through a myriad of cell-to-cell 
communication methods. The cells of the TME can communicate through contact-
dependent and with indirect mechanisms such as the release of diffusible growth factors, 
and cytokines[16], [25]. In recent years several novel behavior and patterns of 
communication of cells have been described including exosomes, cytonemes, and 
tunneling nanotubes (TNT)[123]–[125]. Effective and efficient intercellular cross-talk in 
the complex tumor microenvironment is recognized to be essential for tumor growth and 
invasion.  
 
Intercellular communication in cancer  
As mentioned above, tumors are highly heterogeneous entities comprised of several cell 
types functioning as a unit. Components of the stroma include but are not limited to, 
infiltrating immune cells, vascular endothelial cells organizing as part of an angiogenic 
response, and cancer-associated fibroblasts serving as scaffolds and filling vital 
functional roles through secretion of soluble stimulating factors (chemokines and 
cytokines)[14], [51]. Effective and efficient intercellular cross-talk in this three-
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dimensional complex tumor microenvironment is essential for tumor growth and 
invasion. One important consideration is that stromal, non-malignant cells can comprise 
as much as 80-90% of a given tumor's volume; in fact, a higher proportion of stroma has 
been associated with worse prognosis in invasive solid tumor malignancies[126]–[128]. 
Modes of cancer cell cross-talk are finally being elucidated in greater detail due to 
advances in microscopic techniques and refined experimental methods in both cellular 
and molecular biology. The relatively newest form of such cross-talk consists of long 
membrane-based extracellular extensions called TNTs[58], [129]–[131]. TNTs will be 
described in detail throughout this thesis and is the bases of the primary research work. 
Some of the more well-studied modes of intercellular communication include 
extracellular vesicles, gap junctions, non-TNT membrane bridges, and soluble factors.  
 
Exosomes: Exosomes are membranous vesicles release by eukaryotic cells. By definition, 
exosomes are 30-100 nm in diameter[123]. Other vesicles include 100-1000 nm diameter 
microparticles, and 50-500 nm apoptotic blebs[132]. Exosomes forms within the 
intraluminal vesicles which are late endosomes that can accumulate into multivesicular 
bodies (MVBs). MVBs can fuse with the plasma membrane to release its vesicles to the 
extracellular environment where they then can be considered as exosomes[123].  
Although exosomes were defined over 30 years ago, their role in facilitating intercellular 
communication was not uncovered until years after[133], [134]. They were often thought 
of as “cellular waste” serving an insignificant physiological purpose. Their role was first 
defined by studies done on the red blood cell maturation from reticulocytes into 
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erythrocytes, where it was demonstrated that the shedding of membranous vesicles was 
necessary for the loss of transferrin[135], [136]. Interest in their involvement in 
intercellular communication during both normal and disease state has increased 
significantly over the past two decades. Cells have been shown to utilize exosome to 
share proteins, ions, mitochondria, nucleic acids, viruses, and various other cytoplasmic 
contents[137]. There are characteristic differences between exosomes released by cancer 
and non-cancer cells[137]–[140]. Compromised form or expression of the contents have 
been demonstrated in tumor-related exosomes and shown to promote tumor progression. 
In fact, there are multiple studies indicating their involvement in each of the hallmarks of 
cancer[141]–[144]. Thus, exosomes have generated significant clinical interest. 
Moreover, since tumor cells release distinct exosomes, keen interest lies in the 
development of exosome-based diagnostic strategies. Lastly, exosomes can be exploited 
to package and deliver therapeutic drugs[145]. Anti-disease drug studies using exosome-
loaded suppressing agents have shown promising results[145]–[147].  
 
Gap junctions: Gap junctions are connexin protein-based 2 nm 'gap' microchannels that 
connect adjacent cells[148]. They are the most direct mode of communication between 
cells. Gap junctions are semi-nonspecific, allowing molecular movement of cytoplasmic 
contents smaller than 1000 Daltons to transfer between two cells[149]. With the 
exception of some circulating cells and skeletal muscle, most cells in tissues 
communicate through gap junctions. Studies describing intercellular communication 
between cells through these channels were first performed in the 1950s, primarily noting 
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their involvement in electrical coupling of cells[150], [151]. About a decade later, tumor 
cells were found to have lost their ability to electrically couple[152], [153]. Subsequent 
work further demonstrated that connexins, the major component of gap junctions, were 
absent in certain carcinomas[154]. With approximately 16 different phospho-sites, Cx43 
must be phosphorylated in a specific manner for trafficking and proper gap junction 
formation function[155]–[158]. It is no surprise that multiple pathways implicated in 
cancers, including protein kinase C (PKC) and MAPK, regulate connexin 
phosphorylation[159], [160].  
 
Membrane bridges: Communication between distant cells is not only limited to the 
release of diffusible factors. It is now widely accepted that there are unique intercellular 
channels that can allow non-adjacent cells to communicate by facilitating direct transport 
of cellular messages even at great distance. These structures include plasmodesmata, 
tunneling nanotubes (TNTs), cytonemes, and cellular bridges. Details will not be 
provided here for plasmodesmata as knowledge of that structure is limited to plant 
biology. There are structures formed when dividing plant cells have a region of their 
endoplasmic reticulum (ER) confined to the pectin layer that joins their cell walls. As 
intercellular bridges, these unique channels results in cytoplasmic continuity between the 
plant cells. They mediate the transport of multiple ions, proteins and other 
metabolites[161], [162].  
 
Cytonemes: In the Drosophila wing imaginal disc, the anterior/posterior (AP) 
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compartment emanate Decapentaplegic (Dpp), Hedgehog (Hh), and epidermal growth 
factor (EGF) signals that regulate patterns of development in cells distant from the 
signals origin[163], [164]. These signals traveling from different cells are delivered with 
excellent efficiency. The mechanism by which this occurs was unclear; especially since 
there are borders that confine and compartmentalized the AP cells. In 1999, Ramirez and 
Kornberg described a novel structure coined cytonemes that appeared to be a filopodial 
extension that facilitates direct contact between morphogen-producing cells and cells of 
other compartments[165]. The cytonemes showed a diameter of approximately 0.2 μm 
and distributed molecules amongst cells via simple diffusion. Further examinations 
demonstrated that cytonemes grew abundantly in response to fibroblast growth 
factors[166]. Cytoneme investigations remain challenging as their detection and integrity 
are compromised by exposure to fixatives.  However, their identification in non- 
Drosophila cells including mammalian, and bacteria have created increase in their 
examination[167].  
 
 Cellular bridge can be used broadly to characterize multiple tubular actin-based 
protrusions that have been demonstrated to exist between cells. Many of these structures 
including cytonemes, epithelial/ filopodial bridges, and immunological synapses have 
structural and functional traits relating to that of TNTs which will be discussed 
later[168]–[170]. TNTs are the longest cytoplasmic connections amongst the group[130]. 
The other mammalian cell structures, based on description, could be some variation of 
TNTs. In fact, multiple studies use the term "TNT-like" when referencing to these other 
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protrusions. TNTs are also the only one whose role in cancer has extensively been 
studied[58], [130], [131], [171].  
  
TNTs are ultrafine, long, filamentous actin-based protrusions of the cell plasma 
membrane that are used for long-distance yet direct cell-to-cell cross-talk[129], [172]. 
TNTs serve as a bridge-like “cellular skyway” to transfer proteins, genes, and other 
important signaling cargo between cells[58], [171], [173]–[175]. TNT formation is 
classified according to two different methods. In one case, neighboring cells that have 
come in physical contact can migrate apart and yet remain connected through 
TNTs[176]–[178]. The second form of TNTs are those who first protrude as thin 
filopodia-like extensions of one cell until making contact and anchoring to the plasma 
membrane of another[171]–[173]. TNTs display a range of nano-sized 50-800 nm 
diameter tubes and can stretch several hundred microns in length[129], [179]. In vitro, 
TNTs are non-adherent to the substratum, thus differentiating them from other well-
known membranous protrusions such as filopodia, lamellopodia, and invadopodia. While 
a subset of TNTs are only associated with F-actin; some, with a diameter greater than 500 
nm, contains both F-actin and microtubule[180]. Once connected, bidirectional content 
motility can occur between and TNT-mediated cargo transfer can modify behavior of the 
recipient cell[58], [172], [174].  
 
TNTs and the role their formation plays in cancer is the primary focus of our lab. The 
goal of this thesis project was to investigate TNT-mediated cell-to-cell communication in 
cancer progression. Specially, the studies presented in this thesis were aimed at 
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examining ways in which TNTs are involved in hypoxia, resistance to chemotherapeutic 
drugs, and development of tumor heterogeneity. This thesis highlights the occurrence of 
intercellular communication via TNTs.  
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Figure 1.2. Tumor-stroma and tumor-tumor interactions play an important role in 
the heterogeneous tumor microenvironment. Modes of intercellular communication 
include cytokine or chemokine messaging, gap junction–mediated signaling between 
neighboring cells, and TNT-mediated intercellular transfer of signals between distant 
cells. A. Bright-field microscopy image of TNTs connecting pancreatic cancer cells in 
vitro (pancreatic carcinoma cell line S2013; original magnification ×30). B. Schematic 
representation of diverse components that interact in the tumor-stroma 
microenvironment. (Adapted from Lou et al., Pancreas, November 2013). 
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2.1 Synopsis 
 
Malignant pleural mesothelioma is a particularly aggressive and locally invasive 
malignancy with a poor prognosis despite advances in understanding of cancer cell 
biology and development of new therapies. At the cellular level, cultured mesothelioma 
cells present a mesenchymal appearance and a strong capacity for local cellular invasion. 
One important but underexplored area of mesothelioma cell biology is intercellular 
communication. Our group has previously characterized in multiple histological subtypes 
of mesothelioma a unique cellular protrusion known as tunneling nanotubes (TNTs). 
TNTs are long, actin filament-based, narrow cytoplasmic extensions that are non-
adherent when cultured in vitro and are capable of shuttling cellular cargo between 
connected cells. Our prior work confirmed the presence of nanotube structures in tumors 
resected from patients with human mesothelioma. In our current study, we quantified the 
number of TNTs/cell among various mesothelioma subtypes and normal mesothelial cells 
using confocal microscopic techniques. We also examined TNT length among adherent 
cells and cells in suspension. We further examined potential approaches to the in vivo 
study of TNTs in animal models of cancer. We have developed novel approaches to study 
TNTs in aggressive solid tumor malignancies and define fundamental characteristics of 
TNTs in malignant mesothelioma. There is mounting evidence that TNTs play an 
important role in intercellular communication in mesothelioma and thus merit further 
investigation of their role in vivo. 
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2.2 Introduction 
 
Malignant pleural mesothelioma (MPM) is a clinically devastating and locally invasive 
malignancy. Patients with this disease uniformly carry a poor prognosis despite advances 
in understanding of cancer cell biology and development of new therapies. Unlike other 
solid tumor malignancies, mesothelioma is highly refractory to all forms of current 
treatment including surgery, radiation, and chemotherapy. Treatment of mesothelioma 
and other invasive solid tumor malignancies such as cancers of the colon, pancreas, and 
ovaries is limited by an inadequate understanding of the modes and functions of 
intercellular communication in the tumor microenvironment [181], [182].  Intercellular 
communication is critical to tumor formation, organization, and treatment resistance 
[181], [183], [184].  Mounting evidence suggests that tumor-stromal cell interactions are 
important to the invasive phenotype.  Stromal cells, once seen as passive structural 
components of the tumor infrastructure, are now viewed as dynamic components of 
tumor initiation, progression, and invasion [185]–[187]. Invasive tumors are composed of 
a large proportion of stroma; in MPM this proportion can be as high as 34-45% 
depending on the histologic subtype [188]. The proportion is highest in biphasic and 
sarcomatoid tumors, the latter of which is associated with even worse prognosis than 
other subtypes [188]. This tumor-stroma balance creates a heterogeneous 
microenvironment composed of, among other things, malignant cells, cancer-associated 
fibroblasts, vascular endothelial cells, macrophages, and other inflammatory infiltrates. In 
a study of MPM, inflammatory or desmoplastic stroma types correlated with worse 
patient prognosis, as compared with fibrous or myxoid forms of stroma [189].  
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The most commonly studied avenues of cellular transfer among cancer cells include gap 
junctions, chemokines, cytokine messengers, and microvesicles/exosomes [190]–[196]. 
These forms of intercellular communication are most effective over short distances. 
Furthermore, cell-cell junctions are disrupted upon epithelial-mesenchymal transition, a 
precursor to metastasis [197], [198] making intercellular communication via these 
junctions impossible for separated cells. Additionally, effective cell-cell ‘cross-talk’ via 
diffusible factors could be difficult to achieve because of an increase in interstitial fluid 
pressure in the tumor microenvironment.  There remains considerable uncertainty 
regarding how tumor-stroma exchange of cellular information takes place and how 
distant cells that are not in close proximity are able to communicate within a three-
dimensional matrix composed of a significant proportion of stromatous material.  A 
better understanding of the mechanisms and cellular structures that underlie intercellular 
communication among distant cells in the tumor matrix of malignant tumors is expected 
to lead to new targeted treatments that block progression of mesothelioma and other 
invasive solid tumor malignancies. 
 
Our group has investigated tunneling nanotubes (TNTs), a previously underexplored 
form of cellular protrusions that are distinctly unique from other filamentous cellular 
extensions. TNTs are long, narrow, actin-based cytoplasmic extensions that form de novo 
in vitro.  Nano-sized in width (50-800nm), TNTs can stretch the length of several cell 
diameters or longer (as long as several hundred microns) to form direct cell-to-cell 
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cytoplasmic connections. TNTs display non-adherence to the substratum when cultivated 
in vitro [129]. These characteristics differentiate TNTs from other, well-known actin-
based cytoplasmic extensions including lamellopodia, filopodia, and invadopodia [129].  
TNTs are open-ended ‘intercellular bridges’ whose walls consist of a contiguous lipid 
bilayer that can establish a direct connection between the cytoplasm of connected cells, or 
in some cases interface with gap junctions in plasma membranes [176].  TNT formation 
is largely generated by actin-driven membranous protrusions extending to outlying cells. 
They have been noted to form either by one cell extending a tubular cytoplasmic 
connection to another cell located at some distance (in contrast with gap junctions, which 
connect cells in immediate proximity) or to form between cells in close proximity that 
then move apart via usual mechanisms of cell motility, allowing for continuation of 
intercellular communication even as the cells move in different directions [199]. At least 
one study has suggested that TNTs interface with gap junctions to connect cells and 
mediate intercellular cross-talk [176]. Uniquely, TNTs serve as conduits for intercellular 
shuttling of cellular organelles and other cargo between connected, non-adjacent cells 
[171], [200]. In vitro studies have shown that TNTs have the ability to directly mediate 
cell-to-cell communication by serving as long-range conduits between connected cells for 
intercellular transfer of proteins, mitochondria, Golgi vesicles, and even viruses [171], 
[201]  (For an example of time-lapse imaging we use in our work, please see 
Supplemental Movie S1 demonstrating intercellular transfer of mitochondria between 
mesothelioma cells connected via nanotube). The importance of intercellular transfer of 
genetic material is also a topic of growing interest. Our group recently demonstrated that 
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TNTs can also transport oncogenic microRNAs between malignant cells, as well as 
between malignant and stromal cells, introducing a new aspect of tumor-stromal cross-
talk that warrants further study [58]. 
 
TNTs have been studied in a wide variety of non-cancer cell types including dendritic 
cells and monocytes [202], [203], mature macrophages [204], [205], T cells [206], [207], 
B cells [208], neutrophils,  neuronal cells [209], kidney cells [210], endothelial progenitor 
cells [211], mesothelial cells [200], [212], cardiomyocytes[213], and mesenchymal 
stromal cells [214], [215].  Our group focuses on investigation of TNTs in the context of 
invasive forms of cancer [200]. To investigate TNTs as a physiologically relevant 
structure in human solid tumor malignancies, our initial work successfully visualized 
TNTs in solid tumors resected from patients with mesothelioma and lung 
adenocarcinomas [200], providing the first evidence of the potential in vivo relevance of 
these cellular structures in cancer. We subsequently performed high-resolution 
microscopy and 3-dimensional reconstructions to confirm that nanotube structures are 
present in other invasive malignancies as well, including a murine model of osteosarcoma 
and human ovarian adenocarcinoma [58]. In our in vitro work in mesothelioma, we used 
modified wound-healing assays and demonstrated TNT formation along the leading 
invasive edge of mesothelioma cells in vitro; time-lapse imaging revealed regular 
formation of TNTs by proliferating and migrating mesothelioma cells advancing to fill 
the gap [216]. This finding introduces the possibility that TNTs facilitate intercellular 
communication and the progression of malignancy at the leading edge of invasive 
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mesothelioma tumors. More recently, we showed that exosomes and TNTs may work 
synergistically by demonstrating that exogenous tumor exosomes induced an increased 
rate of TNT formation [217].  Electron microscopy revealed that exosomes were located 
at the base of TNTs and in the extracellular environment.  Our subsequent studies 
identified enrichment of lipid rafts, small intra-cytoplasmic cholesterol microdomains, in 
mesothelioma cells connected via nanotubes [217]. These findings implicate exosomes as 
potential chemotactic stimuli for TNT formation and lipid rafts as a potential biomarker 
for TNTs. The effects of TNT formation and TNT-mediated transport of cellular cargo on 
malignant cell behavior are currently unknown.  
In the current study, we sought to further characterize the properties of TNTs in 
mesothelioma, including differences in formation of TNTs between malignant 
mesothelioma cells and non-malignant mesothelial cells; quantitative differences in TNT 
length in relation to cell proliferation; properties of TNT formation in clinically relevant 
models, such as between non-adherent cells, mimicking the scenario of mesothelioma 
cells floating in peritoneal or thoracic effusions as a hallmark of malignant progression; 
and structural components of TNTs in mesothelioma cells. Finally, we also sought to 
develop new approaches to 3-dimensional in vitro and in vivo modeling for the study of 
TNTs in tumor propagation and resistance to therapy.  
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2.3 Methods 
 
Cell lines and culture media 
MSTO-211H cells were derived from a patient with biphasic mesothelioma (ATCC no. 
CRL-2081); VAMT is a sarcomatoid mesothelioma cell line; and H2052 is a 
mesothelioma cell line of epithelioid histology. All three mesothelioma cell lines 
(MSTO-211H, VAMT, and H2052) were passaged using 10% fetal bovine serum (FBS) 
in RPMI-1640 with 25 mM glucose, supplemented with 1% penicillin-streptomycin (P-S) 
and 2% L-glutamine, at normal pH (7.6). The normal immortalized human mesothelium 
cell line MeT5A was passaged in 10% FBS in M199/MCDB105 (1:1) with 100 U/ml 
penicillin-streptomycin and 2% L-glutamine. All cell lines used in this study were 
authenticated by the Core Fragment Analysis Facility at Johns Hopkins University using 
short tandem repeat profiling. Cells were passaged in 75 cm
2
 tissue culture flasks 
(Falcon, Becton Dickson, Oxnard, CA) at 37°C in 5% CO2. Nanotube formation was 
stimulated by growing cells in 2.5% FBS in RPMI-1640 containing 50 mM glucose, 
supplemented with 1% P-S and 2% L-glutamine as described previously [200]; we refer 
to this combination throughout the text as “TNT medium”.  For 3-dimensional in vitro 
modeling, we mixed MSTO-211H cells in 5% FBS in RPMI medium containing 100mM 
glucose in a 1:1 ratio with 2% agarose to compose a final medium composed of 1% 
agarose and TNT medium for further culture of cells. These cells were then added to 6-
well culture plates for microscopic examination. 
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Quantification of TNTs per cell 
Three MPM cell lines (H2052, VAMT, and MSTO-211H) and one benign mesothelial 
cell line (MeT5A) were plated at a density of 6 x 10
4
 cells/well in 6-well adherent tissue 
culture plates (Fisher Scientific, Pittsburgh, PA) at 37ºC in 5% CO2 with TNT-inducing 
medium (described above).  TNTs were identified using the parameters described by 
Rustom et al. [129] as well as in our previous publications [216].  Briefly, these 
parameters included (i) lack of adherence to the substratum of tissue culture plates, 
including visualization of TNTs passing over adherent cells; (ii) TNTs connecting two 
cells or extending from one cell were counted if the width of the extension was 
appropriately narrow and estimated to be <1000 nm in width; and (iii) a narrow base at 
the site of extrusion from the plasma membrane. Cellular extensions not clearly 
consistent with the above parameters were not included in the final count. An Olympus 
IX70 inverted microscope (Olympus Corporation) with 20× objective lens was used to 
count the number of TNTs and cells in 10 randomly chosen fields of each 6-well plate at 
24, 48, and 72 hrs. A single representative image was taken at all time points for each 
well for analysis of TNT length. Experiments were performed in duplicate for each cell 
line.  The number of TNTs per cell (TNTs/cell) was counted to exclude the possibility 
that increases in TNTs were due to increased cell proliferation. Means were calculated 
and compared using two-sided, two-tailed t-tests assuming unequal variances.  P-values 
<0.05 were considered statistically significant. 
 
Quantification of TNT length 
33 
 
Representative images taken from the previous experiment were analyzed using ImageJ 
software. TNT length was measured by normalizing the 200 micron scale bar from the 
images to the number of pixels. The length of TNTs from each cancer cell line was 
measured at 24, 48, and 72 hours. TNT lengths were not normally distributed; therefore, 
Wilcoxon Rank Sum tests were used to compare TNT lengths for each combination of 
time measurements within each cell line.  P-values <0.05 were considered statistically 
significant.   
 
TNT tethering assays 
Pleural effusion or ascites specimens from cancer patients with malignant pleural 
mesothelioma and lung adenocarcinoma were obtained via a Memorial Sloan-Kettering 
Cancer Center (MSKCC) Institutional Review Board (IRB)-approved protocol.  Informed 
written consent was obtained from all patients, and patient identifiers were removed to 
ensure anonymity.  Malignant cells were histologically confirmed by an experienced 
MSKCC pathologist and seeded in standard tissue culture-treated plates using a clonal 
dilution assay. Cells were seeded in 24-well non-adherent culture (Nunc Non-Treated 
Multidishes) and adherent treated tissue culture plates (Fisher Scientific, Pittsburgh, PA) 
using 10% FBS RPMI. Microscopic imaging was used to confirm the presence of single 
cells per well, and these wells were marked and monitored daily by microscopic imaging. 
We additionally performed similar experiments with mesothelioma cell lines VAMT, 
H2052, and MSTO-211H using an identical approach. 
Fixation and sample preparation 
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To prepare cells for IF staining, cells were cultured in one- or two-well sterile tissue 
culture-treated chamber slides (Lab-Tek II Chamber Slide™ system, Nunc, Rochester, 
NY) or on sterile poly-L-lysine (1 mg/ml; Sigma) coated glass coverslips (VWR 
VistaVision, catalog no. 16004-312) for 48–72 hours using TNT medium to stimulate 
TNT formation. As TNTs are highly sensitive to movement and to light, we have 
modified existing protocols for cell fixation and analysis. To perform fixation and 
prevent disruption of existing nanotubes, 16% w/v paraformaldehyde (PFA) (Alfa Aesar, 
Ward Hill, MA) was added along the sides of the chambers or the dishes with glass 
coverslips, keeping the overlying culture medium intact to a final w/v concentration of 
4%, After incubation at 4°C for 1–2 hours, the fixative and chambers were removed, and 
slides were allowed to air dry. We have found this combination provides optimal 
preservation of intact cells with TNTs to allow for more accurate study of these thin 
structures. Immunofluorescent staining was then performed to detect expression of the 
noted proteins. 
 
Immunofluorescent staining 
The primary antibodies and their working concentrations are as follows: cdc42 (Santa 
Cruz Biotech, 200 ug/ml, rabbit polyclonal IgG; catalog no. SC-87); NF2/merlin (Santa 
Cruz Biotech, 200 ug/ml, rabbit polyclonal IgG; catalog no. SC-332), p-selectin (CD62P) 
(BD Biosciences, 5 µg/ml; catalog no. 556087), beta-tubulin (Sigma-Aldrich, monoclonal 
anti-acetylated tubulin, clone 6-11B-1; catalog no. T6793-0.2ML); monoclonal anti-β-
Tubulin IV (Sigma-Aldrich, catalog no. T7941, clone ONS.1A6); vimentin Alexa Fluor 
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488 (BD Pharmingen, human IgG; catalog no. 562338), Akt (Sigma-Aldrich, rabbit 
polyclonal IgG; catalog no. AAB4300259-100UG). Slides were first blocked with 
blocking solution (10% normal goat serum/2% BSA in PBS) or mouse IgG blocking 
agent from Vector Labs (catalog no. MKB-2213) for 30 minutes. Primary antibody 
incubation lasted 3 to 7 hours at room temperature, followed by 30 minutes incubation 
with biotinylated secondary antibodies (Vector Labs, MOM Kit BMK-2202; 1:200 
dilution). Detection was performed with Streptavidin-HRP D (Ventana Medical Systems) 
followed by Tyramide-Alexa Fluor 488 (Invitrogen, catalog no. T20922). 
 
Drug treatment of cells with migrastatin  
Migrastatin core ether is a synthetic analog of migrastatin obtained courtesy of Dr. 
Samuel Danishefsky; it was used at 100 nM.  MSTO-211H cells were prepared as above 
(ie, 1 x 10
5
 cells per well in 24-well tissue culture plates).  The number of TNTs was 
counted in 10 fields per medium condition, at regular time intervals (0, 24, 48, and 72 
hours) using a 20x objective lens on a Nikon Eclipse Ti inverted microscope (Nikon 
Instruments, Inc.). Experiments were performed in duplicate.  Means were calculated and 
compared using two-sided, two-tailed t-tests assuming unequal variances. P-values <0.05 
were considered statistically significant. 
Treatment of cells with other drugs (tunicamycin, dextran sulfate, 4-
methylumbelliferone) to assess potential association of hyaluronan with TNTs 
 
Treatment of cells with other drugs (tunicamycin, dextran sulfate, 4-
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methylumbelliferone) to assess potential association of hyaluronan with TNTs 
Tunicamycin (Sigma, catalog no. T7765-1MG, lot no. CAS 11089-659) was used at a 
final concentration of 5 µg/ml; Poly I:C (Polyinosinic–polycytidylic acid sodium salt; 
Sigma, catalog no. P0913-10MG, lot no. CAS 42424-50-0) was used at a final 
concentration of 10 µg/ml; dextran sulfate (Sigma, catalog no. D8906-5G) stock solution 
was made by first dissolving in 2% FBS in phosphate-buffered saline (PBS) to create a 
stock solution of 100 µg/ml, which was then added to culture medium to final 
concentration 10 µg/ml; 4-methylumbelliferone (4-MU; Sigma, catalog no. M 1381) was 
prepared as a stock solution 20 mg/ml concentration in DMSO, then added to culture 
medium to final concentration 1.0 mM; Hyaluronidase (Sigma, H3884) was prepared as a 
stock solution of 10 mg/ml and used at a final concentration of 13 µM. For preparation of 
each drug, stock solution was added to 10% FBS RPMI-1640 medium to obtain final 
concentrations as listed; this medium was used in cell culture by adding to 1 x 10
4
 
MSTO-211H cells per well of 6-well tissue-culture treated plates (Fisher Scientific, 
Pittsburgh, PA). Following 48 hours of incubation at 37ºC (5% CO2), exclusion assays 
were performing by adding either U937 mononuclear cells at 4ºC for 1 hour or red blood 
cells (erythrocytes) as noted in the Results section and per standard protocols [218], 
[219], followed by microscopic imaging. For fluorescent imaging, MSTO-211H cells 
transfected with a lentivirus expressing green fluorescent protein (GFP) were used along 
with U937 cells transfected with a lentivirus expressing Tomato Red. 
 
In vivo growth of mesothelioma cells preconditioned with TNT medium 
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GFP-luciferase expressing MSTO cells were grown in either of two conditions: normal 
RPMI (10% FBS RPMI, 25 mM glucose) or TNT-inducing medium, which consists of 
low serum and high glucose RPMI (2.5% FBS RPMI, 50 mM glucose), for 7 days. Both 
sets of media were supplemented with 1% penicillin/streptomycin and 2% L-glutamine. 
All cells were cultured in 6-well adherent tissue culture plates (Fisher Scientific, 
Pittsburgh, PA) at 37°C in 5% CO2. Cells (2.9 x 10
5
) were then suspended in 100 µL of 
RPMI and injected into the peritoneum of each mouse. Ten NOG (NOD/Shi-SCID/IL-
2RƔnull) immunodeficient mice were used for each group.  Each mouse was concurrently 
injected intraperitoneally with 1 ml of thioglycolate as a co-stimulatory inflammatory 
agent; the rationale for this is that inflammation is known to elicit formation of nanotubes 
in in vivo animal models [220]. On days 7, 14, 21 and 31 post-tumor inoculation, mice 
were anesthetized with isoflurane and injected intraperitoneally with 150 μL of luciferin 
(15 mg/mL). Mice were then imaged with an Ivis 200 optical imaging system (Caliper 
Life Sciences, Hopkinton, MA) five minutes after injection. Capture time was 40 
seconds. Living Image software version 2.5 was used to quantify average radiance 
(p/s/cm2/sr).  Means were calculated and compared using two-sided, two-tailed t-tests 
assuming unequal variances.  Overall survival (OS) of the mice was calculated from date 
of tumor inoculation to date of death, or censored at 40 days for those still alive at the end 
of the experiment.   OS was summarized using a Kaplan-Meier curve and a comparison 
between groups was made using a Log-Rank test.   P-values <0.05 were considered 
statistically significant. 
Sectioning, staining, and imaging human tumor samples 
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Tumor specimens from patients with malignant pleural mesothelioma were obtained via a 
Memorial Sloan-Kettering Cancer Center (MSKCC) Institutional Review Board (IRB)-
approved protocol.  Informed written consent was obtained from all patients, and patient 
identifiers were removed to ensure anonymity. Resected intact tumor specimens were 
placed in phosphate-buffered saline (PBS). Vibratome sections (100–300 mm thick) were 
cut and stained using Hoechst 33342 (10 mg/ml) and MitoTracker Red dyes (500 nM) 
using protocols we developed and have described previously [216]. Stained sections were 
mounted between two glass coverslips and imaged on a confocal microscope. 
 
Optical imaging of human tumor samples and image processing 
Confocal imaging of samples was performed using Zeiss LSM 5Live line-scanning or 
Leica SP2 point-scanning microscopes using Zeiss oil 406/1.3NA Plan-Neoflur, Zeiss oil 
636/1.4NA Plan-Apochromat or Leica water 636/1.2NA HCX PL APO CS objectives. 
Serial z-stack images were obtained at optimal step size and maximum intensity 
projection images were produced. The Imaris Viewer program (Bitplane Scientific 
Software, Inc.) was used to construct and visualize 3-dimensional images of tumor 
samples. Metamorph (Molecular Devices) image analysis software was used to create 
still images and movies. 
 
Electron-Microscopic Imaging of Nanotubes 
To perform scanning and transmission EM, 1-3 x 10
6
 MSTO-211H cells were cultured on 
Thermanox plastic tissue culture 25 mm cover slips (Lux Scientific Corporation).  The 
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fixative – 2.5% glutaraldehyde/2% paraformaldehyde in 0.075 M sodium cacodylate 
buffer (pH 7.5; 10 ml, Electron Microscopy Sciences, Hatfield, PA) – was added directly 
to the overlying medium.   
 
Cell culture and RNA isolation 
MSTO-211H cells (8 x 10
5
) were seeded in 150 cm
2
 flasks and grown for 7 days using  
passage medium or TNT medium at 37°C in a standard humidified chamber with 5% 
CO2 as already described in the text. After 7 days, the cells were harvested separately 
following trypsinization and subjected to RNA isolation using mirVana
TM
 total RNA 
isolation protocol following the protocol of the manufacturer (Life Technologies, 
Carlsbad, CA). RNA preparation was quantified on a Nanodrop spectrophotometer 
(Thermo Fisher, Wilmington, DE, USA), and RNA quality was confirmed by resolving 
on a denaturing 1.2% agarose gel following standard electrophoresis protocol.  
 
cDNA synthesis and qRT-PCR 
RNA was subjected to first strand cDNA using miScript II Reverse Transcription kit 
(Qiagen, Valencia, CA). Total RNA was reverse transcribed for 2 hrs at 37°C, and 
reverse transcriptase was heat inactivated by boiling the reaction mix at 95°C for 5 
minutes.  cDNA (5.0 ng) was diluted and amplified with 10µl of miScript SYBR green 
PCR mix following the protocol of the manufacturer using gene-specific forward and 
reverse primers. PCR primers were purchased from a commercial vendor (IDT, 
Coralville, IA). The nucleotide sequence of the primers used are listed in Supplementary 
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Table 1. The samples were run in triplicate in a Roche Light Cycler II (Roche GmbH, 
Germany), and values were normalized to the endogenous expression of 18S rRNA.  Fold 
gene expression was calculated by comparative C(T) method [221] and mean fold 
expression values relative to expression in control medium were compared using two-
sided two-sample t-tests assuming unequal variances.  P-values <0.05 were considered 
statistically significant. 
 
Time-lapse imaging of live samples 
Time-lapse imaging experiments were performed on Perkin Elmer UltraView ERS 
spinning-disk confocal microscope or Zeiss LSM 5Live line-scanning confocal 
microscope.  Both microscopes were enclosed in environmental chambers that were 
maintained at 37°C with 5% CO2 level. Viable Staining of Cell Lines for time-lapse 
imaging was performed as we have described previously [171]. Briefly, in order to assess 
the ability of mitochondria to be transmitted between mesothelioma cells via TNTs, we 
used MitoTracker Red to stain MSTO-211H cells which were then cultured in 
hyperglycemic, low-serum (“TNT”) medium.  The cells were cultured in clear-bottomed 
delta-T culture dishes (Bioptechs Inc., Butler, PA). MitoTracker Red CMX Ros 
(Invitrogen, M-7512, 50 µg/vial) was used at 500 nM to stain mitochondria, per 
manufacturer’s protocols. Stained cells were re-suspended and added to a non-confluent 
culture of adherent, unstained MSTO-211H cells grown in another dish.  Incubation was 
performed in high glucose medium for five hours to stimulate formation of TNTs prior to 
imaging.  
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2.4 Results 
 
Malignant mesothelioma cells form more TNTs than benign mesothelial cells 
We propose that TNTs create intercellular networks with the capability of transmitting 
signals that stimulate proliferation of invasive cancers. To determine whether TNT 
formation occurs at a higher rate in malignant mesothelioma cells than in benign cells, we 
cultured the MPM cell lines H2052, VAMT, and MSTO-211H and the benign 
mesothelial cell line MeT5A.  Cells were cultured in medium that we previously 
demonstrated induces TNT formation [216]. Equivalent numbers of cells were added to 
culture wells and visualized using inverted microscopy at 24, 48, and 72 hours; 
representative images are shown in the accompanying figures (Figure 1A; also 
Supplemental Figure S1 for composite panel of representative images at 24, 48, & 72 
hours). At each time point, we randomly selected ten fields of view using the 20x 
objective and counted the number of TNTs per field. We also counted the number of cells 
present in each selected field to control for cellular proliferation. For all three malignant 
mesothelioma cell lines, the average number of TNTs/cell was significantly higher than 
that seen for the benign mesothelial MeT5A cell line (Figure 1B). No evidence of TNT 
formation was evident in the mesothelial cell line (MeT5A) at 24 hours, and thus a ratio 
could not be reported. As expected, cell proliferation was higher in malignant 
mesothelioma cell lines as compared to normal MeT5A cells (Figure 1C); however, 
among malignant cells proliferation appeared to be inversely associated with the rate of 
TNT formation. The ratio of malignant:mesothelial TNTs/cell doubled or tripled from 48 
to 72 hours for all malignant cell lines (26.73 to 78.16 for H2052, 9.80 to 42.66 for 
42 
 
VAMT, and 9.80 to 18.84 for MSTO) (Figure 1D).  Taken together, these in vitro data 
show that TNTs formed at a markedly higher rate among malignant mesothelioma cell 
lines than among normal mesothelial cells in inverse proportion to the rate of cell 
proliferation, ranging from nearly 20-fold to 80-fold higher by 72 hours of in vitro 
culture.  Moreover, these data support the use of a "nanotube index" to quantitatively 
assess TNT formation in future studies of the biological role of TNTs in aggressive 
malignancies. This markedly higher rate of TNT formation in mesothelioma, and likely in 
other cancers as well, provides evidence to support TNTs as a potential novel target for 
selective therapy of such cancers.  
 
Overall TNT length decreases with time and with proliferation of mesothelioma 
cells 
In the context of a heterogeneous tumor matrix, TNTs may play an important role in 
long-distance cellular communication. To accomplish this, TNTs would need to extend to 
variable lengths depending on the distance of targeted cells. As more cells accumulate, 
this distance would become shorter. We hypothesized that TNT length would decrease as 
cells proliferate and accumulate over time in in vitro culture. We cultured the MPM cell 
lines H2052, VAMT, and MSTO-211H and the mesothelial cell line MeT5A. TNT length 
decreased over time among all malignant cell lines (Figure 2); these changes were 
statistically significant at most time points (Table 1). TNT length decreased slightly from 
day 2 to day 3 among the non-malignant MeT5A cells (Figure 2A); however, this change 
was not statistically significant. We depict the data in the form of box plots in order to 
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demonstrate the median and the wide range of lengths we observed in the malignant 
mesothelioma cell lines(Figure 2). Since TNT formation between MeT5A cells was rare, 
it was not possible to construct box plots for the distribution of TNT length over the 
three-day period for this non-malignant cell line.  The decrease in TNT length observed 
among malignant cells was most noticeable for H2052 and VAMT cells, but was less 
dramatic for MSTO cells. This difference could be due to the relatively steady rate of 
proliferation of H2052 and VAMT cells and high proliferation rate of MSTO cells 
(Figure 1C). In addition, this finding is consistent with our prior study showing that TNTs 
are most prominent in sub-confluent cultures; in fully confluent cultures, cells are in close 
proximity, making it either difficult to discern any present TNTs and/or decreasing the 
number of TNTs that form in conditions that do not require long-distance connections 
[216].  
 
TNT tethering of mesothelioma cells in in vitro model of pleural effusions 
We next obtained pleural effusion specimens from 5 patients diagnosed with malignant 
pleural mesothelioma or lung adenocarcinoma. After isolating malignant cells via 
centrifugation of pleural effusions, we confirmed the presence of malignant cells by 
morphology and TNT formation among these cells by inverted as well as by scanning 
electron microscopy (Figure 4A). We then cultured cells in vitro in standard tissue 
culture-treated plates and confirmed formation of TNTs connecting these patient-derived, 
primary malignant cells (Figure 4B-C).  
We noted that malignant cells presented in effusions as dispersed single cells or as 
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spheroid aggregates that could be disassembled into single cells through trypsinization or 
by physical separation with vigorous pipetting. We hypothesized that clusters of cells 
derived from a single parent cell could form TNTs in suspension and without full cell 
adherence to the substratum of the culture plate. To investigate this possibility, we 
performed separate clonal dilution assays using VAMT and H2052 cell lines cultured in 
24-well non-adherent culture plates. We visually confirmed the presence of single cells 
and marked these wells for further daily follow-up. We performed daily microscopic 
imaging and reproducibly detected growth of groups of cells derived from parent cells 
forming mesh-like syncytial networks of TNTs connecting daughter cells. Cell 
aggregates formed prominently under non-adherent culture conditions while maintaining 
extensive TNT connections; these aggregates were in many instances connected to each 
other by nanotube structures while remaining suspended in culture medium (Figure 4D-
E; also Supplemental Figure S2). 
These data suggest that TNTs may play a role in tethering suspended, non-adherent cells. 
As development of pleural effusions or abdominal ascites is a hallmark of a number of 
aggressive solid tumor malignancies – most especially malignant pleural and peritoneal 
mesotheliomas, as well as lung adenocarcinomas – these results provide potential insight 
into the cellular behavior of malignant cells at the advanced stages of cellular invasion. 
They also build upon our work demonstrating TNT formation between primary malignant 
mesothelioma cells in vitro [216] as well as similar work demonstrating TNTs between 
human peritoneal mesothelial cells in culture [212]. Further in vivo studies will be 
necessary to clarify whether such TNT connections occur among malignant pleural or 
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peritoneal mesothelioma cells invading the mesothelial lining.  
 
Drug inhibition of mesothelioma TNTs using migrastatin, an inhibitor of fascin 
We previously demonstrated that fascin localizes at the site of TNT extrusion from the 
plasma membrane at the leading edges of cells [216].  To determine whether fascin 
inhibition blocks TNT formation, we used migrastatin core ether (ME), a drug derived 
from migrastatin, a polyketide product initially derived from Streptomyces [222]. 
Synthetic analogs of migrastatin inhibit migration of cancer cells by targeting fascin and 
thereby blocking tumor progression [223]. MSTO cells treated with ME exhibited a 
statistically significant difference with fewer TNTs, compared with the Control group 
without drug treatment, at 24 hours (p=0.036) and at 72 hours (p=0.010) (Figure 5). 
There was not significant difference at the 48-hour timepoint.  
 
Three-dimensional in vitro model of mesothelioma tumor microenvironment 
Routine use of 3-dimensional modeling both in vitro and eventually in vivo will be 
critical to advancing the field of TNT biology, in cancer and in other diseases. To 
develop a 3-dimensional in vitro model of the tumor microenvironment, we used 1% 
agarose to culture mesothelioma cells to simulate suspension of cells within a 3-D 
viscous matrix. TNTs visualized in the 3D matrix were readily seen forming TNTs 
vertically and horizontally within the agarose matrix as compared to 2D tissue culture 
(standard tissue culture in Figure 6A; with TNT medium in 1% agarose, Figure 6B). 
Additionally, z-stacked confocal imaging of TNTs connecting cells stained with 
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immunofluorescent antibodies can be used to visualize TNTs 3-dimensionally. Using this 
technology, we depicted a representative TNT stained with an immunofluorescent 
antibody to vimentin (Figure 6C; Movie S2, depicting rotating 3-dimensional model of 
this image). Immunofluorescence staining indicated the presence of vimentin along the 
length of TNTs.  
In the case of solid tumor malignancies, including mesothelioma, standard and 
conventional evaluation of tumors involves histopathologic analysis of extremely thin 2-
dimensional tumor sections (Figure 7A). While slides prepared in this manner may 
potentially yield views of putative nanotube-like structures, advances in microscopic 
imaging are required to more effectively study 3-dimensional tumors. Advances in 
microscopic imaging that allow for layered z-stacked images of cells in vitro and 
methods we have developed to image ex vivo tumors provide an enhanced approach that 
allows for more advanced analysis of nanotubes connecting malignant cells in the stroma-
rich tumor microenvironment (Figure 7B-C; Also see Supplemental Online Video S5). 
These visually detailed 3D images of mesothelioma cells provide further impetus for 
studying TNTs in this manner in vitro.  
 
Hyaluronic acid is not associated with TNTs 
Hyaluronic acid (HA), or hyaluronan, is a well-studied glycosaminoglycan that is 
secreted into the extracellular matrix; increased production of HA induces increased cell 
motility and an invasive phenotype in mesothelioma [223]. Hyaluronan receptors are 
expressed preferentially on malignant mesothelioma cells but not on normal mesothelium 
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[224]. However, normal mesothelial cells and malignant cells derived from several organ 
sites synthesize relatively high quantities of hyaluronan, whose pericellular coat 
comprises bunches of short, adherent membranous protrusions consistent with actin-
based stress fibers and microvilli [219], [225]. These coats create zones that have been 
well-described and are readily visualized microscopically using erythrocyte exclusion 
assays or the equivalent [219], [226]. Conditions of cellular stress induced by either 
hyperglycemia, viral mimetic agent poly I:C, tunicamycin, or dextran sulfate, to name 
just several examples, have been shown to induce increased hyaluronan production and 
hyaluronan-based cellular ‘cables’ that induce monocyte adhesion in vitro [225]; 
tunicamycin and dextran sulfate in particular induce endoplasmic reticulum-related 
metabolic stress that leads to increased production of hyaluronic acid, which in turn 
attracts and leads to increased adhesion of leukocytes via surface binding of CD44 [227]–
[230]. In our earliest studies examining what we later confirmed to be TNTs in 
mesothelioma, we performed standard exclusion assays using primary red blood cells 
(erythrocytes) or U937 lymphocyte (mononuclear) cells [219], [225], but found no visual 
evidence of either pericellular zones or monocyte adhesion to TNT structures, indicating 
that TNTs were unlikely to harbor a significant amount of hyaluronan externally, also 
demonstrating that these entities are distinct from hyaluronan cables (Figure 8; 
Supplemental Figure S3). For fluorescent imaging and confirmation, we used MSTO-
211H cells transfected with a lentivirus expressing green fluorescent protein (GFP) which 
we have used and described previously [200] along with U937 cells transfected with a 
lentivirus expressing Tomato Red. To convincingly confirm that the extensions 
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connecting cells were indeed TNTs, we performed time-lapse imaging that visibly 
demonstrated intercellular transfer of GFP (Supplemental Movies S3 and S4). 
We also applied the HA-stimulating drug tunicamycin (final concentration 5 µg/ml) to 
MSTO cells in culture and examined these cells every 24 hours up to 96 hours. However, 
this led to no changes in TNT formation or morphology. Likewise, separate addition of 
dextran sulfate (10 µg/ml) to MSTO cells in culture led to cellular aggregation not unlike 
aggregates seen in patient effusion samples (Supplemental Figure S4). Poly I:C (10 
µg/ml) induced a transformation of MSTO cells into a more mesenchymal, spindle-cell 
morphologic appearance without alteration of TNTs. This finding is consistent with 
similar effects of this drug on stimulating EMT in other cell types [231]. We further 
treated MSTO cells with 4-methylumbelliferone (1.0 mM), an inhibitor of hyaluronan 
synthase and thus of hyaluronan cables (HAS) [220], [232]; in separate well we also 
assessed potential effects of  the enzyme hyaluronidase (13 µM); neither drug had any 
effect on TNTs, consistent with the above data indicating HA does not play a notable role 
in TNT formation or maintenance (Supplemental Figure S4).  
 
Decreased tumor growth in mice implanted with TNT-primed mesothelioma cells 
also corresponds with decreased survival 
Animal studies have identified nanotubes or similar structures in vivo in an inflammatory 
corneal mouse model [233], [234] and ex vivo in adult mouse heart tissue [235], mouse 
alveoli [236], rabbit kidney parenchyma [234], and mouse embryo non-neural ectoderm 
[173]. Our group was the first to image TNTs in resected human tumor samples, initially 
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on tumors from patients with MPM and lung adenocarcinoma  [200]; we have been able 
to reproduce this finding using human mesothelioma tumors described in the current 
study (Supplemental Movie S5). Our group has further extended demonstration of 
nanotube structures in malignant human ovarian tumors as has another group [237]. 
However, the technical difficulties of imaging nanotubes in the in vivo setting remain 
highly challenging. To assess effects of TNTs on in vitro cell proliferation, we used 
MSTO cells pre-conditioned in culture medium that we previously demonstrated 
increases the rate of TNT formation in vitro [216]. We conditioned MSTO cells in either 
low serum, hyperglycemic (2.5 % FBS, 50 mM glucose) RPMI medium (referred to as 
“TNT medium”) or control passage RPMI medium (10% FBS, 25 mM glucose) for 7 
days. This experiment demonstrated that proliferation of MSTO cells in low-serum, 
hyperglycemic medium was approximately half that of cells cultured in passage medium 
by 72 hours (Figure 9A). To next examine the effect of TNTs on tumor growth in vivo, 
we used a NOG xenograft mouse model of malignant mesothelioma. We conditioned 
MSTO cells transfected with a lentivirus expressing luciferase in either TNT medium or 
control passage RPMI medium (10% FBS, 25 mM glucose) for 7 days.  We then injected 
these cells into the peritoneal cavity of NOG immunocompromised mice. Mice were 
bioimaged every 7 days up to 31 days and the average radiance was measured; 
interestingly, by 31 days the mice injected with cells pre-conditioned in low-serum, 
hyperglycemic medium had developed less tumor burden than mice injected with the 
same cell line pre-conditioned in passage medium (Figure 9B).  Thus, this in vivo finding 
mirrored the in vitro studies that demonstrated that proliferation of MSTO cells in low-
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serum, hyperglycemic medium was approximately half that of cells cultured in passage 
medium. Moreover, none of the NOG mice injected with control medium (n=10) had 
died by day 31, but 2 mice injected with cells pre-conditioned in low serum, 
hyperglycemic medium (n=10) had died by day 31 and an additional one died just after 
imaging (p=0.067, Figure 9C); in a separate experiment repeating this approach, 5 of 10 
mice with injected cells pre-conditioned in TNT medium died by Day 31, whereas 0 of 
10 died by that day (data not shown).  Using weight as a surrogate measure for morbidity, 
mice injected with cells primed with TNT medium displayed a sharper drop in weight 
over time than did mice injected with cells cultured in passaged medium (data not 
shown).  Bioimages demonstrating the visual differences between the two groups are 
shown (Figure 9D). These in vivo findings set the stage for further evaluation of the 
potential role for TNTs in solid tumor malignancies, possibly by increasing the 
locoregional but not distant invasive capability of mesothelioma cells, with a mechanism 
independent of cell proliferation.  
 
Gene expression profiling of TNT-primed mesothelioma cells 
Due to the above findings, we next sought to determine relative differences in gene 
expression between MSTO cells conditioned in low serum, hyperglycemic (2.5 % FBS, 
50 mM glucose) RPMI medium (ie, “TNT medium”) or control passage RPMI medium 
(10% FBS, 25 mM glucose).  We first investigated RNA levels of M-Sec (which is also 
called TNFaip2, or tumor necrosis factor-α-induced protein 2) and leukocyte specific 
transcript 1 (LST1), two gene products that are known to be enriched in TNTs [204], 
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[234]. Both genes were significantly upregulated in MSTO cells cultured in TNT medium 
compared to control medium (Figure 10A). We then investigated whether TNT medium, 
which is significantly lower in essential nutrients and also includes low percent of added 
serum (2.5% FBS) relative to passage medium (10% FBS), affect genes that promote cell 
cycle progression [238], [239]. RNA levels of E2F1, its downstream targets CCNA2 and 
CDC20, and CDKN3 were significantly lower in MSTO cells grown in TNT medium 
than in cells grown in control medium (Figure 10B). This finding is consistent with our 
observation that cells grown in TNT medium undergo a lower rate of cell division.  We 
next studied whether key genes involved in cellular migration, invasion, and metastasis 
are altered in mesothelioma cells cultured in TNT medium [200], [240]–[244]. Relative 
to the MTSO cells grown in normal medium, tenascin-C, CD44, osteopontin, fascin, and 
mesothelin were all significantly induced in MSTO cells grown in TNT medium (Figure 
10C). Further studies will evaluate whether induction of these genes in cells grown in 
TNT medium induce an adaptive gene expression profile leading to TNT formation and a 
higher propensity to invade, migrate, and metastasize.  
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2.5 Discussion 
 
Intercellular communication between cancer cells is crucial to the progression of invasive 
cancers, but the mechanisms by which communication occurs between distant and 
proximal cells in a tumor matrix remains poorly understood.  TNTs are a novel candidate 
to explain how this communication process occurs [20].  Our prior and current work have 
consistently demonstrated TNTs in malignant mesothelioma and lung adenocarcinoma 
tumors from human patients [216]. This observation is consistent with the finding of 
another group that successfully imaged membrane nanotubes in vivo using an 
inflammatory cornea animal model [245]. We have further demonstrated that TNTs are 
not exclusive to malignant mesothelioma and lung adenocarcinoma, but can form 
between malignant cells from a wide variety of histologic cancers, including pancreatic 
cancer as one example [246].  In the present study, we describe our approaches to 
studying the relevance of TNTs in invasive malignancies, specifically in the context of 
malignant pleural mesothelioma. 
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Figure 2.1
 
Figure 2.1. Malignant mesothelioma cells form more TNTs than benign mesothelial 
cells. An Olympus IX70 inverted microscope with 20× objective lens was used to count 
the number of TNTs and cells in 10 randomly chosen fields at 24, 48, and 72 hrs. 
Representative images of TNTs of three malignant mesothelioma cell lines (H2052, 
VAMT, MSTO-211h) and a benign mesothelial cell line (MeT5A) were evaluated and 
are shown (A). The number of TNTs per cell (TNTs/cell) was counted (B) to exclude the 
possibility that increases in TNTs were due to increased cell proliferation (C). 
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Experiments were performed in duplicate for each cell line and results were averaged.  
Means +/- standard errors are plotted.  Double asterisks indicate statistically significant 
differences (p < 0.05) between each mesothelioma cell line compared to the mesothelial 
cell line; single asterisks indicate statistically significant differences between timepoints 
within each malignant mesothelioma cell line. 
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Figure 2.2. 
 
 
Figure 2.2. TNT length decreases with time and with proliferation of mesothelioma 
cells. Microscopy images were taken of cells forming TNTs at 24, 48, and 72 hours. 
Images were representative of the 10 randomly chosen fields from Figure 1. Average 
TNT length was estimated through measurement of image pixels. Box plot depicts 
distribution of lengths of TNTs in the malignant mesothelioma cell lines. Symbols on the 
boxplot are as follows: Box = 1st to 3rd (Q1-Q3) Quartiles. Diamond = Mean.  Line 
inside box = Median. Circle = Outlier.    
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Figure 2.3. 
 
Figure 2.3. TNT tethering of mesothelioma cells in in vitro models of pleural 
effusions.  
A. Scanning electron micrograph of two separate mesothelioma cells tethered by a 
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nanotube. B-C. TNTs connecting primary malignant cells from pleural effusions.  40X 
magnification. D-E. Clonal dilution assay using VAMT (sarcomatoid mesothelioma) 
cells grown in a low-adherence culture plate using 10% FCS RPMI medium; cells are 
shown on day 24 of culture in separate wells from the same plate. 
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Figure 2.4.   
 
Figure 2.4.  Effect of Migrastatin on TNT formation in MSTO cells. Migrastatin was 
used at 100 nM. TNTs were counted in ten fields per timepoint per condition using 20x 
objective lens, and the results averaged. Experiments were performed in duplicate. 
Comparisons between Migrastatin and the Control were statistically significant at 24 
hours (p=0.036) and at 72 hours (p = 0.010). Means ± standard deviations are presented. 
Asterisk indicates statistical significance (p < 0.05). 
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Figure 2.5. 
 
 
Figure 2.5. 3-dimensional modeling of TNTs in vitro. (A) MSTO cells forming TNTs 
in regular tissue culture treated plate; (B) MSTO cells cultured in 1% agarose, forming 
TNTs vertically as well as horizontally within the agarose matrix. (C) 3-dimensional 
modeling of TNT connecting cells using confocal imaging with z-stacking (IF staining 
performed using fluorescent vimentin-specific antibody); also see Supplementary Movie 
S2. 
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Figure 2.6. 
 
Figure 2.6. Comparison of 2-dimensional histopathology section vs. 3-dimensional 
confocal imaging of primary human malignant mesothelioma tumors ex vivo, with 
specific examination for TNTs. (A) Hematoxylin and eosin (H&E) staining of sectioned 
primary human mesothelioma tumor; arrowheads indicate putative nanotube-like 
structures; (B) and (C) compiled confocal image produced by combining individual z-
stacked images of representative portions of tumor tissue resected from a human patient. 
Tumors were stained with MitoTracker and Hoechst 334 dye; arrowheads indicate 
nanotube structures. Please also see Supplemental Movie S5. 
  
61 
 
Figure 2.7. 
 
 
Figure 2.7. Hyaluronic acid is not associated with TNTs. U937 mononuclear cells 
(expressing Tomato Red) were added to cell culture growing MSTO-211H cells 
(expressing GFP) with TNTs. A) Brightfield and B) Fluorescent views of the same field 
of view are shown. 
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Figure 2.8. 
 
Figure 2.8. Decreased tumor growth and survival of mice implanted with TNT-
primed mesothelioma cells. (A) In vitro cellular proliferation rate of MSTO-211H cells 
cultured in passage medium (10% FCS, 25 mM glucose RPMI) vs. TNT medium (2.5% 
FCS, 50mM glucose RPMI); (B) Average radiance of tumor growth at 7,14,21, and 31 
days following peritoneal implantation in immunodeficient NOG mice of MSTO-211H 
cells cultured for 7 days using either passage medium or TNT medium; * indicates 
statistically significant difference between the two groups (p < 0.05); (C) Kaplan-Meier 
curve of survival of injected NOG mice, 10 mice in each group; (D) Bioimaging of NOG 
mice from each cohort.  
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Figure 2.9.  
 
Figure 2.9. Gene expression profiling of mesothelioma cells cultured in passage 
medium vs TNT medium. Expression of selected genes in MSTO cells grown in TNT 
media; samples were run in triplicate and means ± standard deviations are presented. 
Gray columns = results from cells grown in Control medium; black columns = results 
from cells grown in TNT medium. Expression of genes specific to TNTs (A), cell cycle 
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regulation (B), and genes attributed to invasion, migration and metastasis (C) relative to 
cells grown in control media are shown. Note the significant downregulation of genes 
that positively modulate cell cycle in cells grown in TNT media. Conversely, genes 
attributed to cellular invasion, migration and metastasis functions are upregulated 
(asterisks * indicate p values <0.05).   
  
65 
 
Table 2.1. 
 
Table 2.1. P-values from comparisons of TNTs Length in mesothelioma cells by cell 
line and time. 
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3.1 Synopsis 
 
In this study, we demonstrated that hypoxic conditions stimulated an increase in 
tunneling nanotube (TNT) formation in chemoresistant ovarian cancer cells (SKOV3, 
C200).We found that suppressing the mTOR pathway using either everolimus or 
metformin led to suppression of TNT formation in vitro, verifying TNTs as a potential 
target for cancer-directed therapy. Additionally, TNT formation was detected in co-
cultures including between platinum-resistant SKOV3 cells, between SKOV3 cells and 
platinum-chemosensitive A2780 cells, and between SKOV3 cells cultured with benign 
ovarian epithelial (IOSE) cells; these findings indicate that TNTs are novel conduits for 
malignant cell interactions and tumor cell interactions with other cells in the 
microenvironment. When chemoresistant C200 and parent chemosensitive A2780 cells 
were co-cultured, chemoresistant cells displayed a higher likelihood of TNT formation to 
each other than to chemosensitive malignant or benign epithelial cells. Hypoxia-induced 
TNT formation represents a potential mechanism for intercellular communication in 
ovarian cancer and other forms of invasive refractory cancers. 
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3.2 Introduction 
 
Ovarian cancer is the most fatal gynecologic cancer in the United States [1]. Platinum-
based chemotherapy is the primary treatment for ovarian cancer; however, resistance to 
chemotherapy continues to be a major clinical problem [2]. The molecular mechanisms 
of chemotherapy resistance remain unclear. It is widely accepted that chemoresistance 
emerges as a result of mutations in key regulatory genes with cells passing these genetic 
mutations via vertical transmission to daughter cells through mitotic division and clonal 
expansion. However, horizontal (cell-to-cell) transmission of regulatory factors via 
channels of cellular communication could also be responsible for the development of 
chemotherapy resistance. This concept was, in fact, proposed as a model of 
chemoresistance in ovarian cancer over 20 years ago [3].  
 
Modes of intercellular transport that have been well-studied include chemical signaling 
via cytokines or other diffusible signals, packaging of signals in membrane-enclosed 
vesicles such as exosomes or microvesicles, and connexin-based gap junctions 
connecting adjacent cells [4, 5]. Tunneling nanotubes (TNTs) have recently been 
characterized as cellular conduits of intercellular communication increasingly studied for 
their role in mediating long-range transport of cellular cargo via direct cell-to-cell contact 
[6-14]. TNTs are thin, membrane-lined, actin-based conduits that can form connections 
between cells as far as 100-200 µm apart and transport cellular cargo (including 
mitochondria and microRNAs) between cells [9, 10, 12].  They are distinguished from 
other actin-based cellular extensions by their smaller diameter (50-800 nm) and non-
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adherence to the substratum when cultured in vitro [9, 10, 14, 15]. We have successfully 
imaged nanotube protrusions in resected malignant mesothelioma and pulmonary 
adenocarcinoma tumors from human patients and between primary malignant cells 
derived from pleural effusions and ascites [10, 16]. Using confocal microscopy, we also 
recently reported the presence of TNTs in osteosarcoma resected from mice and also in 
ovarian tumors surgically resected from human patients [12]. These findings support the 
potential in vivo role of TNTs for human malignancies, including ovarian cancer.  
 
Elucidating new mechanisms of intercellular communication may provide an innovative 
approach to evaluating the development of chemoresistance. We recently demonstrated 
that microRNAs (miRNAs), including those differentially expressed in chemoresistant 
cancers, can be transported via TNTs between malignant ovarian cells and malignant and 
stromal cells [12]. However, the role of TNTs in cancer pathobiology remains unclear. 
Here, we investigate TNTs as a novel mechanism for development of drug resistance by 
assessing TNT formation among chemoresistant and chemosensitive ovarian cancer cell 
lines under normoxic and hypoxic conditions and the role of TNTs in facilitating 
intercellular transport of cytotoxic drugs from drug-resistant to drug-sensitive cancer cells
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3.3 Methods 
 
Cell lines and cell culture 
A2780, C200, SKOV3, and IOSE cell lines were kindly obtained from Dr. Sundaram 
Ramakrishnan at the University of Minnesota. The A2780 cell line is an ovarian tumor-
derived epithelial cell line; the C200 cell line is derived from the A2780 line, which is 
resistant to 10 times the concentration of cisplatin. The SKOV3 cell line is derived from 
the ovarian adenocarcinoma ascites of an untreated patient. SKOV3 cells are resistant to 
cisplatin, TNF, diphtheria toxin, and doxorubicin [24]. IOSE cells are immortalized from 
normal ovarian epithelial cells. All cell lines were authenticated using sequence tandem 
repeat genotype profiling (Johns Hopkins University, STR Profiling for Human Cell 
Line Authentication) and confirmed by comparison to available genetic profiles 
using the University of Colorado database (website: 
http://dnasequencingcore.ucdenver.edu/pdf-Files/Korch%20et%20al%20-
%20Table%20S4%20Ovarian%20profiles.pdf).  A2780 and SKOV3 cell lines were 
passaged per protocol using RPMI-1640 media with 10% fetal bovine serum (FBS), 1% 
penicillin-streptomycin (P-S), 2% L-glutamine, and 0.002% plasmocin. The C200 cell 
line was cultured per protocol in RPMI-1640 media with 10% FBS, 1% P-S, 2% L-
glutamine, 0.00025% insulin, and 0.002% plasmocin. The IOSE cell line was cultured 
per protocol in DMEM media with 10% FBS, 1% P-S, 2% L-glutamine, and 0.002% 
plasmocin. All cell lines were maintained at 5% CO2 and at 37˚C. Cell lines were 
passaged every 2-3 days using trypsin-0.53 mM EDTA solution, kept in T-75 cm
2
 tissue 
culture flasks, and confirmed to be negative for mycoplasma infection. 
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Procurement and imaging of nanotubes in tumors  
Formalin-fixed primary ovarian tumor tissues and secondary metastatic tumors were 
obtained via the Tissue Procurement Facility at the University of Minnesota following 
Institutional Review Board (IRB) approval and patient consent. Preparation procedures 
and techniques for visualizing nanotubes in intact tumors have been previously published 
[10, 12]. Briefly, tumors were first fixed in 10% Neutral Buffered Formalin (Sigma, St 
Louis, MO) for at least 3 days. For visualization of nanotubes in intact human tumors, 
MitoTracker Red (250 nM), Hoechst 33342 (10 µg/ml), and phalloidin 2.5% were used to 
stain mitochondria, nuclei, and actin, respectively. Fixed tumor specimens were then 
washed with phosphate-buffered saline (PBS) three times and then cut into small slices 
1.0 cm in length and 1.0-1.5 mm in thickness. Tumor slices were then washed again in 
PBS and stained with 500 nM solution of MitoTracker Orange CM-H2TMRos (M-7511, 
Life Technologies, Grand Island, NY) and 0.5 µg/ml Hoechst 33342 (Molecular Probes, 
Life Technologies, Grand Island, NY) in PBS for 10 minutes under cover to avoid 
exposure to light. Excess stain was removed by washing the slices several times with 
PBS. A stained tumor slice was mounted onto an Attofluor Cell Chamber (Cat A-7816, 
Life Technologies, Grand Island, NY) with a 25mm round cover glass of 1.5 mm 
thickness (Warner Instruments, Hamden, CT) on both sides. Sections were mounted for 
use in the Nikon A1R-MP Multiphoton Confocal Microscope at the University of 
Minnesota Imaging Center. Stained tumor slices were imaged on the Nikon A1R-MP 
microscope using a PlanApo LWD 25x water-immersion lens. Imaging data were 
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collected by z-stacked optical sectioning and then analyzed using NIS elements AR 
software (Nikon, version 4.00.07). 
 
Imaging of TNTs in cell lines 
For visual staining of cell lines and primary malignant cells from effusions, all cells were 
cultured in T culture flasks and transferred to 6-well adherent tissue culture plates (Fisher 
Scientific, Pittsburgh, PA) at 37°C in 5% CO2 prior to imaging. Fluorescent lipophilic 
dyes DiI and DiO were used per manufacturer’s instructions (Invitrogen).  
 
Culture conditions for TNT formation in normoxia and hypoxia 
Cells were cultured in a low-serum, high-glucose environment to determine the growth of 
TNTs as previously described [10]. Briefly, the culture conditions consisted of RPMI-
1640 medium with 2.5% FBS, 50mM glucose, 1% P-S, 2% L-Glutamine, 10 nM 
ammonium lactate, and pH 6.6. For hypoxic conditions, cells were then placed in 10-cm 
cell culture plates and placed in a chamber containing 2% oxygen, 5% carbon dioxide, 
and 93% nitrogen. 
 
Quantification of TNTs 
TNTs were identified as previously described [10, 12, 14, 16, 26, 33]. Briefly, these 
parameters included (i) lack of adherence to the substratum of tissue culture plates, 
including visualization of TNTs passing over adherent cells; (ii) TNTs connecting two 
cells or extending from one cell were counted if the width of the extension was estimated 
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to be <1000 nm; and (iii) a narrow base at the site of extrusion from the plasma 
membrane. Cellular extensions not clearly consistent with the above parameters were 
excluded. An Olympus IX70 inverted microscope (Olympus Corporation) with 20× 
objective lens was used to count the number of TNTs and cells in 10 randomly chosen 
fields of each 6-well plate at 24, 48, 72, and 96 hours. A single representative image of 
each field was taken at all time points in each well. Experiments were performed in 
duplicate for each cell line. To determine TNT formation, three ovarian cancer cell lines 
(A2780, C200, SKOV3) and one benign ovarian epithelial cell line (IOSE) were plated at 
a density of 4 x 10
4 
 cells/well in 6-well adherent tissue culture plates (Fisher Scientific, 
Pittsburgh, PA) at 37°C in 5% CO2 with TNT-inducing medium. TNTs and cells were 
counted manually, and the TNT index was calculated as the number of TNTs per cell 
(TNTs/cell) using previously described methods [16]. The variation within each 
experiment was high, and therefore, measures from ten random fields were taken per 
experiment and averaged to calculate a more accurate measure for each experiment.  
 
Western blotting for HIF-1α 
Cells were harvested by centrifugation and lysed in standard radioimmunoprecipitation 
assay (RIPA) buffer containing Roche cOmplete Mini EDTA-Free Buffer with 2 mM 
dithiothreitol (Biocompare, South San Francisco, CA) using four 3-second bursts of 
sonication (Fisher Scientific Sonic Dismembrator Model 100, ThermoFisher Scientific). 
Total protein was quantitated using the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA; 
Cat#500-0006) and read on a Beckman DU-64 Spectrophotometer (Beckman Coulter, 
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Brea, CA). Protein (60 µg) was resolved on a precast 10% Mini-Protean TGX 10-well gel 
(Bio-Rad, Hercules, CA; Cat#456-1033) at 100 V for 1 hour and transferred to a 
nitrocellulose membrane per the manufacturer’s protocols (Bio-Rad, Hercules, CA; 
Cat#162-0097). The membrane was cut into two pieces (upper and lower) and blocked 
for 2 hours at room temperature in 5% milk made with Tris-buffered saline. After 
washing (3 x 5 minutes each, at room temp), the upper half of the membrane was 
incubated with anti-HIF-1α (clone-H1α67) mouse monoclonal primary antibody at 
10µg/ml (Sigma, Cat#H6536), and the lower half was incubated with mouse monoclonal 
anti-β actin (clone-AC15) at 1:10,000 dilution (Sigma,Cat#A5441). Both halves were 
incubated overnight at 4ºC. The next day, membranes were washed and then incubated 
with horseradish peroxidase (HRP) conjugated goat anti-mouse IgG (H+L) secondary 
antibody (Pierce, Prod#31430) for 2 hours at room temperature. After another set of 
washings, detection was achieved using the SuperSignal West Dura Extended Duration 
Substrate (Pierce, Prod#34076) and exposed to Kodak Biomax Light Film (Kodak, 
Prod#178 8207) for 1 to 20 seconds for β-actin and overnight for HIF-1α, following 
standard protocols. 
 
Cell proliferation assays 
Cell proliferation assays were performed using the Cell Counting Kit-8 (CCK8) per the 
manufacturer’s instructions. Cells were plated at a density of 4,000 cells per well in a 96-
well plate in triplicate with 200 µl of medium in each well. Cells were allowed to grow in 
standard conditions. 10 µl of CCK8 reagent was placed in each well at 4 time points (0, 
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24, 48, 72, and 96 hours) and left for incubation. Samples were then read in triplicate 
using a plate reader, and curves were created using Excel.  
 
Pharmacologic treatment of cell lines 
A2780, C200, and SKOV3 cell lines were treated with metformin or everolimus. 
Concentrations of metformin (970 nM) and everolimus (40 µM) were based on previous 
studies of mesothelioma [10].  
 
Time-lapse imaging and quantification of cell-to-cell interactions 
For A2780 and C200 cell interactions, C200–DiO (green) and A2780-DiI (red) cells in a 
ratio of 1:1 were plated simultaneously in 6-well plates at a density of 5 × 10
4
 cells/well. 
For A2780 and SKOV3 interactions, SKOV3–GFP (green) and A2780-DiI (red) cells in a 
ratio of 1:1 were plated in 6-well plates at a density of 5 × 10
4
 cells/well. Plates were 
evaluated after four hours to ensure even distribution of both cell lines. Cells were 
allowed 12 hours to settle and adhere to the plates prior to imaging. For time-lapsed 
imaging, multiple 20x fields of view containing evenly distributed cells were chosen 
using a wide-field Zeiss Axio200M microscope costume-fitted with a stage incubator that 
maintains environmental conditions at 37°C and 5% CO2. The microscope was set up to 
take an image of each chosen field every 12 minutes in the DIC (differential interference 
contrast) red and green fluorescent channels. Twenty-four hours of imaging from the start 
of each time-lapse was used for analyzing cell-to-cell interactions. TNT formation among 
co-cultured cells was identified to occur between resistant-to-resistant (R-to-R), sensitive-
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to-sensitive (S-to-S), resistance-to-sensitive (R-to-S), and sensitive-to- resistance (S-to-R) 
cells based on staining.  
 
Statistical Analysis 
Quantification of TNTs/cell was performed over a four-day period as described above. 
Overall comparisons of the medians for both TNTs/cell per field and cells per field across 
cell lines were analyzed using the Kruskal-Wallis test. For pairwise comparisons of TNT 
formation between resistant and sensitive cells, Wilcoxon Rank Sum two-sample tests 
were conducted and p-values were adjusted for multiple comparisons using a Bonferroni 
correction.  For analyses with sample sizes less than 5, descriptive statistics were 
presented, however formal hypothesis testing was not performed.  Analyses were 
conducted in SAS version 9.3 (Cary, NC), and p-values <0.05 were considered 
statistically significant.  
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3.4 Results 
 
Examination and quantification of TNTs in malignant chemoresistant ovarian cell 
lines 
Using confocal imaging, we had previously identified TNT-like structures in malignant 
ovarian tumors resected from human patients, supporting our hypothesis that TNTs are 
physiologically relevant cellular structures in this form of cancer [12]; a representative 
example is shown in Figure 1A. Using inverted microscopic imaging, we identified TNT 
formation among malignant ovarian cell lines (chemoresistant and chemosensitive) and 
benign ovarian epithelial cells in vitro [10, 12] (Figure 1B). We had previously 
demonstrated that TNTs form reliably at a quantifiably higher rate when cultured under 
conditions of metabolic stress, specifically in a low-serum (2.5% FCS), hyperglycemic 
(50 mM), acidified (pH 6.6) “TNT medium” [10]. We hypothesized that there are 
differences in the rate of TNT formation between chemoresistant and chemosensitive 
cells. To address this hypothesis, we sought to quantify the degree of TNT formation over 
time in malignant (SKOV3, C200, and A2780) as well as benign (IOSE) ovarian cell 
lines. Cell lines SKOV3 and C200 are chemoresistant to platinum; A2780 is platinum-
sensitive. Notably, C200 is a derivation of the platinum-sensitive cell line A2780; to our 
knowledge, these are the only currently available matched platinum-resistant/sensitive 
ovarian cancer cell lines, and thus we used them in our study. We cultured each cell line 
in TNT medium using a predetermined number of sub-confluent cells to allow for 
optimal TNT formation [10]. We then quantified the number of TNTs and cells per high-
power field at 24, 48, 72, and 96 hours (Figure 1C). To account for differences in the 
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rate of cellular proliferation among cell lines, we calculated the average number of TNTs 
per cell (TNTs/cell). These data were not normally distributed and therefore the raw 
values are presented and summarized using the median. Interestingly, while the median 
number of cells per high-power field was significantly higher among chemoresistant cell 
lines (C200 and SKOV3; Supplemental Figure 1; Supplemental Table 1), the overall 
rate of TNT formation was greater for the IOSE cell line when reported as TNTs/cell, due 
to the low proliferation rate of IOSE (Supplemental Table 2). Conversely, for highly 
proliferative cells that produce few TNTs, the median number TNTs/cell produced a low 
“TNT index.” Interestingly, TNT formation occurred to a higher degree among the 
chemosensitive cell line A2780 as compared to chemoresistant cell lines, even accounting 
for differences in cell proliferation.  
 
Hypoxic conditions increase TNT formation between chemoresistant ovarian cancer 
cells 
TNTs are known to be upregulated under conditions of metabolic stress, including 
exposure to hydrogen peroxide, serum deprivation, and hyperglycemia [10, 17, 18]. We 
hypothesized that TNTs would also be induced under conditions of environmental stress 
characteristic of the tumor microenvironment such as hypoxia. Hypoxia is a hallmark of 
aggressively proliferating malignant tumors, and has been implicated in the development 
of chemoresistance [19, 20]. The lack of adequate oxygen in the tumor microenvironment 
triggers a stress response at the molecular and cellular levels, leading to increased 
invasiveness and resistance to drug therapy [20-22]. Expression of hypoxia inducible 
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factor-1α (HIF-1α) in mammalian cells is induced as part of the systemic response to low 
oxygen levels and plays a key role in maintaining cellular homeostasis. As such, HIF-1α 
can serve as an effective molecular marker of hypoxia. Thus, we initially determined 
whether hypoxia induces TNT formation in chemoresistant ovarian cancer cells (SKOV3 
and C200 cell lines); we also assessed the effect on chemosensitive cells (A2780). To 
confirm that oxygen deprivation in our culture system induced hypoxia, we examined 
HIF-1α expression in these cells when cultured in either hypoxic or normoxic conditions 
for up to 24 hours. We found that HIF-1α expression in A2780, C200, and SKOV3 cells 
was respectively 6, 10, and 11-fold higher when cultured in hypoxic conditions as 
compared to normoxic conditions (Figure 2A). 
 
We next determined the effects of hypoxia on TNT formation and cell proliferation in 
several lines of chemoresistant and chemosensitive ovarian cancer cells. Ovarian cancer 
cell lines A2780, C200, and SKOV3 were cultured in standard medium conditions (10% 
fetal calf serum/FCS in RPMI-1640) or TNT medium and under normoxic or hypoxic 
conditions. We quantitated the number of TNTs connecting cells cultured in hypoxic vs. 
normoxic conditions. When cells were cultured in standard passage medium under 
hypoxic conditions, chemoresistant SKOV3 cells demonstrated an increase in TNT 
numbers by 72 hours as compared to cells cultured in normoxic conditions (Figure 2B, 
left panel). Similarly, chemoresistant C200 cells also developed more TNTs under 
hypoxic conditions by 48 and 72 hours (Figure 2C, left panel). No differences were 
observed in TNT numbers among A2780 cells cultured in hypoxic or normoxic 
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conditions at any timepoint using standard passage medium (Figure 2D, left panel). 
When cells were cultured in TNT medium, SKOV3 cells (Figure 2B, right panel) and 
chemoresistant C200 cells (Figure 2C, right panel) again demonstrated a higher rate of 
TNT formation in hypoxia by 48 and 72 hours, respectively.  Notably, chemosensitive 
A2780 cells formed fewer TNTs under hypoxic conditions by 48 and 72 hours as 
compared with cells cultured in normoxia (Figure 2D, right panel). From these 
experiments, we concluded that hypoxia appears to induce TNT formation under 
metabolic conditions already favorable to drug-resistant cell activity.  
To account for differences in cellular proliferation under these conditions, we quantified 
cell number and related changes as well by comparing chemoresistant C200 cells and 
their parent chemosensitive cell line A2780. In standard culture medium, A2780 cells 
proliferated at a lower rate under hypoxic conditions than normoxic conditions 
(Supplemental Figure 2A, left panel). Chemoresistant C200 cells also demonstrated a 
lower rate of cell proliferation when grown in standard medium and exposed to hypoxia 
(Supplemental Figure 2B, left panel). Notably, when cells were cultured in TNT 
medium and subjected to hypoxic conditions, C200 cells proliferated at noticeably higher 
rates under hypoxic conditions as compared to normoxic conditions in TNT medium 
(Supplemental Figure 2B, right panel); however, this rate of increase was not 
proportional to the increased rate of formation of TNTs/cell in the C200 cell line. A2780 
cells, however, remained less proliferative in this setting (Supplemental Figure 2A, 
right panel). Similarly, SKOV3 cells proliferated at a much lower rate in hypoxic 
conditions as compared to normoxia when cultured in passage culture medium 
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(Supplemental Figure 2C, left panel). However, when cultured in TNT medium, there 
was very little difference in cell proliferation under hypoxic or normoxic conditions 
(Supplemental Figure 2C, right panel). These experiments demonstrated that hypoxia 
induced differences in cellular proliferation among chemoresistant and chemosensitive 
cell lines. Taken together, our data indicate that increased TNT numbers among 
chemoresistant (C200 and SKOV3) ovarian cancer cells in a hypoxic environment is not 
due solely to changes in cell proliferation.  
 
TNTs form between chemoresistant and chemosensitive ovarian cancer cells in vitro 
Having confirmed that malignant ovarian cancer cells derived from commonly studied 
cell lines formed TNTs in vitro, we next sought to determine whether chemosensitive 
A2780 cells establish cell-to-cell contact with chemoresistant C200 or SKOV3 cells via 
TNTs. To distinguish the two cell populations, we either stained cells with fluorescent 
lipophilic dyes, using DiO (C200, green) and DiI (A2780, red), or used SKOV3 cells 
transduced with a green fluorescent protein (GFP)-expressing lentiviral vector. Under 
normoxic culture conditions, we reproducibly observed de novo formation of TNTs 
between ovarian chemoresistant and chemosensitive cell lines. We co-cultured these cells 
in a 1:1 ratio using our TNT growth-promoting conditions (TNT medium) and performed 
time-lapse imaging every 15 minutes for 24 hours. The videos and all individual images 
were analyzed for the number of TNT connections and their cells of origin. The number 
of TNT connections between chemosensitive and chemoresistant cell lines and the cells 
initiating these connections varied depending on the cell lines used (Figures 3A & 3C). 
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When chemoresistant (R) SKOV3 cells and chemosensitive (S) A2780 cells were co-
cultured (Figure 3A, 3B), resistant cells formed significantly fewer TNTs to other 
resistant cells than did sensitive-to-sensitive cells (p=0.001).  No significant difference in 
TNT numbers was observed among sensitive-to-resistant cells as compared with 
resistant-to-sensitive cells (p=0.298).  When chemoresistant (R) C200 cells and 
chemosensitive (S) A2780 cells were co-cultured (Figure 3C, 3D), sensitive cells did not 
form significantly more TNTs to each other than did resistant cells (p=0.437). However, 
in the SKOV3 and A2780 co-culture combinations (Figure 3A), sensitive cells formed 
significantly more TNTs to resistant cells than did resistant-to-sensitive cells (p<0.0001). 
These results demonstrated variable, albeit reproducible, patterns in TNT formation 
among chemoresistant and sensitive cell lines. 
 
TNTs form between platinum-resistant ovarian cancer cells and benign ovarian 
epithelial cells in vitro 
We had previously reported that TNTs are responsible for long-range intercellular 
transfer of cellular cargo, including oncogenic microRNAs, from malignant to benign and 
stromal cells [12]. In follow-up studies, we co-cultured the GFP-expressing platinum-
resistant SKOV3 cells in a 1:1 ratio with benign ovarian epithelial (IOSE) cells stained 
with the red-fluorescing lipophilic dye DiI (Figure 3E, 3F). Cells were allowed to adhere 
and form TNTs among co-cultured cells. We again performed time-lapse imaging for 24 
hours using inverted fluorescent microscopy to capture TNT formation between SKOV3 
and IOSE cells (Figure 3F). The benign-to-benign and resistant-to-resistant interactions 
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were equal to one another but greater than resistant-to-benign and benign-to-resistant 
connections.   However, the differences between these possible TNT connections were 
not statistically significant (Figure 3E).  
 
Inhibition of mTOR disrupts TNT-mediated intercellular communication under 
normoxic and hypoxic conditions 
mTOR inhibition suppresses TNT formation in vitro [10]. We determined whether 
mTOR inhibition could interfere with TNT formation in ovarian cancer cells.  
Everolimus is a clinically available direct inhibitor of mTOR, whereas metformin 
indirectly inhibits mTOR through activation of 5' AMP-activated protein kinase (AMPK). 
We found that both metformin and everolimus appeared to decrease the number of TNTs 
in all A2780 and SKOV3, but not in C200 cells (Figure 4A-C). Overall, everolimus was 
minimally more effective than metformin at reducing the number of TNTs. Interestingly, 
TNT formation was most dramatically inhibited in platinum-resistant SKOV3 as well as 
chemosensitive A2780 cells.  
 
We also examined the effects of mTOR inhibition on TNT formation under hypoxic 
conditions in cultures of C200 cells in comparison with its parent cell line A2780. Both 
metformin and everolimus had similar effects in these cells under both hypoxic and 
normoxic conditions in A2780 and SKOV3 cell culture; however, only everolimus 
appeared effective in suppressing TNTs in C200 cells, but metformin did not (Figure 4D, 
4E, 4F). It was interesting that mTOR inhibition dramatically reduced TNT formation in 
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the chemosensitive A2780 cell line under hypoxic conditions, whereas it had much less 
of an effect on TNT formation in its derivative chemoresistant C200 cell line. This 
findings suggested alternative pathways for TNT formation and upregulation in 
chemoresistant ovarian cells compared with chemosensitive cells.  
 
Suppression of the mTOR pathway is known to affect cellular proliferation[23]. Thus, we 
also examined the effects of everolimus and metformin on cell proliferation 
(Supplemental Figure 3). We used a standard CCK-8 assay to assess cell metabolism as 
a surrogate marker for proliferation rate. Metformin effectively suppressed cellular 
proliferation in both A2780 and C200 cells cultured in either a normoxic or hypoxic 
environment (Supplemental Figure 3). Everolimus effectively suppressed cell 
proliferation in both A2780 and C200 cells under normoxic conditions; however, under 
hypoxic conditions, the effect of this drug was attenuated in A2780 cells. Everolimus was 
ineffective in suppressing cell proliferation for C200 cells cultured in hypoxia 
(Supplemental Figure 3). These data support the notion that changes in the number of 
TNTs were independent of cell number and differences in cellular metabolism rate and 
represented absolute changes in TNT formation. 
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3.5 Discussion 
 
In the present study, we focused on the clinically relevant problem of platinum 
chemotherapy resistance by assessing differences in formation between chemoresistant 
and chemosensitive ovarian cancer cells in the setting of hypoxia. We were able to 
reproducibly show TNT formation among chemoresistant and chemosensitive ovarian 
cancer cells. We concluded that there were quantifiable differences in TNT numbers 
between chemoresistant and chemosensitive malignant ovarian cells independent of 
differences in cellular proliferation. Our data suggest that both malignant and normal 
ovarian cell lines can serve as an in vitro model to assess the role of TNTs in ovarian 
cancer. Using chemoresistant ovarian cancer cells as a model, our data suggest that 
cellular stress in the form of hypoxia can also induce TNT-mediated communication and 
that this occurs at a higher rate in chemoresistant cells (Figure 5). The effectiveness of 
mTOR inhibition in suppressing TNT formation represents a potentially novel and 
complementary approach to cancer-directed therapy. 
 
The emergence of resistance to standard-of-care chemotherapy drugs and biologic agents 
remains a major clinical problem, resulting in increased morbidity and mortality in 
cancer. This is especially true in those with high rates of recurrence, such as ovarian 
cancer. The molecular and cellular basis of chemoresistance is poorly understood and 
requires novel approaches for investigation. Common mechanisms may exist and be 
present across many forms of cancer. One example of a critical process responsible for 
tumor cell organization and heterogeneity that may explain development of 
86 
 
chemoresistance is intercellular communication. Here we show that hypoxia-induced 
TNT formation is a novel mechanism of chemoresistance in cancer. In the past few years, 
in vitro studies have begun to elucidate the role of TNTs for facilitating intercellular 
trafficking of cellular signals between connected cancer cells [10, 12, 16, 24-26]. For 
example, our group has demonstrated in vitro direct cell-to-cell transfer of oncogenic 
genetic materials, including microRNAs, via TNTs connecting malignant ovarian cancer 
cells to each other as well as to stromal epithelial cells [10, 12, 16]. Furthermore, there is 
visual proof that TNTs exist in tumors from multiple cancer types imaged ex vivo, 
confirming that these structures are not in vitro artifacts, and may furthermore have a 
functional role in vivo [9, 10, 12]. The role of TNTs in cancer, as well as in other models 
of disease, represents a novel and important area of interest for understanding how long-
distance cellular communication takes place in the complex and heterogeneous solid 
tumor microenvironment.  
 
Intercellular transfer as a mechanism for ovarian cancer drug resistance specifically was 
proposed and studied more than 20 years ago [3]. These data suggested that metabolic 
cooperation between subsets of cells (chemoresistant and chemosensitive malignant 
ovarian cells) occurred to synchronize cells against drug therapy. TNTs have been 
proposed as a specific mode of communication responsible for causing and/or 
maintaining drug resistance [27]. Furthermore, the finding that cell-to-cell transfer of 
antibiotic-resistance genes via TNTs induces changes in recipient bacteria serves as a 
unique and highly pertinent parallel to TNT-mediated chemoresistance [28]. Studies 
87 
 
which have demonstrated the propagation of signals for apoptosis, such as caspase 
proteins [29], via TNTs support the notion that other similar-sized signals could be 
transmitted as well. Together, these studies support the notion that there are multiple 
ways that TNTs are involved in the development of chemoresistance among refractory 
malignancies. 
Our study addressed differences in interactions between specific chemoresistant and 
chemosensitive cells using ovarian cancer as an in vitro model system. It is likely that 
variability exists between different cancer cell types based on properties from site of 
origin, and also depending on resistance to specific drugs and the underlying mechanisms 
of that resistance (eg platinum resistance in our study, as compared to resistance to other 
classes of biologic or chemotherapeutic drugs). Our quantification of cell-cell interactions 
demonstrated that resistant-to-sensitive cell interactions made up only a minority of all 
interactions observed in co-cultures. However, if only a few interactions are needed for a 
chemoresistant cell to connect with a chemosensitive cell, that provides profound 
implications and insight into tumor cell behavior. Do chemoresistant cells efficiently 
connect to cells and transmit signals that could eliminate their “competition” in the tumor 
microenvironment by killing off cells that otherwise would use up valuable nutrients and 
prevent effective local cell invasion? If so, then this would represent a novel and 
powerful mechanism by which chemoresistant cancer cells survive. 
 
If TNTs play a contributing biologic function by facilitating chemoresistance, then their 
targeting in a selective manner may represent a previously undiscovered approach to 
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cancer therapy. Our finding that pharmacologic inhibition of the mTOR pathway 
decreased the rate of formation of TNTs between ovarian cancer cells may provide a 
rationale for a new approach to preventing development of chemotherapy resistance via a 
TNT-mediated mechanism.   
 
Currently, it is well known that drugs used for in vitro studies, such as actin-destabilizing 
agents, can readily disrupt TNTs, but these agents also non-specifically disrupt other 
actin-based filaments as well, including intracytoplasmic actin and their stress fibers [10]. 
In our prior studies, we identified several compounds in clinical use or being investigated 
for treatment for cancer and other metabolic diseases that disrupt and/or suppress TNT 
formation in cancer. Although mTOR inhibitors are not selective for TNTs per se, 
inhibition of mTOR may also affect the cellular stress response and assembly of actin-
based TNTs. This concept is supported by established data regarding the role of the 
mTORC2 complex in actin assembly and formation [30-32]. Further investigation is 
warranted regarding the role of the mTOR pathway as a metabolic impetus for TNT 
formation. 
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Figure 3.1. 
 
 
 
Figure 3.1. Differing patterns of TNT formation among malignant (chemoresistant 
and chemosensitive) and also benign ovarian cells.   
A) Representative confocal microscopy image of a TNT within an intact human 
malignant ovarian tumor (adenocarcinoma). Arrowheads indicate mitochondria 
within a TNT stained with MitoTracker orange-fluorescent dye. 
B) Representative phase contrast microscopy images of TNTs connecting the 
cisplatin- and doxorubicin-resistant SKOV3 ovarian cancer cells; platinum-
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resistant C200 cells, and their parent chemosensitive cell line A2780; and a 
benign ovarian epithelial cell line (IOSE). 
C)  Quantification of TNTs/cell per field in cultures of chemoresistant, 
chemosensitive, and benign ovarian epithelial cell lines across replicates over four 
days plotted and summarized using the median (line). An Olympus IX70 inverted 
microscope with 20x objective lens was used to visualize and count the number of 
TNTs and cells in 10 randomly chosen fields. This experiment was performed in 
duplicate. 
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Figure 3.2. 
 
  
Figure 3.2. Hypoxia induces HIF-1α expression and TNT formation in ovarian 
cancer cell lines.   
A) Quantitative Western blot analysis shows increased expression of HIF-1α in 
SKOV3, C200, and A2780 cells cultured under hypoxic conditions.  
B-D) Number of TNTs (mean ± standard deviation) in chemoresistant SKOV3 (B) 
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and C200 (C) cells and chemosensitive A2780 (D) cells cultured in standard and TNT 
media under normoxic (left panel) or hypoxic (right panel) conditions.  For all 
experiments, the number of TNTs in 10 high-power fields (hpf) were counted and 
averaged.  This experiment was performed in duplicate. 
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Figure 3.3.  
 
 
Figure 3.3. TNT formation between chemoresistant and chemosensitive ovarian 
cancer cell lines and between chemoresistant ovarian cancer and benign epithelial 
ovarian cells.   
A) The number of TNTs in co-cultures of chemoresistant SKOV3 (R) and 
chemosensitive A2780 (S) cells across replicates and summarized using the median 
(line). 
B) Representative Zeiss Axio widefield fluorescence microscopy images of TNTs 
forming among DiI red-labeled A2780 (chemosensitive) and GFP (green)-labeled 
SKOV3 (cisplatin, adriamycin resistant) cell lines.   
C) The number of TNTs in co-cultures of chemoresistant C200 (R) cells and 
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chemosensitive A2780 (S) cells across replicates and summarized using the median 
(line).   
D) Representative microscopy image of TNTs forming among DiI red-labeled A2780 
(chemosensitive) and DiO green-labeled C200 cell lines.  
E) The number of TNTs in co-cultures of chemoresistant SKOV3 (R) cells and normal 
ovarian epithelial IOSE (S) cells across replicates and summarized using the median 
(line).   
F) Representative microscopy image of TNTs forming among GFP green-labeled 
SKOV3 cells and DiI red-labeled IOSE cells.  
For all images in this figure, cells were counted per 20X high power field during a 24-
hour period at 15 minute intervals. 
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Figure 3.4. 
 
Figure 3.4. Effects of metformin and everolimus on TNT formation. 
For all experiments, the number of TNTs in 10 high-power fields (hpf) were counted and 
averaged and each experiment was performed in duplicate. 
A) Number of TNTs (mean ± standard deviation) in A2780 cells with or without 
addition of metformin or everolimus under normoxia.  
B) Number of TNTs (mean ± standard deviation) in C200 cells with or without 
addition of metformin or everolimus under normoxia.  
C) Number of TNTs (mean ± standard deviation) in SKOV3 cells with or without 
addition of metformin or everolimus under normoxia.  
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D) Number of TNTs (mean ± standard deviation) in A2780 cells with or without 
addition of metformin or everolimus under hypoxia.  
E) Number of TNTs (mean ± standard deviation) in C200 cells with or without 
addition of metformin or everolimus under hypoxia. 
F) Number of TNTs (mean ± standard deviation) in SKOV3 cells with or without 
addition of metformin or everolimus under hypoxic conditions. 
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Figure 5 
 
Figure 5: Summary diagram. Physiologic stress induced under hypoxic conditions 
leads to an increase in HIF-1α expression and subsequent increase in TNTs. This increase 
in TNTs allows cells to form cellular networks that facilitate sharing of cellular signals. 
Inhibition of the mTOR pathway using clinically available drugs (everolimus, metformin) 
can suppress TNT-mediated intercellular communication. 
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4.1 Synopsis 
 
Intercellular communication plays a critical role in the ever-evolving landscape of 
invasive cancers. Recent studies have elucidated the potential role of tunneling nanotubes 
(TNTs) in this function. TNTs are long filamentous actin-based cell protrusions that 
mediate direct cell-to-cell communication between malignant cells. In this study, we 
investigated the formation of TNTs in response to variable concentrations of the 
chemotherapeutic drug doxorubicin, which is used extensively in the treatment of cancer 
patients. Doxorubicin stimulated an increased formation of TNTs to form in pancreatic 
cancer cells, and this occurred in a dose-dependent fashion. Furthermore, TNTs 
facilitated the intercellular redistribution of this drug between connected cells in both 
pancreatic and ovarian cancer systems in vitro. In sum, TNT formation is upregulated in 
aggressive forms of pancreatic carcinoma, was further stimulated following 
chemotherapy exposure, and acts as a novel method for drug efflux of therapeutic drug 
doses. We postulate that these findings implicate TNTs as a potential novel mechanism of 
drug resistance in chemorefractory forms of cancer. 
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4.2 Introduction 
 
Cancer cells are, in part, characterized by their capacity for invasion. They reside in a 
context of heterogeneous and stroma-rich tumor microenvironments. The concept of 
tumor heterogeneity to drug resistance in cancer treatment is well-established
1
. This 
property includes heterogeneity within the same cancer type between patients; inter-
tumoral heterogeneity between different tumors (primary or metastatic) within the same 
patient; in addition to intra-tumoral heterogeneity within any given single tumor. Tumor-
stromal proportion may vary widely, and correlates with patient prognosis
2-4
. The 
relationship and interaction between malignant and stromal cells is dynamic and in 
constant flux, as cancer cells react and respond to metabolic and physiologic stressors 
from each other and from the surrounding environment. 
 
Intercellular communication has gained increasing attention as a critical factor to induce 
heterogeneity of these microenvironments. The effects of direct cell-to-cell transfer of 
signals (via horizontal transfer) have long been understood to occur via soluble signals 
such as chemokines and cytokines. More recently, they have been investigated via 
cellular channels or carriers such as gap junctions and extracellular vesicles (EVs), 
including exosomes and microvesicles. These physical conduits of cellular 
communication are responsible for transmission of key signals of cellular proliferation 
and growth that permit tumor progression. Also, their expression appears to be modulated 
in response to external signals, including exposure to drugs administered with therapeutic 
intent.  
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A relatively new form of intercellular communication known as tunneling nanotubes 
(TNTs) represents an addition to the cadre of physical conduits of cellular signaling. 
These structures are long, thin (50-1000 nm) cellular protrusions, allowing cells 
connected by TNTs to perform efficient and direct cell-to-cell horizontal transfer of 
cytoplasmic signals, including mitochondria, microRNAs, and other cellular components. 
TNTs are upregulated in invasive forms of cancer as compared to stromal or non-
malignant cells; and are induced in vitro following exposure to metabolic or physiologic 
forms of stress, including serum-deprivation, hypoxia, hyperglycemia, and hydrogen 
peroxide. We hypothesized that TNTs may be further upregulated following exposure to 
chemotherapeutic drugs, and may represent an unique form of cellular stress response 
that permits cells to redistribute drugs, thereby reducing the overall kill rate of cancer 
cells. Here, we present data demonstrating variable formation of TNTs following 
exposure to the chemotherapeutic anthracycline drug doxorubicin in pancreatic and 
ovarian cancer models, and furthermore examine the effects of intercellular redistribution 
of the drug via TNTs. Our findings showed that TNTs have the ability to effectively 
redistribute a chemotherapeutic drug, and propose this as a potential mechanism for 
emergence of chemotherapeutic drug resistance in cancer. 
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4.3 Methods 
 
Cell lines and cell culture 
MIA PaCa-2 and S2013 cells were derived from human pancreatic adenocarcinoma, and 
HPDE cells from human ductal epithelium. These cell lines were obtained from the 
American Type Culture Collection. A2780 and SKOV3 cell lines were kindly obtained 
from Dr. Sundaram Ramakrishnan at the University of Minnesota. A2780 is an ovarian 
tumor-derived epithelial cell line; and SKOV3 cells were derived from the ovarian 
adenocarcinoma ascites of an untreated patient. SKOV3 cells are resistant to cisplatin, 
TNF, diphtheria toxin, and doxorubicin [24]. All cell lines were authenticated using 
sequence tandem repeat genotype profiling (Johns Hopkins University, STR Profiling for 
Human Cell Line Authentication). Ovarian cancer cell genotypes were confirmed by 
comparison to available genetic profiles using the University of Colorado database 
(website: http://dnasequencingcore.ucdenver.edu/pdf-Files/Korch%20et%20al%20-
%20Table%20S4%20Ovarian%20profiles.pdf). All cancer cell lines were cultured in 
RPMI-1640 medium (Thermo Fisher Scientific, Waltham, MA, USA). All media was 
supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) Antibiotic-
Antimycotic (Thermo Fisher Scientific, Waltham, MA, USA), at 37°C in a humidified 
5% CO2/95% air atmosphere. HPDE cells were cultured in defined keratinocyte medium 
supplemented by epidermal growth factor and bovine pituitary extract (Life 
Technologies, Inc., Grand Island, NY). Cell lines were passaged every 2-3 days using 
trypsin-0.53 mM EDTA solution, kept in T-75 cm
2
 tissue culture flasks, and confirmed to 
be negative for mycoplasma infection. To stimulate TNT formation for in vitro 
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examination, cells were grown in what our group refers to as “TNT-inducing medium”15 
[2.5% FCS in RPMI-1640 containing 50 mM glucose, supplemented with 1% P-S, 2% L-
glutamine with or without 10 mM ammonium lactate] (Sigma Aldrich, St. Louis, 
Missouri) and acidification of medium to pH 6.6, per our prior study
15
.  Cell cultures 
were done in 75cm
2
 tissue culture flasks (Falcon, Becton Dickson, Oxnard, CA) at 37°C 
in 5% CO2.  
 
Quantification of TNTs/cell 
TNTs were visually identified and quantified as previously described 
15,18,51-54
. Briefly, 
these parameters included (i) lack of adherence to the substratum of tissue culture plates, 
including visualization of TNTs passing over adherent cells; (ii) TNTs connecting two 
cells or extending from one cell were counted if the width of the extension was estimated 
to be <1000 nm; and (iii) a narrow base at the site of extrusion from the plasma 
membrane. Cellular extensions not clearly consistent with the above parameters were 
excluded. An Olympus IX70 inverted microscope (Olympus Corporation) with 20× 
objective lens was used to count the number of TNTs and cells in 10 randomly chosen 
fields of each 6-well plate at 24, 48, 72, and 96 hours.  
 
Representative images of each field were taken at all time points in each well. 
Experiments were performed in triplicate for each cell line. To determine TNT formation, 
cells were plated at a density of 2.5 x 10
5 
cells/well in 6-well adherent tissue culture 
plates (Fisher Scientific, Pittsburgh, PA) at 37°C in 5% CO2 with TNT-inducing 
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medium
15
. TNTs and cells were counted manually, and the TNT index was calculated as 
the number of TNTs per cell (TNTs/cell) using previously described methods 
51
.  
 
Pharmacologic treatment of cell lines 
Doxorubicin (Doxo) (D-4000, LC Laboratories) is an anthracycline chemotherapeutic 
drug. It was used in this study for its autofluorescent properties.  
 
Incubation with doxorubicin  
MIA PaCa-2 and S2013 cells were cultured in T-flasks before trypsinization. Cells were 
then treated for 8 minutes in suspension with either 0, 200, 400, 600, 800, 1000, or 
1200ng/mL doxorubicin (D-4000, LC Laboratories, Woburn, MA) in RPMI media. Cells 
were then washed, pelleted, and plated into 12-well plates (0.1x10
6
 cells/well), marking 
time point 0 hours. Cells were allowed to culture at 37°C in a humidified 5% CO2/95% 
air atmosphere for either 24, 48, or 72 hours. A2780 and SKOV3 cell lines were treated 
with doxorubicin for time-lapse imaging experiments. Doxorubicin was used at 
optimized concentrations to maximize its autofluorescent properties. 
 
Imaging and TNT quantification  
An Olympus IX70 inverted microscope (Olympus Corporation, Waltham, MA) with 20× 
objective lens was used to identify TNTs using the aforementioned criteria via live 
imaging. For each cell line, concentration, and time point, 3 fields of view (FOV) were 
taken from each of 5 wells, in triplicate.  
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Time-lapse microscopy 
To visualize doxorubicin transfer via TNTs, we performed time-lapse microscopy 
imaging every 15 minutes for 24 hours (ovarian cancer experiment) or every 10 minutes 
for 5 hours (pancreatic cancer experiment). Cells were first allowed 12 hours to settle and 
adhere to the plates prior to imaging. For time-lapsed imaging, multiple 20x fields of 
view containing evenly distributed cells were chosen using a wide-field Zeiss Axio200M 
microscope costume-fitted with a stage incubator that maintains environmental 
conditions at 37°C and 5% CO2. The microscope was set up to take an image of each 
chosen field every 12 minutes in the DIC (differential interference contrast) red 
fluorescent channel. 
 
Imaging TNTs/TNT-like structures in pancreatic adenocarcinoma tumor specimens 
from human patients 
Tumor specimens from patients with pancreatic carcinomas were obtained from the 
University of Minnesota (UMN) Tissue Procurement Facility under the auspices of a 
UMN IRB-approved protocol.  Informed written consent was obtained from all patients, 
and patient identifiers were removed to ensure anonymity. All procedures for tumor 
procurement were in compliance with ethical regulations for obtaining and using human 
tissue. For all patient tumors, sections (100–300 mm thick) were cut using a Vibratome 
and then stained using Hoechst 33342 (10 mg/ml) and MitoTracker Orange dyes (500 
nM).  
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Stained sections were mounted between two glass coverslips and imaged as previously 
described. 3D reconstructions were performed using  Nikon NIS elements AR software. 
 
Statistical Analysis 
TNT indices and lengths were not normally distributed and therefore Wilcoxon Rank 
Sum tests were used to compare TNT indices and lengths for each combination of dose 
and time measurements within each cell line. P-values were conservatively adjusted for 
multiple comparisons within each experiment using a Bonferroni correction. Analyses 
were conducted in SAS version 9.4 (Cary, NC), and p-values <0.05 were considered 
statistically significant.   
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4.4 Results 
 
TNTs can be visualized in intact pancreatic carcinomas resected from human 
patients 
There is significant heterogeneity in tumor-stroma proportions between patients, even 
with the same type of cancer. This biologic characteristic poses a challenge to achieving 
uniform efficacy of targeted therapeutics in many solid tumor types. This is especially 
true in pancreatic carcinomas, in which the stromal matrix is particularly dense as a result 
of desmoplastic reaction that takes places throughout the process of tumor formation
5,6
. 
As a direct result, malignant cells are separated by distance, and thus they are not located 
in immediate proximity. Furthermore, the vast majority (90-95%) of pancreatic 
adenocarcinomas harbor mutant forms of the KRAS oncogene
7-9
. Cells harboring mutant 
KRAS do not form connexin-lined gap junctions
10-13
. Exosomes have been implicated as 
one form of long-distasnce cellular signaling in pancreatic cancer
14
. In this context, there 
is also a clear niche for long-range cell communication that can be further explained by 
formation of TNTs. Thus to investigate TNTs in intact human tumor tissue, we obtained 
resected specimens from patients with resected chemo-naïve pancreatic carcinoma 
tumors at the time of Whipple surgery (Figure 1), lending further support to the notion 
that the in vitro findings reported in this paper have potential clinical relevance. The 
specimen shown was resected from a 75 year old patient with a pathologically staged T3 
tumor (invasive pancreatic carcinoma extending beyond the pancreas, with invasion of 
duodenal submucosa and peripancreatic adipose tissue), exhibiting poor prognostic 
features including lymphovascular and perineural invasion and positive lymph nodes in 
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the setting of chronic pancreatitis. This patient received neoadjuvant chemotherapy 
treatment (gemcitabine) prior to surgical resection. 
 
 
TNT formation is significantly higher in pancreatic adenocarcinoma cells derived 
from metastatic tumors compared to primary tumor cells, and also negligible in 
pancreatic stromal epithelium 
We have previously quantitatively examined the formation of TNTs in a variety of cancer 
cell types in vitro, including malignant pleural mesothelioma and ovarian cancer. To 
determine the TNT index (i.e. average number of TNTs per cell)
15,16
 we cultured two 
commonly used pancreatic adenocarcinoma cell lines (MIA PaCa-2 and S2013) in 
medium previously reported to stimulate formation of TNTs. (Figure 2A). TNTs and 
cells were counted at 24, 48, 72, and 96 hours, and summarized as the median number of 
TNTs/cell at these time intervals since TNT formation is not normally distributed (Figure 
2B; cell proliferation curve in Supplementary Figure 1). We determined that the cell 
line derived from metastatic pancreatic adenocarcinoma (S2013) formed significantly 
more TNTs/cell than that of primary tumor-derived cells (MIA PaCa-2), although the 
MIA PaCa-2  had an overall higher cell proliferation rate. We specifically analyzed the 
differences for each cell line over time as follows. For S2013, the TNT indices were 
statistically significantly greater at 48 hours (p=0.02), 72 hours (p<0.0001) and 96 hours 
(p<0.0001) compared to 24 hours.  For MIA PaCa-2, TNT indices were statistically 
significantly greater at 48 hours (p<0.0001), 72 hours (p<0.0001) and 96 hours 
(p<0.0001) compared to 24 hours.   
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For comparison, we calculated that the TNT index of HPDE, a non-malignant cell line of 
pancreatic stellate cells that are representative of the tumor microenvironment in 
pancreatic adenocarcinoma tumors, was negligible in HPDE cells. For HPDE, TNT 
indices were statistically significantly greater at 72 hours (p=0.02) and 96 hours 
(p<0.0001) compared to 24 hours; but not statistically significantly different between 48 
and 24 hours (p=1.00). 
 
To assess potential changes in TNT length for the cell line that had the highest index 
(S2013), we measured TNT lengths over time (Figure 2C). TNT lengths were 
statistically significantly greater at 96 hours (p=0.04) compared to 24 hours; and not 
statistically significantly different between 72 (p=0.06) and 48 hours (p=1.00) and 24 
hours. 
 
TNTs form in a dose-dependent fashion following exposure to doxorubicin  
Having confirmed a higher rate of TNT formation in pancreatic carcinoma cell lines 
compared with stroma, and in cells derived from metastatic tumors compared with 
primary-derived cells, we next examined the effects of chemotherapeutic drug exposure 
on formation of TNTs between these cells. We again used MIA PaCa-2, S2013, and 
HPDE cells cultured in the presence of six different concentrations of doxorubicin, an 
anthracycline chemotherapeutic drug that has been used extensively for in vitro studies of 
pancreatic cancer (Figure 3A). The TNT index was assessed at 24, 48, 72, and 96 hours 
following initial incubation (Figure 3B, 3C; cell proliferation curves in 
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Supplementary Figure 2). At 24 hours, none of the comparisons of TNT index was 
statistically significant. However, we did observe a heterogeneous response to variable 
concentrations of this drug, with a peak in TNT index occurring at the 800 ng/ml dose by 
72 hours (Table 1; Figure 3B). The difference in TNT formation between the most 
stimulating (800 ng/ml) compared to that for the least (1200 ng/ml) was 3-fold by this 
last time-point in the S2013 cell line (p=0.02), and 1.5-fold in the Mia PaCa-2 cell line 
(p<0.0001). 
 
TNTs facilitate intercellular redistribution/efflux of doxorubicin between 
chemoresistant and chemosensitive cancer cells 
TNTs are known to facilitate the intercellular transfer of many cytosolic components, 
including but not limited to mitochondria, Golgi vesicles, microRNAs, exosomes, and 
even nuclei
15-19
. Our group recently reported that TNTs can facilitate direct cell-to-cell 
transfer and redistribution of therapeutic cancer-targeting vehicles, specifically oncolytic 
viruses engineered to selectively target cancer cells
20
. Furthermore, we also demonstrated 
that following infection with an oncolytic virus, TNTs also mediated intercellular 
distribution of the viral thymidine kinase-activated nucleoside analog ganciclovir. This 
transport of cytotoxic drug from non-virus infected to virus-infected resulted in increased 
cell-kill
20
, representing a newly described form of bystander effect in the treatment of 
cancer.  If sensitive cells expel drugs to resistant cells via TNTs, this could potentially 
allow drug-treated cells to survive by minimizing drug exposure. Conversely, resistant 
cells expelling drugs to sensitive cells via TNTs could induce cell death, thereby 
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enriching the population of drug-resistant cells and allowing them to thrive with a 
reduced competition in the microenvironment. The chemotherapeutic drug doxorubicin 
which was the focus of the current study, auto-fluoresces (excitation: 480 nm, emission: 
560-590 nm), and can be easily examined using fluorescence microscopy
21
. Taking 
advantage of this drug’s unique property, we attempted to capture microscopy evidence 
of cancer cells harnessing TNTs as conduits for intercellular redistribution of doxorubicin 
following short-term treatment. We initially determined that S2013 cells readily 
internalized the doxorubicin via fluorescence microscopy (Figure 3); and then performed 
automated time-lapse microscopy by taking images every 10 minutes for 5 hours to track 
movement of the drug. We confirmed the formation of TNTs and the successful transfer 
of doxorubicin from doxorubicin-positive cells to the TNT-connected recipient cells 
(composite images and schematic shown in Figure 4B, and Supplementary Movie 1).  
 
To confirm this finding in an additional cancer model, we repeated the experiment using 
a chemoresistant ovarian cancer model form TNTs at differential rates based on 
chemoresistant vs chemosensitive status of co-cultured cells
22
. In this experiment, we 
treated SKOV3 (multi-drug resistant ovarian carcinoma cells) with doxorubicin, and co-
cultured them with untreated A2780 cells, which are known to be sensitive to 
doxorubicin. Using time-lapse microscopy, we analyzed images for TNT formation 
between the cell populations. In one particularly striking instance, we observed transfer 
of fluorescing doxorubicin granules from a SKOV3 cell to an A2780 cell via a TNT 
(Figure 4A, and Supplementary Movie 2). Notably, only a minimal amount of effluxed 
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drug was required for the recipient chemosensitive A2780 cell to undergo cell death 
within 3 hours of drug transfer via the TNT.  
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4.5 Discussion 
 
Chemoresistance remains a significant clinical problem, yet the underlying cellular 
mechanisms remain unclear despite advances in the field of cancer treatment. Our studies 
were designed to evaluate the formation of TNTs – a unique form of cellular protrusion 
implicated in long-distance cell communication – as a cellular stress response.  We found 
that the response following exposure of pancreatic cancer cells to doxorubicin was dose-
dependent; and that TNTs facilitate a novel and direct form of cell-to-cell drug efflux 
among pancreatic and ovarian cancer cells through transport of a cytotoxic drug 
(doxorubicin). To our knowledge, direct cell-to-cell transfer and efflux of chemotherapy 
agents via TNTs has been reported in one other instance, in an in vitro model of acute 
myelogenous leukemia. In that study, researchers detected localization of the drug 
daunorubicin to lysosomes, and visualized cell-to-cell transfer of the drug via TNTs
23
. In 
2012, we reported that TNTs, or at least TNT-like structures, could be visualized 
connecting cells in intact tumors resected from human patients with malignant pleural 
mesothelioma
15,24
. Additional tumor types for which we have reported similar findings 
include lung carcinomas, ovarian carcinomas, osteosarcomas, breast carcinomas, 
neuroendocrine tumors, and colon cancers
15,19,22,25
. Here, we provide visual evidence that 
pancreatic adenocarcinomas can be added to this growing list of aggressive cancer types 
that are capable of forming TNTs for mediating long-range intercellular communication. 
 
We used doxorubicin, an anthracycline chemotherapeutic drug in extensive clinical use 
for a variety of epithelial malignancies including breast and ovarian cancers, because of 
its wide use in cancer chemotherapy-based treatment and in vitro autofluorescent 
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properties
21
. Its primary mechanism of action involves DNA intercalation and 
topoisomerase inhibition. Our observations underscore a possible role for TNTs in drug-
efflux of either chemo-naïve or in more advanced chemorefractory cancers. We exposed 
cells to varied concentrations of this drug (200, 400, 600, 800, 1000, and 1200 ng/mL), 
and compared the results to no drug. In a clinical setting, doxorubicin follows a fast 
distribution phase followed by a slow elimination phase; the drug reaches a peak 
concentration of ~600 ng/ml before being distributed to other tissues following 
intravenous administration
26,27
.  Adding an optimized concentration of the drug (low 
enough not to induce immediate toxicity leading to cell death, but high enough to be 
detected using fluorescent microscopy) allowed us to perform time-lapse imaging over 
24-48 hours. We visualized direct outgrowth of TNTs from drug-treated chemoresistant 
(SKOV3) cells to chemosensitive (A200) ovarian cancer cells, confirming that resistant 
cells were capable of initiating this unique form of cellular interaction. Following co-
culture of doxorubicin-treated SKOV3 cells with A2780 cells, we visualized a TNT 
connecting these cells and facilitating transfer of a minimal amount of this 
autofluorescent drug; and within hours, the recipient chemosensitive (A2780) cell 
involuted and underwent cell death.  As we have previously reported, when these cells 
were co-cultured, formation of TNTs from chemoresistant to chemosensitive ovarian 
cancer cells constituted the fewest number of interactions, as compared with sensitive-to-
resistant, resistant-to-resistant, or sensitive-to-sensitive
22
. The finding that a drug can be 
redistributed via TNTs poses a potential new paradigm for cellular mechanisms of drug 
efflux and the development of drug resistance in cancers. We speculate that this finding 
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suggests TNTs may serve as an alternate mechanism capable of exporting 
chemotherapeutic drugs in an efficient manner between connected cells.  
 
In 2013, we published a review of the potential impact of intercellular communication on 
tumor heterogeneity in pancreatic cancer
28
. At that time, we speculated on the role that 
TNTs could play in tumor-tumor interactions in this particularly heterogeneous tumor 
microenvironment. Our current study supports the notion that TNTs represent a non-
genetic intercellular stress response by which tumors can survive despite exposure to 
cytotoxic chemotherapeutic drugs in an hypoxic tumor microenvironment. This supports 
the notion that physiologic or metabolic stressors in the microenvironment can induce or 
activate other forms of cellular protrusions as well, including invadopodia responsible for 
invasive cancer cell migration
29
.  
 
Over the past decade, therapeutic strategies for treatment of several forms of potentially 
resectable cancers including ovarian
30
, breast
31
, and also pancreatic carcinomas
32,33
,  have 
shifted to the use of neoadjuvant (pre-operative) chemotherapy. This approach is 
increasingly taken for multiple cancers, The intent is to chemically debulk the tumor prior 
to surgical resection, to treat early micrometastatic disease, and to ensure that patients 
receive at least some chemotherapy treatment in light of potential post-surgical 
complications. However, there are concerns that this approach generates more 
chemoresistant strains of these cancers. Retrospective studies of ovarian cancer patients 
who received preoperative therapy treatment with platinum-based therapy did lead to a 
higher long-term risk of platinum resistance compare to patients who initially had 
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primary debulking surgery
34
. Animal models support the influence of chemotherapy in 
promoting the rise in population of minor or previously dormant clinical lineage 
(colorectal cancer)
35
, and in direct inducing metastatic potential (breast cancer)
36
. The 
ability of TNTs to form variable in response to chemotherapeutic drug-induced stress 
may at least in part explain this response and early emergence of drug resistance. Further, 
the ability of TNTs to mediate intercellular efflux, or redistribution, of drugs – potentially 
to subtherapeutic levels – may allow cells connected via these cellular ‘networks’ to 
protect each other from drug susceptibility. In this potential translational model, with 
continued administration of chemotherapy over time, the cells that adapt best to 
chemotherapeutic stress would survive and overtake other clonal subpopulations. 
 
There is precedence for evolution of drug efflux in cancer cells, as development of 
chemoresistance via overexpression of P-glycoprotein (P-gp) is already well 
established
37
. This protein is a member of the ABC transporter family; when 
overexpressed, it becomes embedded within the plasma membrane, serving effectively as 
an ATP-dependent pump for efflux of chemotherapeutic agents 
38,39
. The potential for 
intercellular transfer of P-gp to occur, and for the protein to remain functional following 
this horizontal transfer, has also been demonstrated 
40
. Furthermore, P-gp has been 
studied in the context of TNTs, and specifically in ovarian cancer 
41
. TNT-mediated 
transfer of both mitochondria and P-gp has been demonstrated in breast and ovarian 
cancer cell lines, in addition to transfer mediated without cell-to-cell contact, via 
microparticles, have been associated with chemoresistance 
17,41
. Several recent studies 
have in fact confirmed cell-to-cell transport of chemotherapeutic drugs via cellular 
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microparticles or exosomes 
42-46
. Compared with TNTs, exosomes are diffusible vessels 
of cell transport but may not be as efficient for cargo delivery as TNTs, which act as 
nanoscale pipelines between distant cells that cannot be connected via connexin-lined 
(gap junction) channels. Our results support the notion that TNTs represent a newly 
identified mechanism of drug efflux, which comprises both cytoplasm-to-cytoplasm 
extrusion of drug via TNTs. Intercellular transfer of P-gp has been examined in other 
cancer models (e.g. in bladder cancer); and at least one study concluded that cell-to-cell 
contact is not necessary for this transfer to take place and mediate drug resistance 
47
. The 
authors concluded microparticles were the most likely mode of transfer in that study. In 
this context TNT-mediated transfer of P-gp may play a more complementary or 
secondary role to cytoplasm-to-extracellular environment extrusion via P-gp/multidrug 
resistance (MDR) channels. 
 
We have shown that TNT formation is significantly higher in malignant pancreatic cells 
as compared to pancreatic ductal non-malignant epithelial cells within the stromal 
microenvironment. This result and difference in TNTs between malignant and benign 
cells is consistent with our data in other invasive cancers, such as malignant pleural 
mesothelioma among others
24
. We have previously speculated that TNTs play a role in 
cancers that may allow us to harness them as conduits for more effective drug 
delivery
25,48
. This concept would be particularly intriguing and applicable to pancreatic 
cancer, in which effective drug penetration remains a challenge due to dense 
desmoplastic reaction and thick hyaluronan coats that preclude diffusion of drugs into 
tumors
28,49
. Interestingly, TNTs have been shown to provide mesenchymal stem cells 
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rescue of cardiomyocytes damaged following exposure to anthracycline drugs by TNT-
mediated transfer of mitochondria
50
. In the setting of cancer, the effects may actually be 
reversed, in which chemotherapeutic damage and the resultant rise in TNT formation 
leads to redistribution of the drug to other cells – in an effort for the affected cells to save 
themselves – or induce a stress response that leads damaged cells to “offer” their 
mitochondria and other vital cell components to other neighboring cells as a “sacrifice” to 
benefit the overall cancer cell population. The niche of TNTs and drug delivery is 
thought-provoking and one that we predict will gain increased interest. 
 
In summary, chemoresistant cells can initiate TNTs to chemosensitive cancer cells and 
stimulate redistribution of cytotoxic drug. We postulate that this efflux can result in cell 
death of chemosensitive recipient cells, providing a new and additional mechanism for 
establishing drug chemoresistance.
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Figure 4.1. 
 
 Figure 4.1. TNTs are identified in resected human pancreatic adenocarcinoma. 
Tunneling nanotube-like structures, likely TNTs, were visualized connecting cells in 
tissue samples resected from pancreatic ductal adenocarcinoma patients. The tumors were 
stained with fluorescing MitoTracker Orange dye and imaged using confocal microscopy 
with z-stacking of images under 40x oil objective lens. 3-dimensional reconstruction was 
done using NIS elements AR (version 4.00.07) software analysis (Nikon Instruments, 
Inc, Melville, NY).  
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Figure 4.2. 
 
Figure 4.2. TNT formation amongst pancreatic cancer cells. 
A. Representative images of TNTs connecting pancreatic adenocarcinoma cells from the 
S2013 and MIA PaCa-2 cell lines, and human pancreatic ductal epithelial (HPDE) cells 
characteristic of tumor stroma. Images were taken using an Olympus IX70 inverted 
microscope. Scale bar = 20 m. 
B. Number of TNTs/cell (TNT index) over time, comparing results for the S2013, MIA 
PaCa-2 and HPDE cell lines.  The symbols represent individual data points and the solid 
lines represent the median.  
C. Box plots depicting the length of TNTs forming between S2013 cells at 24, 48 72 and 
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96 hours.  The box indicates the 25
th
 to 75
th
 percentiles, the solid line represents the 
median and the whiskers represent the minimum and maximum values.   
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Figure 4.3.  
 
Figure 4.3. Variable dose-dependent response of TNTs forming following exposure 
to the chemotherapeutic drug doxorubicin. A. Representative images of TNTs 
transmitting autofluorescing (red) doxorubicin between S2013 cells. Images were taken 
using a Zeiss Axio widefield microscope. Scale bars = 50 m. 
Scatter-plot graph depicting the median number of TNTs/cell (TNT index) over time, 
comparing results for the S2013 (Panel B) and MIA PaCa-2 (Panel C) cell lines 
following exposure to six concentrations of doxorubicin. This experiment was done in 
triplicate, with a sample size of 18 fields of view per dose/per time point. 
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Figure 4.4.  
 
Figure 4.4. TNTs act as a direct conduit for intercellular transfer and redistribution 
of the chemotherapeutic drug doxorubicin. 
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A. Composite of serial images from time-lapse microscopy demonstrating 
intercellular transfer of doxorubicin from a chemoresistant ovarian cancer cell 
(SKOV3) to a chemosensitive cell (A2780) via a TNT, resulting in cell death of 
the chemosensitive cell.   
B. TNT formation and intercellular transfer of doxorubicin between S2013 
pancreatic adenocarcinoma cells. 
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Chapter Five 
   
Summary 
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TNTs were uncovered as a novel mechanism of intercellular communication rat 
pheochromocytoma (PC12) cells by Amin Rustom et al. They published their seminal 
findings in 2004[129]. Rustom and hiss graduate advisor, Dr. Hans-Hermann Gerdes 
named the nano-scaled, undulating, ultra-thin filaments “tunneling nanotubes” and 
focused their efforts on deciphering their structure and function. They found that cells 
connected via TNTs were capable of sharing organelles and other cytoplasmic content 
within hours after coculture. At the time, TNTs were recognized to be structurally 
similar to cytonemes of Drosophila wing imaginal disc, which was first described only a 
year prior to the discover of TNTs[247]. Functionally, the mediation of cell-cell 
continuity destined that TNTs act more like structures known as plasmodesmata that 
facilitate intercellular trafficking macromolecules in plants[162]. Since that 2004 study, a 
handful of researchers have published work demonstrating TNTs in tissues[171], [248].  
 
To date, functional insights on TNTs have almost exclusively been performed through in 
vitro culture studies. Technical limitations, at the moment, still make it very difficult to 
study TNTs in vivo. The lack of in vivo evaluation has led some researchers to be 
extremely critical of the field, stating that TNTs are primarily a phenomenon of cells in 
culture. However, numerous studies that showed TNT-like structures in in vivo models of 
development demonstrate otherwise. In fact, prior to the discovery and classification of 
TNTs, these structures were observed and studied in multiple embryonic models. Due to 
the ease of handling and transparent morphology, embryos made ideal models for 
studying TNT in vivo.  
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Over 50 years ago, developmental biologists Tryggve Gustafson and Lewis 
Wolpert published their famous work on spatial differentiation. Their work was critical in 
elucidating the method by which the fate and characteristic of individual cells was 
determined during gastrulation of sea urchin embryo. It was found that interactions 
amongst the cells facilitated cellular patterning. Primary mesenchymal cells (PMCs), 
which can be easily observe using a light-microscope, must interact with ectoderm and 
dictate its correct skeletal pattern. The interaction between these cells can occur across 
great cellular distances. While analyzing filopodia formed by migrating PMCs for 
motility and structure, Gustafson and Wolpert observed the presence of thinner “cellular 
bridges” facilitating connections between PMCs and ectoderm that were dozens of 
micrometers apart. They referred to these structures as “pseudopods.” The pseudopods 
were 500 nm or less in diameter, were actin-based and break easily[249], [250]. In later 
investigations, advance resolution microscopy enabled investigators to correlate 
patterning sensory signals with formation of these pseudopods[251]. Often, the 
movement of bulges could be observed along the pseudopods. This is similar to what we 
and other researchers have seen in TNT studies. In addition, it was demonstrated that, 
unlike filopodia, degradation of the extracellular matrix influence the formation 
pseudopods[252]. Remarkably, these same characteristic were described almost 50 years 
later for what we now know as TNTs[129].  
 
Today, we are elucidating more about the molecular and cell functions of TNTs. My 
work has been at the forefront of TNT related studies. Most of TNT studies were 
branches of immunology work. Our group has primarily focused on investigating TNTs 
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in cancer. TNTs potentially provide cancer cells a direct route for transmitting influential 
messages across long distances in the complex tumor microenvironment. We have 
demonstrated that malignant cells have significantly higher rates of TNT formation 
compared to stromal cells of their corresponding tumor. We believe that upregulation of 
TNTs in cancer may amplify cellular cross-talk and thus increase rates of tumor 
recurrence and invasion. The first set of experiments that we performed involved the 
characterization of TNT in several cancers. The rate of TNT formation in cell lines from 
four cancers (colorectal, mesothelioma, pancreatic, and ovarian cancer) were quantitated. 
Across these cancers, we found that the rate of TNT formation was greater amongst 
metastatic or aggressive cancer cells compare to primary derived or non-malignant cells.  
  
Studies evaluating TNTs in the four cancers named above have all been published or are 
close to being published by the completion of this thesis. The aim of my work was to 
deepen the depth of knowledge on the functionally of TNTs in cancers and the role they 
may play in well-known characteristics of malignant tumors. Some of these 
characteristics include metastasis, the ability to thrive in hypoxic environments, 
resistance to chemotherapeutic drugs, and in the development of tumor heterogeneity. My 
first TNT-related peer-reviewed work, for which I earned a second authorship, was a 
follow up to studies initially published by Dr. Emil Lou on the presence of TNTs in 
mesothelioma tumors[130]. In his 2012 published studies, Dr. Lou was able to identify 
and developed a culture media condition that enhanced TNT formation[171]. I was able 
to use that culture condition to evaluate TNT formation in several different mesothelioma 
cancer cells and present a new way in which data on TNT studies could be presented. The 
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study of TNTs in mesothelioma remains attractive because cells of this cancer type form 
more TNTs than any other ones we have encountered. Clinically, mesothelioma is a 
highly migratory cancer where the cells tend to spread beyond the abdominal on 
lining[253], [254]. Interestingly, we found in many cancers that the metastatic cells form 
high amounts of TNTs as compare to non-metastatic cells of the same cancer. 
Furthermore, mice implanted with TNT-primed mesothelioma cells had a decreased 
survival rate[130]. Correlating markers of metastasis to TNT is a future direction that 
could prove to be very fruitful.   
 
A proof of concept experiment that involves the examination of the cadherins and other 
metastasis-related proteins could also be part of a future study. Cells that does not form 
high amount of TNTs could be stimulated to form more TNTs. It would be interesting to 
see if these cells, upon forming more TNTs, become more motile and have increased 
expression of N-cadherin or vimentin. From such studies we would also have an 
opportunity to understanding the role of TNTs in non-malignant pathological events as 
well. It is no surprise that much of what we know about TNTs have come from the field 
of immunology. Immune cells are highly mobile and are frequently involved in cross-talk 
amongst themselves and other cell type[105], [107]. The more “successful” and invasive 
cancer cells can be said to have done well at mimicking some of the migratory and 
intercellular networking capabilities of immune cells and TNTs may play a role. 
 
Hypoxia is one of the major characteristic of the tumor micro environment. The high 
proliferative cells tend to starve the microenvironment of adequate and other important 
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nutrients[255], [256]. For reasons currently not well elucidated, the malignant cells are 
highly adaptable to this environment and can respond to hypoxia with molecular and 
cellular changes and increased invasiveness and even resistance to drug therapy. 
Communication is known to play a major role in the ability of these cells to survive and 
thrive in such environment[20], [83]. To evaluate TNTs and hypoxia in cancer, we used 
ovarian cancer as a model disease as we were able to acquire tumor cell lines that were 
resistant and sensitive to Platinum-based chemodrugs[131]. In this study, we subjected 
chemosensitive and chemoresistant cells to hypoxic conditions. The chemoresistant cells 
did not form more TNTs under normal passage conditions in this cancer. However, TNT 
formation was a hypoxia-induced stress response for these cells but not the 
chemosensitive cells. Although cancer cells rely on intercellular cross-talk, hypoxia can 
impair some junctional proteins such as connexins that are involved in cell-cell 
connections. This damage has been implicated in the loss of cellular polarity that is often 
characteristic of malignant tumors[155], [257], [258]. To date there have been no studies 
on the role that TNTs may play in as an alternative or additional means of 
communicating for these “rogue” malignant cells. The main contributors to the loss of 
junctional integrity are well known proinflammatory cytokines such as TNF-alpha and 
interleukin related proteins[259]–[262]. Interestingly, proinflammatory factors have been 
shown to stimulate TNTs[177], [212]. In our study, there were no TNF-alpha and IL 
proteins producing cells present, thus the TNT enhancing effects of hypoxia was due to 
other inducers. In addition, we did not perform follow up studies to determine the 
purpose of increase TNT formation by the resistant cells. Perhaps the cells were using 
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TNTs as a means creating a network-like communication system to share nutrients and 
other cargos that were scared in the hypoxic environment. It is well established that TNTs 
can mediate the transfer of mitochondria between cells. The sharing of mitochondria 
through TNTs has been shown to facilitate rescue of mito-comprimised cells[180]. In 
PC12 cells mitochondria transfer can prevent UV-induced apoptosis[174]. Since hypoxia 
lead to a lack of ATP production, the cancer cells forming TNTs may be using it to 
shuttle mitochondria amongst the population as immediate short term solution. We can 
examine if preventing TNT formation reduces survivability of these cells under hypoxia. 
In my 2016 paper, we co-cultured the resistant and sensitive cells and quantified whether 
these two populations were more likely to form TNTs amongst their own or to the 
other[131]. We can design a future experiment where applying similar concepts using 
hypoxia-primed cells. Under hypoxic stress, cancer cells may form more TNTs or 
produce factors to attract TNT from neighboring cells. Our lab has published work that 
certain tumor released exosomes are associated with TNT formation[217]. If we co-
culture labelled hypoxia-primed (cell
hypoxia
) cells with labelled normoxic cells (cell
nomoxia
) 
and observe majority of TNTs form are A) from cell
hypoxia
 to cell
nomoxia
 or B) cell
nomoxia
 to 
cell
hypoxia
, we can gain further understanding about whether the stress respond is to 
produce or attract TNTs for rescue.  
 
Tumor cells are constantly evolving and do so in a non-linear manner. As a tumor 
progresses over time, it can develop great genetic diversity amongst the proliferating 
subclones[263]. We are now beginning to acquire more understandings on how 
intercellular cross-talk mechanisms may contribute to genetic diversity in cancer. TNTs 
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potentially have a role in providing a fast and direct mechanism of genetic mixing[58], 
[217]. We have previously demonstrated that direct cell-to-cell transfer of tumor 
associated microRNAs via TNTs. The impact this phenomenon may have on intratumoral 
heterogeneity lies in the possibility of such event eliciting genetic alteration that leads 
cellular transformation. My contribution to the idea of TNTs playing a role in 
heterogeneity is the work I have done examining TNTs in a highly heterogeneous, 
especially colorectal cancer (CRC). We are currently working to publish studies related 
to TNTs and CRC heterogeneity in the near future. Our work thus far provides 
foundation for TNTs as potential novel therapeutic target as we continue to develop 
strategies for treating cancer.  
  
133 
 
Bibliography 
 
[1] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics,” CA Cancer J Clin, 
vol. 66, no. 1, pp. 7–30, 2016. 
[2] T. N. Chirikos, “Cancer economics,” in International Encyclopedia of Public 
Health, 2008, pp. 408–415. 
[3] American Cancer Society, “Cancer Facts & Figures 2017,” 2017. 
[4]  et al Howlader N, Noone AM, Krapcho M, “**SEER Cancer Statistics Review, 
1975-2013,” Natl. Cancer Institute. (Accessed January 16, 2017), pp. 1992–2013, 
2013. 
[5] Y. J. Zhang and J. Y. Fang, “Molecular staging of gastric cancer,” Journal of 
Gastroenterology and Hepatology (Australia), vol. 23, no. 6. pp. 856–860, 2008. 
[6] M. C. Paoloni and C. Khanna, “Comparative Oncology Today,” Veterinary Clinics 
of North America - Small Animal Practice, vol. 37, no. 6. pp. 1023–1032, 2007. 
[7] A. C. Reese, J. E. Cowan, J. S. Brajtbord, C. R. Harris, P. R. Carroll, and M. R. 
Cooperberg, “The quantitative Gleason score improves prostate cancer risk 
assessment,” Cancer, vol. 118, no. 24, pp. 6046–6054, 2012. 
[8] N. M. Corcoran et al., “Upgrade in Gleason score between prostate biopsies and 
pathology following radical prostatectomy significantly impacts upon the risk of 
biochemical recurrence,” BJU Int., vol. 108, no. 8 B, 2011. 
[9] J. D. Davies et al., “Prostate size as a predictor of Gleason score upgrading in 
patients with low risk prostate cancer,” J. Urol., vol. 186, no. 6, pp. 2221–2227, 
2011. 
[10] D. O. Morgan, “Regulation of the APC and the exit from mitosis.,” Nat. Cell Biol., 
vol. 1, no. 2, pp. E47–E53, 1999. 
[11] S. F. Bakhoum, L. Kabeche, J. P. Murnane, B. I. Zaki, and D. a Compton, “DNA 
damage response during mitosis induces whole chromosome mis-segregation.,” 
Cancer Discov., vol. 1304, no. 1304, pp. 1281–1289, 2014. 
[12] S. F. Bakhoum, L. Kabeche, D. A. Compton, S. N. Powell, and H. Bastians, 
“Mitotic DNA Damage Response: At the Crossroads of Structural and Numerical 
Cancer Chromosome Instabilities,” Trends in Cancer, vol. 3, no. 3. pp. 225–234, 
2017. 
[13] Y. Stewenius et al., “Structural and numerical chromosome changes in colon 
cancer develop through telomere-mediated anaphase bridges, not through mitotic 
multipolarity,” Proc. Natl. Acad. Sci., vol. 102, no. 15, pp. 5541–5546, 2005. 
[14] D. Hanahan and R. A. Weinberg, “The hallmarks of cancer.,” Cell, vol. 100, no. 1, 
pp. 57–70, 2000. 
[15] Y. Lazebnik, “What are the hallmarks of cancer?,” Nat. Rev. Cancer, vol. 10, no. 
4, pp. 232–233, 2010. 
[16] D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: The next generation,” 
Cell, vol. 144, no. 5. pp. 646–674, 2011. 
[17] J. L. Bos, “Ras Oncogenes in Human Cancer: A Review,” Cancer Res., vol. 49, 
no. 17, pp. 4682–4689, 1989. 
[18] S. Renaud et al., “KRAS and BRAF mutations are prognostic biomarkers in 
134 
 
patients undergoing lung metastasectomy of colorectal cancer.,” Br. J. Cancer, vol. 
112, no. 4, pp. 720–8, 2015. 
[19] A. D. Cox, S. W. Fesik, A. C. Kimmelman, J. Luo, and C. J. Der, “Drugging the 
undruggable RAS: Mission Possible?,” Nat. Rev. Drug Discov., vol. 13, no. 11, pp. 
828–851, 2014. 
[20] E. Lou, S. Subramanian, and C. J. Steer, “Pancreatic cancer: modulation of KRAS, 
MicroRNAs, and intercellular communication in the setting of tumor 
heterogeneity.,” Pancreas, vol. 42, no. 8, pp. 1218–26, 2013. 
[21] E. R. Fearon, “Molecular genetics of colorectal cancer.,” Annu. Rev. Pathol., vol. 
6, pp. 479–507, 2011. 
[22] R. Fodde, “The APC gene in colorectal cancer.,” Eur. J. Cancer, vol. 38, no. 7, pp. 
867–71, 2002. 
[23] B. Rubinfeld et al., “Association of the APC gene product with beta-catenin,” 
Science (80-. )., vol. 262, no. 5140, pp. 1731–1734, 1993. 
[24] R. Fodde et al., “Mutations in the APC tumour suppressor gene cause 
chromosomal instability.,” Nat. Cell Biol., vol. 3, no. 4, pp. 433–438, 2001. 
[25] D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1. 
pp. 57–70, 2000. 
[26] S. W. Lowe and  a W. Lin, “Apoptosis in cancer.,” Carcinogenesis, vol. 21, no. 3, 
pp. 485–495, 2000. 
[27] J. M. Brown and L. D. Attardi, “The role of apoptosis in cancer development and 
treatment response.,” Nat. Rev. Cancer, vol. 5, no. 3, pp. 231–237, 2005. 
[28] J. T. Zilfou and S. W. Lowe, “Tumor suppressive functions of p53.,” Cold Spring 
Harbor perspectives in biology, vol. 1, no. 5. 2009. 
[29] J. Liu, C. Zhang, and Z. Feng, “Tumor suppressor p53 and its gain-of-function 
mutants in cancer The p53 Signaling Pathway Introduction Tumor Suppressive 
Functions of p53,” Acta biochimica et biophysica …, vol. 46, no. 3. pp. 1–10, 
2013. 
[30] C. A. Schmitt, J. S. Fridman, M. Yang, E. Baranov, R. M. Hoffman, and S. W. 
Lowe, “Dissecting p53 tumor suppressor functions in vivo,” Cancer Cell, vol. 1, 
no. 3, pp. 289–298, 2002. 
[31] P. A. J. Muller and K. H. Vousden, “Mutant p53 in cancer: New functions and 
therapeutic opportunities,” Cancer Cell, vol. 25, no. 3. pp. 304–317, 2014. 
[32] V. Marcel et al., “Biological functions of p53 isoforms through evolution: lessons 
from animal and cellular models,” Cell Death Differ., vol. 18, no. 12, pp. 1815–
1824, 2011. 
[33] C. W. Greider, “Telomere Length Regulation,” Annu. Rev. Biochem., vol. 65, no. 
1, pp. 337–365, 1996. 
[34] M. T. Hayashi, A. J. Cesare, T. Rivera, and J. Karlseder, “Cell death during crisis 
is mediated by mitotic telomere deprotection,” Nature, vol. 522, no. 7557, pp. 
492–496, 2015. 
[35] L. Xu, S. Li, and B. A. Stohr, “The Role of Telomere Biology in Cancer,” Annu. 
Rev. Pathol. Mech. Dis., vol. 8, no. 1, pp. 49–78, 2013. 
[36] C. Autexier and C. W. Greider, “Telomerase and cancer: Revisiting the telomere 
135 
 
hypothesis,” Trends in Biochemical Sciences, vol. 21, no. 10. pp. 387–391, 1996. 
[37] D. Hanahan and J. Folkman, “Patterns and emerging mechanisms of the 
angiogenic switch during tumorigenesis,” Cell, vol. 86, no. 3. pp. 353–364, 1996. 
[38] A. M. F. Aranha, Z. Zhang, K. G. Neiva, C. A. S. Costa, J. Hebling, and J. E. Nör, 
“Hypoxia enhances the angiogenic potential of human dental pulp cells,” J. 
Endod., vol. 36, no. 10, pp. 1633–1637, 2010. 
[39] C. Brahimi-Horn, E. Berra, and J. Pouysségur, “Hypoxia: The tumor’s gateway to 
progression along the angiogenic pathway,” Trends in Cell Biology, vol. 11, no. 
11. 2001. 
[40] J. Fang, L. Yan, Y. Shing, and M. A. Moses, “HIF-1??-mediated up-regulation of 
vascular endothelial growth factor, independent of basic fibroblast growth factor, 
is important in the switch to the angiogenic phenotype during early 
tumorigenesis,” Cancer Res., vol. 61, no. 15, pp. 5731–5735, 2001. 
[41] A. Wicki and G. Christofori, “The angiogenic switch in tumorigenesis,” in Tumor 
Angiogenesis: Basic Mechanisms and Cancer Therapy, 2008, pp. 67–88. 
[42] P. Hahnfeldt, D. Panigrahy, J. Folkman, and L. Hlatky, “Tumor development 
under angiogenic signaling: A dynamical theory of tumor growth, treatment 
response, and postvascular dormancy,” Cancer Res., vol. 59, no. 19, pp. 4770–
4775, 1999. 
[43] J. A. Joyce and J. W. Pollard, “Microenvironmental regulation of metastasis,” Nat. 
Rev. Cancer, vol. 9, no. 4, pp. 239–252, 2009. 
[44] G. P. Gupta and J. Massagué, “Cancer Metastasis: Building a Framework,” Cell, 
vol. 127, no. 4. pp. 679–695, 2006. 
[45] N. H. Ha, F. Faraji, and K. W. Hunter, “Mechanisms of metastasis,” in Cancer 
Targeted Drug Delivery: An Elusive Dream, 2013, pp. 435–458. 
[46] T. R. Geiger and D. S. Peeper, “Metastasis mechanisms,” Biochimica et 
Biophysica Acta - Reviews on Cancer, vol. 1796, no. 2. pp. 293–308, 2009. 
[47] D. S. Tan, R. Agarwal, and S. B. Kaye, “Mechanisms of transcoelomic metastasis 
in ovarian cancer,” Lancet Oncology, vol. 7, no. 11. pp. 925–934, 2006. 
[48] M. Yin et al., “Tumor-associated macrophages drive spheroid formation during 
early transcoelomic metastasis of ovarian cancer,” J. Clin. Invest., vol. 126, no. 11, 
pp. 4157–4173, 2016. 
[49] R. C. Gebbie, M. R. Hardcastle, S. A. Hunter, and A. C. Hartman, “Transcoelomic 
spread and metastasis of a squamous cell carcinoma of presumed pancreatic duct 
origin in a cat,” N. Z. Vet. J., vol. 60, no. 2, pp. 154–159, 2012. 
[50] G. K. Alderton, “Metastasis: Polarizing metastasis.,” Nat. Rev. Cancer, vol. 13, no. 
2, p. 75, 2013. 
[51] J. A. Joyce and J. W. Pollard, “Microenvironmental regulation of metastasis,” Nat. 
Rev. Cancer, vol. 9, no. 4, pp. 239–252, 2009. 
[52] M. Xia and H. Land, “Tumor suppressor p53 restricts Ras stimulation of RhoA and 
cancer cell motility,” Nat. Struct. Mol. Biol., vol. 14, no. 3, pp. 215–223, 2007. 
[53] C.-I. Hwang et al., “Wild-type p53 controls cell motility and invasion by dual 
regulation of MET expression.,” Proc. Natl. Acad. Sci. U. S. A., vol. 108, no. 34, 
pp. 14240–14245, 2011. 
136 
 
[54] E. Sahai, M. F. Olson, and C. J. Marshall, “Cross-talk between Ras and Rho 
signalling pathways in transformation favours proliferation and increased 
motility,” EMBO J., vol. 20, no. 4, pp. 755–766, 2001. 
[55] A. T. Sasaki et al., “G protein-independent Ras/PI3K/F-actin circuit regulates 
basic cell motility,” J. Cell Biol., vol. 178, no. 2, pp. 185–191, 2007. 
[56] M. De Menna et al., “Wnt4 inhibits cell motility induced by oncogenic Ras,” 
Oncogene, vol. 32, no. 35, pp. 4110–4119, 2013. 
[57] M. C. Mendoza, E. E. Er, and J. Blenis, “The Ras-ERK and PI3K-mTOR 
pathways: Cross-talk and compensation,” Trends in Biochemical Sciences, vol. 36, 
no. 6. pp. 320–328, 2011. 
[58] V. Thayanithy, E. L. Dickson, C. Steer, S. Subramanian, and E. Lou, “Tumor-
stromal cross talk: Direct cell-to-cell transfer of oncogenic microRNAs via 
tunneling nanotubes,” Transl. Res., vol. 164, no. 5, pp. 359–365, 2014. 
[59] E. I. Deryugina and W. B. Kiosses, “Intratumoral Cancer Cell Intravasation Can 
Occur Independent of Invasion into the Adjacent Stroma,” Cell Rep., vol. 19, no. 
3, pp. 601–616, 2017. 
[60] J. P. Quigley and P. B. Armstrong, “Tumor cell intravasation Alu-cidated: The 
chick embryo opens the window,” Cell, vol. 94, no. 3. pp. 281–284, 1998. 
[61] M. B. Chen, J. A. Whisler, J. S. Jeon, and R. D. Kamm, “Mechanisms of tumor 
cell extravasation in an in vitro microvascular network platform,” Integr. Biol., 
vol. 5, no. 10, p. 1262, 2013. 
[62] C. Strell and F. Entschladen, “Extravasation of leukocytes in comparison to tumor 
cells,” Cell Commun. Signal., vol. 6, no. 1, p. 10, 2008. 
[63] H. Shiozaki et al., “Expression of immunoreactive E-cadherin adhesion molecules 
in human cancers.,” Am. J. Pathol., vol. 139, no. 1, pp. 17–23, 1991. 
[64] K. Gravdal, O. J. Halvorsen, S. A. Haukaas, and L. A. Akslen, “A switch from E-
cadherin to N-cadherin expression indicates epithelial to mesenchymal transition 
and is of strong and independent importance for the progress of prostate cancer,” 
Clin. Cancer Res., vol. 13, no. 23, pp. 7003–7011, 2007. 
[65] E. Janda, M. Nevolo, K. Lehmann, J. Downward, H. Beug, and M. Grieco, “Raf 
plus TGFβ-dependent EMT is initiated by endocytosis and lysosomal degradation 
of E-cadherin,” Oncogene, vol. 25, no. 54, pp. 7117–7130, 2006. 
[66] Y. Su, J. Li, C. Shi, R. H. Hruban, and G. L. Radice, “N-cadherin functions as a 
growth suppressor in a model of K-ras-induced PanIN,” Oncogene, vol. 35, no. 25, 
pp. 3335–3341, 2016. 
[67] K. Shimamura, S. Hirano,  a P. McMahon, and M. Takeichi, “Wnt-1-dependent 
regulation of local E-cadherin and alpha N-catenin expression in the embryonic 
mouse brain.,” Development, vol. 120, pp. 2225–2234, 1994. 
[68] B. Rubinfeld et al., “Association of the APC gene product with beta-catenin,” 
Science (80-. )., vol. 262, no. 5140, pp. 1731–1734, 1993. 
[69] R. V. Iozzo, “Basement membrane proteoglycans: from cellar to ceiling,” Nat. 
Rev. Mol. Cell Biol., vol. 6, no. 8, pp. 646–656, 2005. 
[70] R. G. Rowe and S. J. Weiss, “Breaching the basement membrane: who, when and 
how?,” Trends in Cell Biology, vol. 18, no. 11. pp. 560–574, 2008. 
137 
 
[71] K. Hotary, X. Y. Li, E. Allen, S. L. Stevens, and S. J. Weiss, “A cancer cell 
metalloprotease triad regulates the basement membrane transmigration program,” 
Genes Dev., vol. 20, no. 19, pp. 2673–2686, 2006. 
[72] J. Tímár, J. Tóvári, E. Rásó, L. Mészáros, B. Bereczky, and K. Lapis, “Platelet-
mimicry of cancer cells: Epiphenomenon with clinical significance,” Oncology, 
vol. 69, no. 3. pp. 185–201, 2005. 
[73] P. Jurasz, D. Alonso-Escolano, and M. W. Radomski, “Platelet-cancer interactions: 
mechanisms and pharmacology of tumour cell-induced platelet aggregation,” Br. J. 
Pharmacol., vol. 143, no. 7, pp. 819–826, 2004. 
[74] N. M. Bambace and C. E. Holmes, “The platelet contribution to cancer 
progression,” Journal of Thrombosis and Haemostasis, vol. 9, no. 2. pp. 237–249, 
2011. 
[75] M. B. Chen, J. A. Whisler, J. S. Jeon, and R. D. Kamm, “Mechanisms of tumor 
cell extravasation in an in vitro microvascular network platform,” Integr. Biol., 
vol. 5, no. 10, p. 1262, 2013. 
[76] C. Strell and F. Entschladen, “Extravasation of leukocytes in comparison to tumor 
cells,” Cell Commun. Signal., vol. 6, no. 1, p. 10, 2008. 
[77] P. Jurasz, D. Alonso-Escolano, and M. W. Radomski, “Platelet-cancer interactions: 
mechanisms and pharmacology of tumour cell-induced platelet aggregation,” Br. J. 
Pharmacol., vol. 143, no. 7, pp. 819–826, 2004. 
[78] N. Reymond, B. B. d’Água, and A. J. Ridley, “Crossing the endothelial barrier 
during metastasis,” Nat. Rev. Cancer, vol. 13, no. 12, pp. 858–870, 2013. 
[79] E. Lee, N. B. Pandey, and A. S. Popel, “Crosstalk between cancer cells and blood 
endothelial and lymphatic endothelial cells in tumour and organ 
microenvironment.,” Expert Rev. Mol. Med., vol. 17, p. e3, 2015. 
[80] R. R. Langley and I. J. Fidler, “The seed and soil hypothesis revisited-The role of 
tumor-stroma interactions in metastasis to different organs,” Int. J. Cancer, vol. 
128, no. 11, pp. 2527–2535, 2011. 
[81] D. X. Nguyen, P. D. Bos, and J. Massagué, “Metastasis: from dissemination to 
organ-specific colonization,” Nat. Rev. Cancer, vol. 9, no. 4, pp. 274–284, 2009. 
[82] I. J. Fidler, “Timeline: The pathogenesis of cancer metastasis: the ‘seed and soil’ 
hypothesis revisited,” Nat. Rev. Cancer, vol. 3, no. 6, pp. 453–458, 2003. 
[83] E. Lee, N. B. Pandey, and A. S. Popel, “Crosstalk between cancer cells and blood 
endothelial and lymphatic endothelial cells in tumour and organ 
microenvironment.,” Expert Rev. Mol. Med., vol. 17, p. e3, 2015. 
[84] G. F. Baronzio, A. Gramaglia, A. Baronzio, and I. Freitas, “Influence of Tumor 
Microenvironment on Thermoresponse,” in Hyperthermia in Cancer Treatment: A 
Primer, 2006, pp. 67–91. 
[85] V. Djonov, M. Schmid, S. A. Tschanz, and P. H. Burri, “Intussusceptive 
Angiogenesis,” Circ. Res., vol. 86, no. 3, pp. 286–292, 2000. 
[86] V. Djonov, O. Baum, and P. H. Burri, “Vascular remodeling by intussusceptive 
angiogenesis,” Cell and Tissue Research, vol. 314, no. 1. pp. 107–117, 2003. 
[87] P. H. Burri, R. Hlushchuk, and V. Djonov, “Intussusceptive angiogenesis: Its 
emergence, its characteristics, and its significance,” Developmental Dynamics, vol. 
138 
 
231, no. 3. pp. 474–488, 2004. 
[88] F. Hillen and A. W. Griffioen, “Tumour vascularization: Sprouting angiogenesis 
and beyond,” Cancer and Metastasis Reviews, vol. 26, no. 3–4. pp. 489–502, 
2007. 
[89] R. Hlushchuk et al., “Tumor Recovery by Angiogenic Switch from Sprouting to 
Intussusceptive Angiogenesis after Treatment with PTK787/ZK222584 or Ionizing 
Radiation,” Am. J. Pathol., vol. 173, no. 4, pp. 1173–1185, 2008. 
[90] B. a Aiuti, I. J. Webb, C. Bleul, and T. Springer, “New Mechanism to Explain the 
Mobilization of CD34 ϩ Progenitors to Peripheral Blood,” In Vivo (Brooklyn)., 
vol. 185, no. 1, pp. 111–20, 1997. 
[91] L. Nikitenko and C. Boshoff, “Endothelial cells and cancer,” Handb. Exp. 
Pharmacol., vol. 176, no. PART2, pp. 307–334, 2006. 
[92] A. Schmidt, K. Brixius, and W. Bloch, “Endothelial precursor cell migration 
during vasculogenesis,” Circulation Research, vol. 101, no. 2. pp. 125–136, 2007. 
[93] M. Capillo et al., “Continuous infusion of endostatin inhibits differentiation, 
mobilization, and clonogenic potential of endothelial cell progenitors,” Clin. 
Cancer Res., vol. 9, no. 1 I, pp. 377–382, 2003. 
[94] R. Folberg and A. J. Maniotis, “Vasculogenic mimicry,” APMIS, vol. 112, no. 7–8. 
pp. 508–525, 2004. 
[95] D. M. McDonald, L. Munn, and R. K. Jain, “Vasculogenic mimicry: How 
convincing, how novel, and how significant?,” American Journal of Pathology, 
vol. 156, no. 2. pp. 383–388, 2000. 
[96] M. J. C. Hendrix, E. A. Seftor, A. R. Hess, and R. E. B. Seftor, “Angiogenesis: 
Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma,” Nat. 
Rev. Cancer, vol. 3, no. 6, pp. 411–421, 2003. 
[97] Y. W. J. Paulis, P. M. M. B. Soetekouw, H. M. W. Verheul, V. C. G. Tjan-
Heijnen, and A. W. Griffioen, “Signalling pathways in vasculogenic mimicry,” 
Biochimica et Biophysica Acta - Reviews on Cancer, vol. 1806, no. 1. pp. 18–28, 
2010. 
[98] W. P. J. Leenders, B. Küsters, and R. M. W. De Waal, “Vessel co-option: How 
tumors obtain blood supply in the absence of sprouting angiogenesis,” 
Endothelium: Journal of Endothelial Cell Research, vol. 9, no. 2. pp. 83–87, 2002. 
[99] C. N. Qian, M. H. Tan, J. P. Yang, and Y. Cao, “Revisiting tumor angiogenesis: 
Vessel co-option, vessel remodeling, and cancer cell-derived vasculature 
formation,” Chinese Journal of Cancer, vol. 35, no. 2. 2016. 
[100] T. Donnem et al., “Vessel co-option in primary human tumors and metastases: An 
obstacle to effective anti-angiogenic treatment?,” Cancer Medicine, vol. 2, no. 4. 
pp. 427–436, 2013. 
[101] V. L. Bridgeman et al., “Vessel co-option is common in human lung metastases 
and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis 
models,” J. Pathol., vol. 241, no. 3, pp. 362–374, 2017. 
[102] T. F. Gajewski, H. Schreiber, and Y.-X. Fu, “Innate and adaptive immune cells in 
the tumor microenvironment,” Nat. Immunol., vol. 14, no. 10, pp. 1014–1022, 
2013. 
139 
 
[103] B. Beutler, “Innate immunity: An overview,” Molecular Immunology, vol. 40, no. 
12. pp. 845–859, 2004. 
[104] A. Iwasaki and R. Medzhitov, “Regulation of Adaptive Immunity by the Innate 
Immune System,” Science (80-. )., vol. 327, no. 5963, pp. 291–295, 2010. 
[105] A. Shanker, M. C. Thounaojam, M. K. Mishra, and M. M. Dikov, “Innate-adaptive 
immune crosstalk 2016,” Journal of Immunology Research, vol. 2017, 2017. 
[106] A. Iwasaki and R. Medzhitov, “Regulation of Adaptive Immunity by the Innate 
Immune System,” Science (80-. )., vol. 327, no. 5963, pp. 291–295, 2010. 
[107] T. F. Gajewski, H. Schreiber, and Y.-X. Fu, “Innate and adaptive immune cells in 
the tumor microenvironment,” Nat. Immunol., vol. 14, no. 10, pp. 1014–1022, 
2013. 
[108] F. Cavallo, C. De Giovanni, P. Nanni, G. Forni, and P. L. Lollini, “2011: The 
immune hallmarks of cancer,” in Cancer Immunology, Immunotherapy, 2011, vol. 
60, no. 3, pp. 319–326. 
[109] X. Zhao, L. Li, T. Starr, and S. Subramanian, “Tumor location impacts immune 
response in mouse models of colon cancer,” Oncotarget, pp. 1–13, 2017. 
[110] F. Pagès, J. Galon, M.-C. Dieu-Nosjean, E. Tartour, C. Sautès-Fridman, and W.-H. 
Fridman, “Immune infiltration in human tumors: a prognostic factor that should 
not be ignored,” Oncogene, vol. 29, no. 8, pp. 1093–1102, 2010. 
[111] A. Corthay, “Does the immune system naturally protect against cancer?,” 
Frontiers in Immunology, vol. 5, no. MAY. 2014. 
[112] P. Parcesepe, G. Giordano, C. Laudanna, A. Febbraro, and M. Pancione, “Cancer-
Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal 
Cancer,” Gastroenterology Research and Practice, vol. 2016. 2016. 
[113] R. Kalluri and M. Zeisberg, “Fibroblasts in cancer,” Nat. Rev. Cancer, vol. 6, no. 
5, pp. 392–401, 2006. 
[114] K. Räsänen and A. Vaheri, “Activation of fibroblasts in cancer stroma,” 
Experimental Cell Research, vol. 316, no. 17. pp. 2713–2722, 2010. 
[115] D. J. Tschumperlin, “Fibroblasts and the Ground They Walk On,” Physiology, vol. 
28, no. 6, pp. 380–390, 2013. 
[116] H. Y. Chang et al., “Diversity, topographic differentiation, and positional memory 
in human fibroblasts,” Proc. Natl. Acad. Sci., vol. 99, no. 20, pp. 12877–12882, 
2002. 
[117] P. Cirri and P. Chiarugi, “Cancer associated fibroblasts: the dark side of the coin.,” 
Am. J. Cancer Res., vol. 1, no. 4, pp. 482–97, 2011. 
[118] F. Xing, J. Saidou, and K. Watabe, “Cancer associated fibroblasts (CAFs) in tumor 
microenvironment.,” Front. Biosci. (Landmark Ed., vol. 15, no. 2, pp. 166–79, 
2010. 
[119] R. Kalluri and M. Zeisberg, “Fibroblasts in cancer,” Nat. Rev. Cancer, vol. 6, no. 
5, pp. 392–401, 2006. 
[120] H. Y. Chang et al., “Diversity, topographic differentiation, and positional memory 
in human fibroblasts,” Proc. Natl. Acad. Sci., vol. 99, no. 20, pp. 12877–12882, 
2002. 
[121] F. Xing, J. Saidou, and K. Watabe, “Cancer associated fibroblasts (CAFs) in tumor 
140 
 
microenvironment.,” Front. Biosci. (Landmark Ed., vol. 15, no. 2, pp. 166–79, 
2010. 
[122] H.-O. Lee, S. R. Mullins, J. Franco-Barraza, M. Valianou, E. Cukierman, and J. D. 
Cheng, “FAP-overexpressing fibroblasts produce an extracellular matrix that 
enhances invasive velocity and directionality of pancreatic cancer cells.,” BMC 
Cancer, vol. 11, no. 1, p. 245, 2011. 
[123] R. Kalluri, “The biology and function of exosomes in cancer,” Journal of Clinical 
Investigation, vol. 126, no. 4. pp. 1208–1215, 2016. 
[124] F.-A. Ramirez-Weber and T. B. Kornberg, “Cytonemes,” Cell, vol. 97, no. 5, pp. 
599–607, 1999. 
[125] A. Rustom, “Nanotubular Highways for Intercellular Organelle Transport,” 
Science (80-. )., vol. 303, no. 5660, pp. 1007–1010, 2004. 
[126] E. M. De Kruijf et al., “Tumor-stroma ratio in the primary tumor is a prognostic 
factor in early breast cancer patients, especially in triple-negative carcinoma 
patients,” Breast Cancer Res. Treat., vol. 125, no. 3, pp. 687–696, 2011. 
[127] F. J. A. Gujam, J. Edwards, Z. M. A. Mohammed, J. J. Going, and D. C. 
McMillan, “The relationship between the tumour stroma percentage, 
clinicopathological characteristics and outcome in patients with operable ductal 
breast cancer.,” Br. J. Cancer, vol. 111, no. 1, pp. 157–65, 2014. 
[128] Y. Chen, L. Zhang, W. Liu, and X. Liu, “Prognostic Significance of the Tumor-
Stroma Ratio in Epithelial Ovarian Cancer,” Biomed Res. Int., vol. 2015, 2015. 
[129] A. Rustom, “Nanotubular Highways for Intercellular Organelle Transport,” 
Science (80-. )., vol. 303, no. 5660, pp. 1007–1010, 2004. 
[130] J. W. Ady et al., “Intercellular communication in malignant pleural mesothelioma: 
properties of tunneling nanotubes.,” Front. Physiol., vol. 5, no. October, p. 400, 
2014. 
[131] S. Desir et al., “Tunneling nanotube formation is stimulated by hypoxia in ovarian 
cancer cells,” Oncotarget, vol. 7, no. 28, pp. 43150–43161, 2016. 
[132] L. Abbro and L. Dini, “Common morphological features of apoptotic cell blebs,” 
Ital. J. Zool., vol. 70, no. 4, pp. 297–299, 2003. 
[133] C. Harding and P. Stahl, “Transferrin recycling in reticulocytes: pH and iron are 
important determinants of ligand binding and processing,” Biochem. Biophys. Res. 
Commun., vol. 113, no. 2, pp. 650–658, 1983. 
[134] C. Harding, J. Heuser, and P. Stahl, “Receptor-mediated endocytosis of transferrin 
and recycling of the transferrin receptor in rat reticulocytes.,” J. Cell Biol., vol. 97, 
no. 2, pp. 329–339, 1983. 
[135] K. Bengler, K. Dietmayer, B. Farber, M. Maurer, C. Stiller, and H. Winner, “Three 
decades of driver assistance systems: Review and future perspectives,” IEEE 
Intelligent Transportation Systems Magazine, vol. 6, no. 4. pp. 6–22, 2014. 
[136] C. V. Harding, J. E. Heuser, and P. D. Stahl, “Exosomes: Looking back three 
decades and into the future,” Journal of Cell Biology, vol. 200, no. 4. pp. 367–371, 
2013. 
[137] C. Kahlert and R. Kalluri, “Exosomes in tumor microenvironment influence cancer 
progression and metastasis,” Journal of Molecular Medicine, vol. 91, no. 4. pp. 
141 
 
431–437, 2013. 
[138] K. Koga et al., “Purification, characterization and biological significance of tumor-
derived exosomes,” in Anticancer Research, 2005, vol. 25, no. 6 A, pp. 3703–
3707. 
[139] D. D. Taylor and C. Gercel-Taylor, “MicroRNA signatures of tumor-derived 
exosomes as diagnostic biomarkers of ovarian cancer,” Gynecol. Oncol., vol. 110, 
no. 1, pp. 13–21, 2008. 
[140] F. André et al., “Tumor-derived exosomes: A new source of tumor rejection 
antigens,” in Vaccine, 2002, vol. 20, no. SUPPL. 4. 
[141] P. Kharaziha, S. Ceder, Q. Li, and T. Panaretakis, “Tumor cell-derived exosomes: 
A message in a bottle,” Biochimica et Biophysica Acta - Reviews on Cancer, vol. 
1826, no. 1. pp. 103–111, 2012. 
[142] V. Luga and J. L. Wrana, “Tumor-stroma interaction: Revealing fibroblast-
secreted exosomes as potent regulators of Wnt-planar cell polarity signaling in 
cancer metastasis,” Cancer Research, vol. 73, no. 23. pp. 6843–6847, 2013. 
[143] C. Yang and P. D. Robbins, “The roles of tumor-derived exosomes in cancer 
pathogenesis,” Clinical and Developmental Immunology, vol. 2011. 2011. 
[144] Y. Liu, Y. Gu, and X. Cao, “The exosomes in tumor immunity,” 
Oncoimmunology, vol. 4, no. 9, pp. 1–8, 2015. 
[145] Y. Tian et al., “A doxorubicin delivery platform using engineered natural 
membrane vesicle exosomes for targeted tumor therapy,” Biomaterials, vol. 35, 
no. 7, pp. 2383–2390, 2014. 
[146] M. J. Haney et al., “Exosomes as drug delivery vehicles for Parkinson’s disease 
therapy,” J. Control. Release, vol. 207, pp. 18–30, 2015. 
[147] L. Barile and G. Vassalli, “Exosomes: Therapy delivery tools and biomarkers of 
diseases,” Pharmacology and Therapeutics, vol. 174. pp. 63–78, 2017. 
[148] N. M. Kumar and N. B. Gilula, “The gap junction communication channel.,” Cell, 
vol. 84, no. 3, pp. 381–388, 1996. 
[149] J. C. Hervé and M. Derangeon, “Gap-junction-mediated cell-to-cell 
communication,” Cell and Tissue Research, vol. 352, no. 1. pp. 21–31, 2013. 
[150] S. Weidmann, “the Electrical Constants of Purkinje Fibres,” J. Physiol., vol. 8, no. 
case 1, pp. 348–360, 1952. 
[151] E. J. Furshpan and D. D. Potter, “Transmission At the Giant Motor Synapses of the 
Crayfish,” J. Physiol., vol. 45, pp. 289–325, 1959. 
[152] W. R. Loewenstein and Y. Kanno, “Intercellular communication and tissue 
growth. I. Cancerous growth.,” J. Cell Biol., vol. 33, no. 2, pp. 225–234, 1967. 
[153] R. F. Ashman, Y. Kanno, and W. R. Loewenstein, “Intercellular Electrical 
Coupling At a Forming Membrane Junction in a Dividing Cell.,” Science, vol. 145, 
no. 1955, pp. 604–605, 1964. 
[154] R. G. Johnson and J. D. Sheridan, “Junctions between cancer cells in culture: 
ultrastructure and permeability,” Science (80-. )., vol. 174, no. 10, pp. 717–719, 
1971. 
[155] J. L. Solan and P. D. Lampe, “Specific Cx43 phosphorylation events regulate gap 
junction turnover in vivo,” in FEBS Letters, 2014, vol. 588, no. 8, pp. 1423–1429. 
142 
 
[156] J. L. Solan and P. D. Lampe, “Connexin43 phosphorylation: structural changes and 
biological effects,” Biochem. J., vol. 419, no. 2, pp. 261–272, 2009. 
[157] L. S. Musil, B. A. Cunningham, G. M. Edelman, and D. A. Goodenough, 
“Differential phosphorylation of the gap junction protein connexin43 in junctional 
communication-competent and -deficient cell lines,” J. Cell Biol., vol. 111, no. 5, 
pp. 2077–2088, 1990. 
[158] D. W. Laird, K. L. Puranam, and J. Revel, “Turnover and phosphorylation 
dynamics of connexin43 gap junction protein in cultured cardiac myocytes,” 
Biochem J, vol. 273, pp. 67–72, 1991. 
[159] S. M. Ngai and R. S. Hodges, “Inhibition of connexin43 gap junctional 
intercellular communication by TPA requires ERK activation,” J. Cell. Biochem., 
vol. 83, no. 1, pp. 163–169, 2001. 
[160] S. Sirnes, A. Kjenseth, E. Leithe, and E. Rivedal, “Interplay between PKC and the 
MAP kinase pathway in Connexin43 phosphorylation and inhibition of gap 
junction intercellular communication,” Biochem. Biophys. Res. Commun., vol. 382, 
no. 1, pp. 41–45, 2009. 
[161] J. A. Raven, “Evolution of Plasmodesmata,” in Plasmodesmata, 2007, pp. 33–52. 
[162] P. Zambryski, “Plasmodesmata,” Current Biology, vol. 18, no. 8. 2008. 
[163] F. A. Martin and G. Morata, “Compartments and the control of growth in the 
Drosophila wing imaginal disc,” Development, vol. 133, no. 22, pp. 4421–4426, 
2006. 
[164] M. Zecca and G. Struhl, “Control of growth and patterning of the Drosophila wing 
imaginal disc by EGFR-mediated signaling.,” Development, vol. 129, no. 6, pp. 
1369–1376, 2002. 
[165] F. A. Ramírez-Weber and T. B. Kornberg, “Cytonemes: Cellular processes that 
project to the principal signaling center in Drosophila imaginal discs,” Cell, vol. 
97, no. 5, pp. 599–607, 1999. 
[166] K. Koizumi et al., “RhoD activated by fibroblast growth factor induces cytoneme-
like cellular protrusions through mDia3C,” Mol. Biol. Cell, vol. 23, no. 23, pp. 
4647–4661, 2012. 
[167] J. C. Snyder, L. K. Rochelle, S. Marion, H. K. Lyerly, L. S. Barak, and M. G. 
Caron, “Lgr4 and Lgr5 drive the formation of long actin-rich cytoneme-like 
membrane protrusions,” J. Cell Sci., vol. 128, no. 6, pp. 1230–1240, 2015. 
[168] B. Onfelt, S. Nedvetzki, K. Yanagi, and D. M. Davis, “Cutting Edge: Membrane 
Nanotubes Connect Immune Cells,” J. Immunol., vol. 173, no. 3, pp. 1511–1513, 
2004. 
[169] F. Baluska, D. Volkmann, and P. W. Barlow, “cell-cell channels and their 
implications for cell theory,” in Cell-cell channels, 2006, pp. 1–18. 
[170] N. M. Sherer and W. Mothes, “Cytonemes and tunneling nanotubules in cell-cell 
communication and viral pathogenesis,” Trends in Cell Biology, vol. 18, no. 9. pp. 
414–420, 2008. 
[171] E. Lou et al., “Tunneling nanotubes provide a unique conduit for intercellular 
transfer of cellular contents in human malignant pleural mesothelioma,” PLoS 
One, vol. 7, no. 3, 2012. 
143 
 
[172] X. Wang and H. H. Gerdes, “Long-distance electrical coupling via tunneling 
nanotubes,” Biochimica et Biophysica Acta - Biomembranes, vol. 1818, no. 8. pp. 
2082–2086, 2012. 
[173] J. Pasquier et al., “Preferential transfer of mitochondria from endothelial to cancer 
cells through tunneling nanotubes modulates chemoresistance,” J. Transl. Med., 
vol. 11, no. 1, p. 94, 2013. 
[174] X. Wang and H.-H. Gerdes, “Transfer of mitochondria via tunneling nanotubes 
rescues apoptotic PC12 cells,” Cell Death Differ., vol. 22, no. 7, pp. 1181–1191, 
2015. 
[175] S. Abounit and C. Zurzolo, “Wiring through tunneling nanotubes - from electrical 
signals to organelle transfer,” J. Cell Sci., vol. 125, no. 5, pp. 1089–1098, 2012. 
[176] X. Wang, M. L. Veruki, N. V. Bukoreshtliev, E. Hartveit, and H.-H. Gerdes, 
“Animal cells connected by nanotubes can be electrically coupled through 
interposed gap-junction channels,” Proc. Natl. Acad. Sci., vol. 107, no. 40, pp. 
17194–17199, 2010. 
[177] S. Kimura, K. Hase, and H. Ohno, “Tunneling nanotubes: Emerging view of their 
molecular components and formation mechanisms,” Exp. Cell Res., vol. 318, no. 
14, pp. 1699–1706, 2012. 
[178] H. H. Gerdes, N. V. Bukoreshtliev, and J. F. V Barroso, “Tunneling nanotubes: A 
new route for the exchange of components between animal cells,” FEBS Letters, 
vol. 581, no. 11. pp. 2194–2201, 2007. 
[179] S. Naphade et al., “Brief reports: Lysosomal cross-correction by hematopoietic 
stem cell-derived macrophages via tunneling nanotubes,” Stem Cells, vol. 33, no. 
1, pp. 301–309, 2015. 
[180] M. L. Vignais, A. Caicedo, J. M. Brondello, and C. Jorgensen, “Cell connections 
by tunneling nanotubes: Effects of mitochondrial trafficking on target cell 
metabolism, homeostasis, and response to therapy,” Stem Cells International, vol. 
2017. 2017. 
[181] F. Rückert, R. Grützmann, and C. Pilarsky, “Feedback within the inter-cellular 
communication and tumorigenesis in carcinomas,” PLoS One, vol. 7, no. 5, 2012. 
[182] R. Axelrod, D. E. Axelrod, and K. J. Pienta, “Evolution of cooperation among 
tumor cells.,” Proc. Natl. Acad. Sci. U. S. A., vol. 103, no. 36, pp. 13474–9, 2006. 
[183] P. A. Kenny, G. Y. Lee, and M. J. Bissell, “Targeting the tumor 
microenvironment,” Front Biosci, vol. 12, no. June, pp. 3468–3474, 2007. 
[184] M. J. Bissell and W. C. Hines, “Why don’t we get more cancer? A proposed role 
of the microenvironment in restraining cancer progression,” Nature Medicine, vol. 
17, no. 3. pp. 320–329, 2011. 
[185] K. Pietras and A. Ostman, “Hallmarks of cancer: Interactions with the tumor 
stroma - stroma_hallmarks.pdf,” Exp Cell Res, 2010. [Online]. Available: 
https://www.researchgate.net/profile/Arne_Ostman/publication/41824562_Pietras_
K_Ostman_AHallmarks_of_cancer_interactions_with_the_tumor_stroma_Exp_Ce
ll_Res_316_1324-1331/links/54cf61c40cf298d656633bae/Pietras-K-Ostman-
AHallmarks-of-cancer-interactions-wit. 
[186] M. M. Mueller and N. E. Fusenig, “Friends or foes - Bipolar effects of the tumour 
144 
 
stroma in cancer,” Nature Reviews Cancer, vol. 4, no. 11. pp. 839–849, 2004. 
[187] T. D. Tlsty and L. M. Coussens, “Tumor stroma and regulation of cancer 
development.,” Annu. Rev. Pathol., vol. 1, no. October, pp. 119–50, 2006. 
[188] A. B. Motta et al., “Marcadores morfológicos de prognóstico no mesotelioma 
maligno: um estudo de 58 casos,” J. Bras. Pneumol., vol. 32, pp. 322–332, 2006. 
[189] C. A. Cerruto, E. A. Brun, D. Chang, and P. H. Sugarbaker, “Prognostic 
significance of histomorphologic parameters in diffuse malignant peritoneal 
mesothelioma,” Arch. Pathol. Lab. Med., vol. 130, no. 11, pp. 1654–1661, 2006. 
[190] J. P. J. J. Hegmans et al., “Proteomic Analysis of Exosomes Secreted by Human 
Mesothelioma Cells,” Am. J. Pathol., vol. 164, no. 5, pp. 1807–1815, 2004. 
[191] M. J. Bissell and D. Radisky, “Putting tumours in context,” Nat. Rev. Cancer, vol. 
1, no. 1, pp. 46–54, 2001. 
[192] S. Cottin, K. Ghani, P. O. de Campos-Lima, and M. Caruso, “Gemcitabine 
intercellular diffusion mediated by gap junctions: New implications for cancer 
therapy,” Mol. Cancer, vol. 9, 2010. 
[193] C. C. Naus and D. W. Laird, “Implications and challenges of connexin connections 
to cancer,” Nature Reviews Cancer, vol. 10, no. 6. pp. 435–441, 2010. 
[194] S. Strassburg, N. W. Hodson, P. I. Hill, S. M. Richardson, and J. A. Hoyland, “Bi-
directional exchange of membrane components occurs during co-culture of 
mesenchymal stem cells and nucleus pulposus cells,” PLoS One, vol. 7, no. 3, 
2012. 
[195] A. Bobrie, M. Colombo, G. Raposo, and C. Thery, “Exosome secretion: molecular 
mechanisms and roles in immune responses,” Traffic, vol. 12, no. 12, pp. 1659–
1668, 2011. 
[196] E. Pap, E. Pallinger, and A. Falus, “The role of membrane vesicles in 
tumorigenesis,” Crit Rev Oncol Hematol, vol. 79, no. 3, pp. 213–223, 2011. 
[197] M. A. Huber, N. Kraut, and H. Beug, “Molecular requirements for epithelial-
mesenchymal transition during tumor progression,” Curr Opin Cell Biol, vol. 17, 
no. 5, pp. 548–558, 2005. 
[198] L. Lamorte, I. Royal, M. Naujokas, and M. Park, “Crk adapter proteins promote an 
epithelial-mesenchymal-like transition and are required for HGF-mediated cell 
spreading and breakdown of epithelial adherens junctions,” Mol Biol Cell, vol. 13, 
no. 5, pp. 1449–1461, 2002. 
[199] P. Veranic et al., “Different types of cell-to-cell connections mediated by 
nanotubular structures,” Biophys J, vol. 95, no. 9, pp. 4416–4425, 2008. 
[200] E. Lou et al., “Tunneling nanotubes: A new paradigm for studying intercellular 
communication and therapeutics in cancer,” Commun. Integr. Biol., vol. 5, pp. 
399–403, 2012. 
[201] S. Sowinski et al., “Membrane nanotubes physically connect T cells over long 
distances presenting a novel route for HIV-1 transmission,” Nat. Cell Biol., vol. 
10, no. 2, pp. 211–219, 2008. 
[202] R. D. Salter and S. C. Watkins, “Dynamic properties of antigen uptake and 
communication between dendritic cells.,” Immunol. Res., vol. 36, pp. 211–220, 
2006. 
145 
 
[203] S. C. Watkins and R. D. Salter, “Functional connectivity between immune cells 
mediated by tunneling nanotubules,” Immunity, vol. 23, pp. 309–318, 2005. 
[204] K. Hase et al., “M-Sec promotes membrane nanotube formation by interacting 
with Ral and the exocyst complex.,” Nat. Cell Biol., vol. 11, pp. 1427–1432, 2009. 
[205] E. A. Eugenin, P. J. Gaskill, and J. W. Berman, “Tunneling nanotubes (TNT) are 
induced by HIV-infection of macrophages: A potential mechanism for intercellular 
HIV trafficking,” Cell. Immunol., vol. 254, pp. 142–148, 2009. 
[206] S. Sowinski, J. M. Alakoskela, C. Jolly, and D. M. Davis, “Optimized methods for 
imaging membrane nanotubes between T cells and trafficking of HIV-1,” Methods, 
vol. 53. pp. 27–33, 2011. 
[207] S. Sowinski et al., “Membrane nanotubes physically connect T cells over long 
distances presenting a novel route for HIV-1 transmission.,” Nat. Cell Biol., vol. 
10, pp. 211–219, 2008. 
[208] W. Xu et al., “HIV-1 evades virus-specific IgG2 and IgA responses by targeting 
systemic and intestinal B cells via long-range intercellular conduits.,” Nat. 
Immunol., vol. 10, pp. 1008–1017, 2009. 
[209] K. Gousset et al., “Prions hijack tunnelling nanotubes for intercellular spread.,” 
Nat. Cell Biol., vol. 11, pp. 328–336, 2009. 
[210] S. Gurke, J. F. Barroso, E. Hodneland, N. V Bukoreshtliev, O. Schlicker, and H. 
H. Gerdes, “Tunneling nanotube (TNT)-like structures facilitate a constitutive, 
actomyosin-dependent exchange of endocytic organelles between normal rat 
kidney cells,” Exp Cell Res, vol. 314, no. 20, pp. 3669–3683, 2008. 
[211] K. Yasuda et al., “Adriamycin nephropathy: a failure of endothelial progenitor 
cell-induced repair,” Am J Pathol, vol. 176, no. 4, pp. 1685–1695, 2010. 
[212] J. Ranzinger et al., “Nanotube action between human mesothelial cells reveals 
novel aspects of inflammatory responses,” PLoS One, vol. 6, no. 12, 2011. 
[213] M. Koyanagi, R. P. Brandes, J. Haendeler, A. M. Zeiher, and S. Dimmeler, “Cell-
to-cell connection of endothelial progenitor cells with cardiac myocytes by 
nanotubes: a novel mechanism for cell fate changes?,” Circ Res, vol. 96, no. 10, 
pp. 1039–1041, 2005. 
[214] E. Y. Plotnikov, T. G. Khryapenkova, S. I. Galkina, G. T. Sukhikh, and D. B. 
Zorov, “Cytoplasm and organelle transfer between mesenchymal multipotent 
stromal cells and renal tubular cells in co-culture,” Exp Cell Res, vol. 316, no. 15, 
pp. 2447–2455, 2010. 
[215] A. Cselenyak, E. Pankotai, E. M. Horvath, L. Kiss, and Z. Lacza, “Mesenchymal 
stem cells rescue cardiomyoblasts from cell death in an in vitro ischemia model via 
direct cell-to-cell connections,” BMC Cell Biol, vol. 11, p. 29, 2010. 
[216] E. Lou et al., “Tunneling nanotubes provide a unique conduit for intercellular 
transfer of cellular contents in human malignant pleural mesothelioma,” PLoS 
One, vol. 7, 2012. 
[217] V. Thayanithy et al., “Tumor exosomes induce tunneling nanotubes in lipid raft-
enriched regions of human mesothelioma cells,” Exp. Cell Res., vol. 323, no. 1, pp. 
178–188, 2014. 
[218] P. E. DiCorleto and C. A. de la Motte, “Characterization of the adhesion of the 
146 
 
human monocytic cell line U937 to cultured endothelial cells,” J Clin Invest, vol. 
75, no. 4, pp. 1153–1161, 1985. 
[219] K. Rilla, R. Tiihonen, A. Kultti, M. Tammi, and R. Tammi, “Pericellular 
hyaluronan coat visualized in live cells with a fluorescent probe is scaffolded by 
plasma membrane protrusions,” J Histochem Cytochem, vol. 56, no. 10, pp. 901–
910, 2008. 
[220] H. R. Chinnery, E. Pearlman, and P. G. McMenamin, “Cutting edge: Membrane 
nanotubes in vivo: a feature of MHC class II+ cells in the mouse cornea.,” J. 
Immunol., vol. 180, pp. 5779–5783, 2008. 
[221] T. D. Schmittgen and K. J. Livak, “Analyzing real-time PCR data by the 
comparative C(T) method,” Nat Protoc, vol. 3, no. 6, pp. 1101–1108, 2008. 
[222] L. Chen, S. Yang, J. Jakoncic, J. J. Zhang, and X. Y. Huang, “Migrastatin 
analogues target fascin to block tumour metastasis,” Nature, vol. 464, no. 7291, 
pp. 1062–1066, 2010. 
[223] T. Asplund and P. Heldin, “Hyaluronan receptors are expressed on human 
malignant mesothelioma cells but not on normal mesothelial cells,” Cancer Res, 
vol. 54, no. 16, pp. 4516–4523, 1994. 
[224] A. Kultti, K. Rilla, R. Tiihonen, A. P. Spicer, R. H. Tammi, and M. I. Tammi, 
“Hyaluronan synthesis induces microvillus-like cell surface protrusions,” J Biol 
Chem, vol. 281, no. 23, pp. 15821–15828, 2006. 
[225] W. H. McBride and J. B. Bard, “Hyaluronidase-sensitive halos around adherent 
cells. Their role in blocking lymphocyte-mediated cytolysis,” J Exp Med, vol. 149, 
no. 2, pp. 507–515, 1979. 
[226] A. Wang and V. C. Hascall, “Hyaluronan structures synthesized by rat mesangial 
cells in response to hyperglycemia induce monocyte adhesion,” J Biol Chem, vol. 
279, no. 11, pp. 10279–10285, 2004. 
[227] A. K. Majors et al., “Endoplasmic reticulum stress induces hyaluronan deposition 
and leukocyte adhesion,” J Biol Chem, vol. 278, no. 47, pp. 47223–47231, 2003. 
[228] M. E. Lauer, D. Mukhopadhyay, C. Fulop, C. A. de la Motte, A. K. Majors, and V. 
C. Hascall, “Primary murine airway smooth muscle cells exposed to poly(I,C) or 
tunicamycin synthesize a leukocyte-adhesive hyaluronan matrix,” J Biol Chem, 
vol. 284, no. 8, pp. 5299–5312, 2009. 
[229] C. A. de La Motte, V. C. Hascall, A. Calabro, B. Yen-Lieberman, and S. A. 
Strong, “Mononuclear leukocytes preferentially bind via CD44 to hyaluronan on 
human intestinal mucosal smooth muscle cells after virus infection or treatment 
with poly(I.C),” J Biol Chem, vol. 274, no. 43, pp. 30747–30755, 1999. 
[230] K. Harada et al., “Epithelial-mesenchymal transition induced by biliary innate 
immunity contributes to the sclerosing cholangiopathy of biliary atresia,” J Pathol, 
vol. 217, no. 5, pp. 654–664, 2009. 
[231] H. Morohashi et al., “Study of hyaluronan synthase inhibitor, 4-
methylumbelliferone derivatives on human pancreatic cancer cell (KP1-NL),” 
Biochem Biophys Res Commun, vol. 345, no. 4, pp. 1454–1459, 2006. 
[232] A. Kultti et al., “4-Methylumbelliferone inhibits hyaluronan synthesis by depletion 
of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 
147 
 
3,” Exp Cell Res, vol. 315, no. 11, pp. 1914–1923, 2009. 
[233] K. M. Bullard et al., “Hyaluronan synthase-3 is upregulated in metastatic colon 
carcinoma cells and manipulation of expression alters matrix retention and cellular 
growth,” Int J Cancer, vol. 107, no. 5, pp. 739–746, 2003. 
[234] C. Pyrgaki, P. Trainor, A. K. Hadjantonakis, and L. Niswander, “Dynamic imaging 
of mammalian neural tube closure,” Dev Biol, vol. 344, no. 2, pp. 941–947, 2010. 
[235] K. He et al., “Long-distance intercellular connectivity between cardiomyocytes 
and cardiofibroblasts mediated by membrane nanotubes,” Cardiovasc. Res., vol. 
92, pp. 39–47, 2011. 
[236] W. W. Minuth and L. Denk, “Cell projections and extracellular matrix cross the 
interstitial interface within the renal stem/progenitor cell niche: accidental, 
structural or functional cues?,” Nephron Exp Nephrol, vol. 122, no. 3–4, pp. 131–
140, 2012. 
[237] C. Schiller et al., “LST1 promotes the assembly of a molecular machinery 
responsible for tunneling nanotube formation,” J Cell Sci, vol. 126, no. Pt 3, pp. 
767–777, 2013. 
[238] G. Nalepa et al., “The tumor suppressor CDKN3 controls mitosis,” J Cell Biol, 
vol. 201, no. 7, pp. 997–1012, 2013. 
[239] D. S. Guttery et al., “Association of invasion-promoting tenascin-C additional 
domains with breast cancers in young women,” Breast Cancer Res, vol. 12, no. 4, 
p. R57, 2010. 
[240] A. Pietras et al., “Osteopontin-CD44 signaling in the glioma perivascular niche 
enhances cancer stem cell phenotypes and promotes aggressive tumor growth,” 
Cell Stem Cell, vol. 14, no. 3, pp. 357–369, 2014. 
[241] S. R. Rittling and A. F. Chambers, “Role of osteopontin in tumour progression,” 
Br J Cancer, vol. 90, no. 10, pp. 1877–1881, 2004. 
[242] N. Scholler et al., “Soluble member(s) of the mesothelin/megakaryocyte 
potentiating factor family are detectable in sera from patients with ovarian 
carcinoma,” Proc Natl Acad Sci U S A, vol. 96, no. 20, pp. 11531–11536, 1999. 
[243] E. L. Servais et al., “Mesothelin overexpression promotes mesothelioma cell 
invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid 
pleural mesothelioma patients,” Clin Cancer Res, vol. 18, no. 9, pp. 2478–2489, 
2012. 
[244] M. Al-Alwan et al., “Fascin is a key regulator of breast cancer invasion that acts 
via the modification of metastasis-associated molecules,” PLoS One, vol. 6, no. 11, 
p. e27339, 2011. 
[245] M. Herrera et al., “Functional heterogeneity of cancer-associated fibroblasts from 
human colon tumors shows specific prognostic gene expression signature,” Clin 
Cancer Res, vol. 19, no. 21, pp. 5914–5926, 2013. 
[246] A. Gottehrer, D. A. Taryle, C. E. Reed, and S. A. Sahn, “Pleural fluid analysis in 
malignant mesothelioma. Prognostic implications,” Chest, vol. 100, no. 4, pp. 
1003–1006, 1991. 
[247] F.-A. Ramirez-Weber and T. B. Kornberg, “Cytonemes,” Cell, vol. 97, no. 5, pp. 
599–607, 1999. 
148 
 
[248] H. R. Chinnery, E. Pearlman, and P. G. McMenamin, “Cutting Edge: Membrane 
Nanotubes In Vivo: A Feature of MHC Class II+ Cells in the Mouse Cornea,” J. 
Immunol., vol. 180, no. 9, pp. 5779–5783, 2008. 
[249] L. Wolpert and T. Gustafson, “Studies on the cellular basis of morphogenesis of 
the sea urchin embryo,” Exp. Cell Res., vol. 25, no. 2, pp. 311–325, 1961. 
[250] T. Gustafson and L. Wolpert, “The Cellular Basis of Morphogenesis and Sea 
Urchin Development,” Int. Rev. Cytol., vol. 15, no. C, pp. 139–214, 1963. 
[251] J. Hardin, “The role of secondary mesenchyme cells during sea urchin gastrulation 
studied by laser ablation.,” Development, vol. 103, pp. 317–324, 1988. 
[252] J. Miller, S. E. Fraser, and D. McClay, “Dynamics of thin filopodia during sea 
urchin gastrulation,” Development, vol. 121, no. 8, pp. 2501–2511, 1995. 
[253] S. Rao, “Malignant pleural mesothelioma,” Lung India, vol. 26, no. 2, pp. 53–54, 
2009. 
[254] T. K.C., O. A. A., G. D., S. R., G. A., and A. A., “Multiple distant metastases in a 
case of malignant pleural mesothelioma,” Respir. Med. Case Reports, vol. 13, pp. 
16–18, 2014. 
[255] W. Zeng, P. Liu, W. Pan, S. R. Singh, and Y. Wei, “Hypoxia and hypoxia 
inducible factors in tumor metabolism,” Cancer Letters, vol. 356, no. 2. pp. 263–
267, 2015. 
[256] M. Hockel and P. Vaupel, “Tumor Hypoxia: Definitions and Current Clinical, 
Biologic, and Molecular Aspects,” JNCI J. Natl. Cancer Inst., vol. 93, no. 4, pp. 
266–276, 2001. 
[257] A. Danon et al., “Hypoxia causes connexin 43 internalization in neonatal rat 
ventricular myocytes,” Gen. Physiol. Biophys., vol. 29, no. 3, pp. 222–233, 2010. 
[258] X. Wu, W. Huang, G. Luo, and L. A. Alain, “Hypoxia induces connexin 43 
dysregulation by modulating matrix metalloproteinases via MAPK signaling,” 
Mol. Cell. Biochem., vol. 384, no. 1–2, pp. 155–162, 2013. 
[259] J. Scheller, A. Chalaris, D. Schmidt-Arras, and S. Rose-John, “The pro- and anti-
inflammatory properties of the cytokine interleukin-6,” Biochimica et Biophysica 
Acta - Molecular Cell Research, vol. 1813, no. 5. pp. 878–888, 2011. 
[260] L. S. Poritz, K. I. Garver, A. F. Tilberg, and W. A. Koltun, “Tumor necrosis factor 
alpha disrupts tight junction assembly,” J. Surg. Res., vol. 116, no. 1, pp. 14–18, 
2004. 
[261] P. R. Clark, R. K. Kim, J. S. Pober, and M. S. Kluger, “Tumor necrosis factor 
disrupts claudin-5 endothelial tight junction barriers in two distinct NF-κB-
dependent phases,” PLoS One, vol. 10, no. 3, 2015. 
[262] C. Gabay, “Interleukin-6 and chronic inflammation.,” Arthritis Res. Ther., vol. 8 
Suppl 2, no. 2, p. S3, 2006. 
[263] J. S. Lowengrub et al., “Nonlinear modelling of cancer: bridging the gap between 
cells and tumours,” Nonlinearity, vol. 23, no. 1, pp. R1–R91, 2010. 
 
